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Malaria More than 40 percent of the world’s population is at risk of exposure to malaria. An estimated 250-450 million clinical cases of malaria occur annually, resulting in a death toll of 655.000 to 1.200.000 [1,2]. Besides morbidity and mortality, the social 
and economic burden of malaria, specifically in underdeveloped countries, remains enormous [3]. Malaria forms one of the most dreadful global health problems. Malaria is caused by the protozoan parasite of the genus Plasmodia which is transmitted to humans by the bite of infected Anopheles mosquitoes. There are five malaria species known to infect man: P. falciparum, P. vivax, P. ovale, P. malariae and P. 
knowelsi [4,5], all of which have a distinct global distribution and clinical outcome. P. 
falciparum is the most prevalent malaria species and is by far responsible for most of 
the malaria associated severe disease and mortality. Over 90% of malaria morbidity and mortality is restricted to Sub-Saharan Africa, where especially young children 
and pregnant women are most vulnerable [6].  
Life CycleMore than 200 Plasmodium species have been described, which can infect 
mammalian, avian and reptilian hosts [7]. Here we focus on P. falciparum for the human host and the murine P. berghei and P. yoelii, with particular emphasis on the 
sporozoite and liver stage. The following outline of the parasite’s life cycle contains an in-depth description (mainly based on P. berghei studies) of the sporozoite and 
liver stage biology (depicted in Figure 1). 
For its survival and procreation, the Plasmodium parasite is dependent on two hosts; 
the definitive host, which is the female Anopheles mosquito, and a mammalian host. 
Plasmodium parasites enter the mammalian body by the bite of an infected Anopheles mosquito. The mosquito probes the skin for a blood meal and either imbibes from a pool of blood generated by capillary damage or by directly cannulating from 
a subcutaneous blood vessel [8]. To prevent the blood from coagulating, saliva is 
deposited [9] containing up to a few hundred sporozoites. The sporozoites now 
start an active gliding locomotion of 4 µm/s leaving a trail of circum-sporozoite-protein (CSP) and enter the blood stream by breaking the endothelial barrier [10]. 
Alternatively, around 20% of the sporozoites enter a lymphatic vessel and are drained to a lymph node where most are internalized inside dendritic cells, and some can 
(partially) develop into exoerythrocytic forms [11]. Sporozoites that reach the blood 
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vessel rapidly travel to the liver. It is unknown how the sporozoites exactly select and 
recognize the liver as the preferred organ for further development. Possibly a family 
of liver specific highly sulfated heparan sulfate proteoclycans (HSPGs) play a role. 
In the liver the sporozoites glide alongside and adhere to the sinusodial epithelium before entering a Kupffer cell and crossing into the space of Disse [12]. Sporozoites 
can enter a host cell in two distinct ways. Firstly, they can disrupt the host cell membrane and migrate through the cells, a feature used by the sporozoite in the skin, 
the Kupffer cells and hepatocytes, leaving the latter in a state of necrosis [13,14,15]. 
Alternatively, the sporozoite can invade a hepatocyte by invagination of the host cell 
membrane forming a so called parasitophorous vacuole (PV). The HSPGs appear to play an essential role in guiding the sporozoite from its migration mode of cell entry 
into its invasion mode. It is unclear how sporozoites precisely switch mode. Proteins 
like P52 and P36 seem to be essential in host cell invasion and the formation of a 
PVM [16,17,18,19]. By forming the PV with a parasitophorous vacuole membrane 
(PVM), the sporozoite creates a homeostatic environment and shields itself from 
the interior of the hepatocyte. The proper formation and subsequent modification 
of the PV and PVM are considered essential for development and survival of the 
intrahepatic parasites [20]. At very low frequencies however, Plasmodium can 
develop in the nucleus of the hepatocyte, in the absence of an apparent PVM [21,22]. These parasites are thought to enter the cell through migration, and start nuclear replication following an arrest inside the hepatocyte nucleus, thereby using the 
nuclear envelope as a surrogate for the PVM. Nonetheless, contrary to the parasites 
residing in the cytosol, these intranuclear parasites seem unable to fully develop into blood stage parasites [22]. 
Besides an extensive manipulation of the hepatocyte, allowing for parasite growth 
and an uptake of host nutrients, the invaded sporozoite prohibits the infected 
hepatocyte to undergo a programmed cell death [12]. The invaded sporozoite 
undergoes nuclear replication and in a period of days (e.g 48-52 hours for P. 
berghei and 5-7 days for P. falciparum) the sporozoites fully develop into mature 
liver schizonts. These mature liver schizonts contain tens of thousands of infectious merozoites, which are released into the bloodstream as merosomes, each containing 100-200 merozoites [23]. Merosomes bud from the infected hepatocyte, exit the 
liver, survive the subsequent passage through the right heart and accumulate in the 
lungs. Here the merosomes burst in the pulmonary capillaries with the subsequent 
liberation of merozoites into the bloodstream. These merozoites now invade erythrocytes thereby entering the blood stage of the Plasmodium life cycle. 
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In the blood stage, parasites rapidly multiply and invade new erythrocytes. A small proportion of the blood stage parasites undergoes sexual differentiation and matures into male or female gametocytes. These gametocytes may be taken up in the blood meal of a new mosquito, where in the female mosquito midgut male and female gamets fuse to form an ookinete. 
Figure 1: Plasmodium sporozoite and liver stage biology.    Sporozoites are injected by a female Anopheles mosquito (1). They start migrating through the dermis 
(2) and enter the blood capillary (2), the lymphatic system (3), or they start (incomplete) development 
in the skin (4). Once inside the blood vessel, sporozoites are rapidly distributed through the blood 
circulation (5). In the liver, sporozoites adhere to the endothelial cells (6) and cross the sinusoidal barrier 
by transmigrating through Kupffer cells (7). The parasites now actively traverse through a number of 
hepatocytes (8), before invading a final hepatocyte by the formation of a PV (9). Inside the PV, sporozoites 
rapidly transform into round early liver stages (10). Intrahepatic parasites commence cell division 
resulting in merozoite formation in a process called schizogony (11). Infectious merozoites are released 
as membrane-shielded merosomes (12), which are transported away (13) and eventually rupture in the 
lung microvasculature. (Reprinted from [49] with permission of Elsevier )
After invasion of the midgut wall these ookinetes form oocyst. Inside the oocyst, sporozoites are formed and when the oocyst bursts after a number of days, the 
sporozoites migrate through the hemacoel to the salivary glands. The infectious sporozoites can re-infect another host after the mosquito takes a blood meal thereby completing the Plasmodium life cycle.
The fight against malaria: Rationale for a pre-erythrocytic 
malaria vaccineThere are many ways in which malaria and its disease burden can be combated. 
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Vector control is a primary intervention for the reduction of malaria transmission. 
While impregnated bednets and indoor spraying are effective there is an increasing resistance of mosquitoes to insecticides, particularly in Africa [2]. Resistance has 
also been observed to the currently available anti-malarial drugs [24], and at present 
new drugs in advanced stages of development are scarce [24]. An effective malaria 
vaccine is needed to support malaria control and eradication.
In this thesis we focus on the development of a pre-erythrocytic malaria vaccine, 
effective against the parasite’s sporozoite and liver stage. Vaccines directed against 
the parasite’s liver stage might have some theoretical advantages over vaccines 
directed against the pathogenic erythrocytic stage. Firstly, in the liver stage the number of parasites and infected host cells is low compared to erythrocytic stages. 
Moreover, the liver stage is clinically silent and as such, provides a relatively large 
time window for an effective immune response against the parasites [25,26]. 
Vaccines directed against the erythrocytic stage have a much shorter time window to 
act. Finally, antigenic polymorphisms might be limited during the liver stage [26,27].
To date, the most advanced vaccine candidate is a subunit vaccine based on the 
immunogenicity of the sporozoite and early liver stage CSP, GlaxosmithKline’s 
RTS,S. It is currently in phase III clinical development and has shown 30-50% 
clinical protection in a number of clinical trials [28,29,30]. While promising, a pre-
erythrocytic vaccine with a (much) higher protective efficacy would be preferred. 
The Malaria Vaccine Technology Roadmap has set ambitious goals, aiming to develop 
and license a malaria vaccine with more than 80% protective efficacy against clinical disease that lasts longer than four years, by the year 2025 [31]. 
Attenuated sporozoites: a promising vaccine approach.
The identification of CSP as potential vaccine candidate followed the observation by 
Ruth Nussenzweig over 40 years ago, that immunization of mice with live irradiated sporozoites resulted in protection from a sporozoite challenge [32,33]. This whole 
organism vaccine approach with irradiated sporozoites, from now on referred to as Radiation Attenuated Sporozoites (RAS), held promise and the bite of human 
volunteers by 1000 P. falciparum infected, irradiated Anopheles stephensi mosquitoes 
protected from subsequent challenge [34]. The >80 % protection achieved in these 
human volunteers was much higher than the 30-50 % protection achieved by immunization with RTS,S and can potentially meet the  goals set by The Malaria 
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Vaccine Technology Roadmap [32]. 
While promising, several issues have been raised with respect to the safety of RAS 
immunization. First under-radiated sporozoites are able to complete liver stage 
development and cause a blood-stage parasitemia. Second, over-radiation inactivates 
sporozoites  by limiting the efficiency to invade hepatocytes and transform into 
liver stage parasites, resulting in poor protection against malaria [35]. Based 
on the success of RAS immunizations, several distinct whole sporozoite vaccine 
approaches have been pursued. Using the DNA sequence-specific alkylating agent centamycin, sporozoites were chemically attenuated (CAS) which were then used to 
efficaciously immunize mice [36,37]. However, much like for RAS a major theoretical 
disadvantage of this immunization protocol is  formed by the need for a correct dose 
of centamycin to obtain adequate attenuation. Another sporozoite vaccine approach consists of the inoculation of life sporozoites concomitantly with the anti-malarial 
drug chloroquine (CQ). Chloroquine is a potent malaria schizonticide that efficiently 
eliminates erythrocytic parasites. Immunization of mice with sporozoites under 
chemoprofylactic coverage (CPS) protects against a subsequent sporozoite challenge 
[38,39]. More importantly, in men, CPS immunization leads to protection in more 
than 90% of the volunteers [40] for a period of up to 28 months [41]. Despite this 
unambiguous success, it might be difficult to translate the CPS approach to the field. 
Following CPS immunization, blood stage parasites are formed and the clearance of these parasites is reliant on the effect of chloroquine. The absence of the onset of a pathogenic blood stage infection is therefore dependant on the (pharmacokinetic) 
uptake and metabolism of chloroquine presenting obvious potential safety risks.  An immunization approach that does not rely on the external attenuation of 
sporozoites or the metabolic killing of parasites is the Genetically Attenuated Parasite 
(GAP) approach. Through targeted deletion of genes or a combination of genes, live 
sporozoites are made to arrest in the liver. These parasites form a homogenous mutant population and are therefore not troubled with the restrictions of RAS, CAS and CPS. 
Genetically attenuated parasites 
The GAP approach started with the nearly simultaneous observation by independent 
laboratories that mutant parasites, deleted of a specific gene, arrested specifically 
in the liver stage [17,42]. A number of GAP with distinct gene deletions have been 
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described which, following immunization protected mice against challenge. Most 
GAP, including ∆p52, ∆p36, ∆uis3 and ∆uis4 mutant parasites arrest at early liver 
stage and are likely involved in the formation or maintenance of the PVM [17,42,43]. 
Other gene deletion mutants like P. berghei ∆slarp, and its P. yoelii orthologue ∆sap1 
are involved in the (post-)transcriptional regulation of sporozoites and early liver stages [44,45,46]. The ∆fabb/f parasite arrests in late liver stage, due to a defect in 
the type II fatty acid synthesis pathway [47].
Despite the apparent abundance of GAP vaccine candidates it has been difficult 
to directly translate findings in mice and generate a safe and protective GAP in 
P. falciparum. For instance, unequivocal orthologs for the two rodent uis-genes are absent in the P. falciparum genome (www.PlasmoDB.org). Moreover, the 
developmental arrest of ∆p52 and the ∆p36 parasites was incomplete and low 
numbers of parasites maturated in the liver, resulting in a blood stage infection in 
mice [17,18]. 
Requisites for an effective and safe GAP vaccine
Ultimately, immunization with GAP has to be safe and lead to protection against 
challenge. Moreover, sporozoites have to be administered in a manner suitable for 
human immunization (e.g not by mosquito bite or by intravenous injection). These 
criteria are schematically visualized in Figure 2. 
The first challenge will be to generate a safe GAP candidate (Figure 2, Challenge 
I). Some (murine) GAPs, like  ∆p52 partially develop into infectious merozoites in 
the liver and cause a blood stage infection. While GAPs based on the deletion of 
one individual gene, might not be fully safe (i.e lead to breakthrough blood stage 
infection), a GAP consisting of multiple gene deletions might be. At present, only the 
∆slarp/∆sap1 mutant parasites completely arrest in the liver of murine P. berghei and P. yoelii and a clear orthologue of the gene is present in P. falciparum. The ∆slarp 
GAP is therefore a potential safe candidate for a GAP vaccine.  However, there is 
controversy over the protective efficacy of these ∆slarp/∆sap1 parasites upon 
immunization [44,45,46]. Immunization of mice with P. berghei ∆slarp did not confer sterile long lasting protection, contrary to immunization with P. yoelii ∆sap1. In order 
to find a GAP that completely arrests in the liver stage and following immunization, 
confers long-lasting protection, one can i) combine known GAP candidates to one 
multiple attenuated GAP or ii) pursue new GAP candidates. 
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Here, we pursue new GAP candidates by selecting genes based on their high protein 
expression profiles in the sporozoite stage. Supposedly, these genes have a function 
in the (early) liver stage. The high efficiency of the transfection technology in the P. 
berghei model allows for a fast screening of potential GAP candidates. Once protective 
efficacy and GAP safety have been assessed in the P. berghei model a P. falciparum 
GAP consisting of the orthologue gene deletions can subsequently be generated.  
The effective delivery of GAP sporozoites for human immunization forms a next great 
obstacle in the clinial development of a GAP vaccine. Firstly, immunization with dead 
sporozoites is ineffective and has to be performed with live sporozoites that can 
be preserved (Figure 2, Challenge  II). In fact, for long the production of any whole 
sporozoite vaccine was not considered feasible based on mainly logistic reasons. It 
requires a standardized isolation, purification and (cryo-)preservation of parasites 
from mosquito salivary glands [50]. Specifically Sanaria Inc. (http://www.sanaria.
com), a company devoted to the generation of a whole sporozoite vaccine, has taken a lead and made much progress in tackling the problems associated with the production 
and the cryopreservation of a sporozoite vaccine [48]. Secondly, irrespective of the 
whole sporozoite vaccine approach (e.g CPS, RAS or GAP), live sporozoites need to 
be effectively administered by needle and syringe (Figure 2, Challenge III). While 
the immunization of mice with life sporozoites have thus far almost exclusively 
been performed by intravenous injection, nearly all human immunizations have 
been performed by infected mosquito bite. Intravenous injection of sporozoites 
and immunization by infectious mosquito bite are not preferred/feasible for immunization of large groups of people in Sub-Saharan Africa. Besides the generation 
of a safe and protective GAP it is therefore crucial to understand and optimize 
the route of sporozoite administration for further clinical vaccine development.
It is essential to have the correct tools so that both the safety of GAP candidates (i.e 
absence of development into blood stage)  and the fate of sporozoites subsequent 
to injection can be assessed. At the start of this thesis, a quantitative analysis of the 
liver stage of Plasmodium parasites was hampered by time consuming techniques 
like qRT-PCR and RNA hybridization or microscopy, which is often prone to a large 
variation between observers . Low levels of parasite liver infection in vivo in laboratory animals and in vitro in cultured hepatocytes further complicated the quantification.
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Figure 2: Challenges of whole sporozoite vaccination.       
Schematic of challenges that need to be overcome for the generation of a whole sporozoite malaria 
vaccine. GAP parasites have to be safe, indicating that they must fully arrest in the liver stage and not 
develop into the pathogenic blood stage (Challenge I). Secondly, the sporozoites need to be purified and 
cryopreserved so that they can be administered by needle and syringe (Challenge II). A large percentage 
of the sporozoites might not be viable after cryopreservation. A third challenge (Challenge III) will be to administer the sporozoites by needle and syringe so that the sporozoites enter the circulation. 
Irrespective of the whole sporozoite vaccine approach (e.g CPS, RAS or GAP) parasites will need to be 
cryopreserved and administered by needle and syringe. (Adapted from [50] with permission of Elsevier).
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Aims
At the outset, this thesis aims to develop the tools for the simple and sensitive 
quantification of liver stage parasites in a murine model. These tools are instrumental 
in the quest for a GAP vaccine approach that meets the requisites for further clinical 
development.
The first objective is to develop and characterize a GAP that fully arrests in the 
liver stage and induces long-lived protection in the murine P. berghei model. The 
quantification of liver stage parasites will be a practical tool in the assessment of 
murine GAP safety. Once safe and fully protective, a P. falciparum GAP consisting 
of the orthologue gene deletions can be considered to serve as a pre-erythrocytic 
malaria vaccine candidate in humans.
The second objective is to decipher the role of the route of sporozoite immunization 
(e.g intravenous or intradermal) on the protective outcome. We further aim to optimize the administration of sporozoites in a P. berghei model to improve the levels 
of conferred protection. These results can possibly be used to advance the current 
knowledge of the efficient administration of sporozoites, essential for further clinical 
vaccine development of an attenuated P. falciparum sporozoite vaccine. 
Thesis outlineThe work described in this thesis can be grouped into three sections. 
Section 1. Characterization and evaluation of luciferase expressing parasites 
in the P. berghei liver stage.
In this section we characterize and evaluate the use of luciferase expressing parasites for the real-time in vivo and in vitro imaging of parasite liver load. In 
Chapter 2 we report the use of a transgenic P. berghei parasite, PbGFP-Luccon, 
expressing the bioluminescent reporter protein luciferase to visualize and quantify 
parasite development in liver cells both in culture and in live mice using real-time 
luminescence imaging. In Chapter 3 we describe the use of these PbGFP-Luccon 
parasites for the evaluation of immunity against malaria. 
Section 2. Assessment of GAP attenuation and protective efficacy.
In this section we explore different GAP vaccine candidates for their level of 
attenuation and protective efficacy. For this, we use the luminescent P. berghei parasites characterized in section 1. Chapter 4 describes the lack of complete 
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attenuation of two leading GAP, ∆p52+p36 and ∆fabb/f parasites. In Chapter 5 
we study the phenotype of developing intrahepatic ∆p52+p36 P. berghei parasites 
and describe a non-conventional pathway, by which these parasites are capable of maturing into asexual parasites. Chapter 6 describes the  generation and 
characterization of a new GAP vaccine candidate, ∆b9. Moreover, it reports on the 
safety and the protective efficacy of a multiple attenuated GAP, ∆b9∆slarp.  
Section 3.  Inoculation of whole sporozoites. 
In this section we focus on the route of sporozoite inoculation and its effect on 
protective efficacy. These studies are important in the light of a potential future 
human whole sporozoite vaccine. In Chapter 7 we study the protective efficacy of 
intradermal (ID) and intravenous (IV) RAS and CPS sporozoite immunization and 
its relation to the parasite liver load following either route. Moreover we assess 
both the humoral and cellular immune responses in ID and IV immunized mice. In 
Chapter 8 we explore alternative routes of sporozoite administration to increase 
efficiency of liver infection. By a stepwise selection process we study the effects of 
route of administration, number of injections and location and volume of sporozoite 
injection on subsequent parasite liver load.
In conclusion, we will summarize and discuss the data from the above sections in 
Chapter 9.
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Abstract
The quantitative analysis of Plasmodium development in the liver in laboratory animals in cultured cells is hampered by low parasite infection rates and the complicated 
methods required to monitor intracellular development. As a consequence, this important phase of the parasite’s life cycle has been poorly studied compared to 
blood stages, for example in screening anti-malarial drugs. Here we report the use of a transgenic P. berghei parasite, PbGFP-Luccon, expressing the bioluminescent 
reporter protein luciferase to visualize and quantify parasite development in liver 
cells both in culture and in live mice using real-time luminescence imaging. The 
reporter-parasite based quantification in cultured hepatocytes by real-time imaging 
or using a microplate reader correlates very well with established quantitative 
RT-PCR methods. For the first time the liver stage of Plasmodium is visualized in 
whole bodies of live mice and we were able to discriminate as few as 1–5 infected 
hepatocytes per liver in mice using 2D-imaging and to identify individual infected 
hepatocytes by 3D-imaging. The analysis of liver infections by whole body imaging 
shows a good correlation with quantitative RT-PCR analysis of extracted livers. The 
luminescence-based analysis of the effects of various drugs on in vitro hepatocyte 
infection shows that this method can effectively be used for in vitro screening of compounds targeting Plasmodium liver stages. Furthermore, by analysing the effect of primaquine and tafenoquine in vivo we demonstrate the applicability of real-time 
imaging to assess parasite drug sensitivity in the liver. The simplicity and speed of 
quantitative analysis of liver stage development by real-time imaging compared to 
the PCR methodologies, as well as the possibility to analyse liver development in 
live mice without surgery, opens up new possibilities for research on Plasmodium 
liver infections and for validating the effect of drugs and vaccines on the liver stage of Plasmodium.
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Introduction
Malaria remains a major cause of global morbidity and mortality. New anti-malarial drugs are urgently needed, especially with the increase in drug resistant 
parasites and the lack of effective vaccines and vector control measures [1–4]. 
The main site for intracellular development of human and rodent Plasmodium 
sporozoites after they are injected by an infected mosquito is the liver. This stage 
of the parasite’s development is clinically silent and therefore regarded as an ideal 
point of intervention for prophylactic or vaccine strategies [5–7]. The liver stage of Plasmodium’s life cycle has also received particular attention in the context of P. 
vivax, the second most important agent of human malaria, which can generate cryptic 
forms called hypnozoites that persist in the liver for long periods of time [8–10]. These dormant forms of the parasite are responsible for what is termed relapsing 
malaria, which may occur following latent periods of months or even years without 
new infection [10-11]. In comparison with drugs that kill blood stage parasites, only 
a limited number of drugs exist that act on liver stages; most notable amongst these 
are primaquine, atovaquone and tafenoquine [12-13], and only primaquine [14-15] has been shown to act on the hypnozoite stage of P. vivax [14-15]. Clearly, the 
development of new inhibitors/drugs against the malaria liver stage would target 
an important and under-exploited site of intervention [1,16].
Quantitative analysis of liver stage Plasmodium development both in vivo in laboratory rodents and in vitro in cultured liver cells is hampered by the low levels of parasite infection and by the complicated methods required to monitor parasite 
development. As a consequence, the development of novel and efficient methods for 
analysing/screening the effect of drugs and small molecule inhibitors on the parasite’s 
intracellular growth in the liver lags well behind the more rapid developments being 
made in the automated drug/inhibitor screening assays for blood stage parasites 
[17–20]. Currently, one of the standard ways to assess drug efficacy against liver stages is to monitor in vitro liver stage development by quantitative RT-PCR (qRT-
PCR) methods [21-25] that are time consuming and expensive. Other studies have 
involved direct quantification and viability of parasite development by microscopy 
[26,27], RNA hybridization [28], or infrared fluorescence scanning system  However, 
these methods are not only prone to large variations between observers but are also 
time consuming given the very low infection rates (generally less than 2%) observed 
in cultured hepatocytes [29]. Moreover, simple and efficient methods for analysing in 
vivo liver stage development in small laboratory animals are completely absent. The 
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recent generation of new transgenic rodent malaria parasites expressing fluorescent reporter proteins has enabled an intimate analysis of Plasmodium sporozoites 
interacting with host hepatocytes during invasion and subsequent development inside hepatocytes, both in vitro and in vivo [30-34]. Recently, GFP-expressing 
parasites have been used in conjunction with flow cytometry to provide quantitative 
information on the parasites development in hepatic cells [35]. However, the use 
of fluorescent parasites in in vivo analysis of Plasmodium liver stage development 
requires complex surgery and when such parasites are used in conjunction with flow cytometry, their usefulness is presently restricted to in vitro and ex vivo analyses.
We have previously reported the use of transgenic P. berghei parasites expressing the bioluminescent reporter protein, luciferase, to examine the distribution and 
development of sequestering blood stage parasites in live animals using real-
time imaging [36-37]. Recently, we have also shown the effectiveness of such 
bioluminescent reporter parasites in simple and sensitive microplate reader assays for screening of drugs against blood stage parasites both in vitro and in vivo in 
rodents [19]. For these assays we generated a transgenic P. berghei parasite line 
that expresses a luciferase-GFP fusion protein and is free of a drug-selectable-
marker [38]. In the study described here, we utilised the luminescent properties of this reporter parasite, PbGFP-Luccon, to analyse liver stage development by real-
time imaging both in cultured hepatocytes and within the liver of living mice. We established that the changes in bioluminescence are directly proportional to the 
level of hepatocyte infection in vitro and in vivo, determined by comparison with 
standard qRT-PCR methodologies. As the liver parasite infection progresses real-time in vivo imaging allows the identification of individual infected hepatocytes in 
living animals. We demonstrated the application of the technique for the in vitro 
screening of compounds targeting the liver stage and the use of real-time imaging to determine in vivo drug sensitivity of liver stages through analysis of the effect 
of primaquine. Importantly, bioluminescence imaging also allows the course of an 
infection to be monitored, both throughout liver stage parasite development and 
in the blood stage of infection without sacrificing the animal, and therefore, can greatly reduce the number of experimental animals required to determine drug 
sensitivity. Since bioluminescence imaging is relatively simple to execute, the use of the methodologies described in this paper will greatly simplify the analysis of drug 
toxicity and small molecule inhibition on liver stage parasite growth.
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Material and Methods 
     
Experimental animals        
Female C57BL/6 and Swiss CD1 mice, 6–8 weeks old (Charles River), weighing 20 to 35 g 
at the time of primary infection and female Wistar rats (Harlan; 175–200 g) were used. All 
studies in which animals were involved have been performed according to the regulations of 
the Dutch “Animal On Experimentation act” and the European guidelines 86/609/EEG.
Transgenic parasite line        The transgenic P. berghei line 676m1cl1 line (PbGFP-Luccon) has been used in this study 
(mutant RMgm-29 in www.pberghei.eu). It expresses a fusion GFP (mutant 3) and firefly 
luciferase (LucIAV) and has been generated in the reference clone of ANKA strain cl15cy1 
[38]. Parasites of line 676m1cl1 contain the PbGFP-Luc gene fusion stably integrated as a 
single copy gene by double cross over recombination into the 230p locus and the reporter 
gene is under control of the constitutive eef1α promoter [39]. This line has been selected by 
FACS-sorting of GFP-expressing parasites and therefore does not contain a drug-selectable marker. This line can be obtained from the Malaria Research and Reference Reagent Resource Center, MR4 (www.malaria.mr4.org).                               
Collection of sporozoites       
Anopheles stephensi mosquitoes were infected by feeding on infected mice using standard 
methods of mosquito infection. On day 21–28 after infection, the salivary glands of the 
mosquitoes were collected by hand-dissection. Salivary glands were collected in DMEM 
(Dulbecco’s Modified Eagle Medium from GIBCO) and homogenized in a home-made glass grinder. The free sporozoites were counted in a Bürker-Türk counting chamber using phase-contrast microscopy.                 
Sporozoites traversal and gliding       
Traversal assays were performed as described previously [40]. Briefly, Huh7 cells were plated in 24 well plates (104 cells/ml) and an equivalent number of sporozoites was added 
to the wells with the addition of FITC labeled dextran (Invitrogen, NL). No sporozoites were 
added to the negative control wells that were used as threshold for the FACS analysis. FACS analysis was performed on 25 000 cells per well (wells were prepared in triplicate) using a 
FACScalibur flowcytometer (Becton Dickinson, NL).     
Gliding assays were performed in precoated (3D11, 10 ug/ml) Labtek slides (Nunc, NL) and 2×104 sporozoites were added. After 30 minutes of incubation at 37°C sporozoites were fixed 
with 4% PFA and after washing with PBS, the sporozoites and the trails (‘gliding circles’) were 
stained with 3D11-Alexa 488 conjugated antibody (Dylight 488 antibody labelling kit; Thermo 
Scientific, NL). Slides were mounted with Fluoromount-G (SouthernBiotech, NL) and ‘gliding 
circles’ were analyzed using a Leica DMR fluorescence microscope at ×1000 magnification.
26
Chapter 2
In vitro development of liver stages in hepatocyte cultures                    
To measure the luciferase activity of liver stages in HepG2 cells, a total of 2×104 to 1.5×105 sporozoites were added to monolayers of 2×105 HepG2 cells (1 ml/well in 24 well plates) 
as described previously [41]. Cells were prepared in quadruplet wells. In several assays, 
Cytochalasin D (Sigma, NL) was added to the cells at a concentration of 10 µg/ml prior to 
addition of the sporozoites as described [42]. At different time points after invasion, 100 µl of 
cells were collected, transferred to 96-well plates and processed for imaging with the Lumina 
system (see below). Four hundred µl of the remaining cells were harvested and lysed with 
either 200 µl of RLT buffer (RNA easy kit, Quiagen, NL) or 200 µl of cell culture lysis reagent 
obtained from the Promega Luciferase Assay System Kit® (Promega, NL) and stored at −80°C until further analysis by qRT-PCR or bioluminescence with a microplate reader(see below). To 
measure the luciferase activity of liver stages in Huh7 cells a total of 5×103 to 7×104 sporozoites 
were added to triplicate wells containing monolayers of 7×104 Huh7 cells (400 µl/well in 24 
well plates) as previously described [35]. At different time points after sporozoite addition, 
cells were harvested and lysed with either 150 µl of qRT-PCR buffer (RNA easy kit, Quiagen, 
NL) or 100 µl of cell culture lysis reagent obtained from the Promega Luciferase Assay System Kit® (Promega, PT). Samples in Promega lysis buffer were either stored at −80°C or processed 
immediately to measure luminescence intensity with the Lumina system (see below) or bioluminescence analysis by microplate reader (see below) and qRT-PCR samples were 
stored at −80°C until further analysis by qRT-PCR analysis (see below).            
Real-time measurements of bioluminescence of in vitro cultured liver stages using 
the Lumina system        The in vivo imaging system Lumina (Caliper Life Sciences, USA) was used to measure 
luciferase activity of infected HepG2 and Huh7 cells. Imaging data were analysed using the 
Living Image® 3.0 software (Caliper Life Sciences, USA). For the infected HepG2 cells, 100 µl of 
Assay Substrate (Promega Luciferase Assay System Kit®) were added to 100 µl of hepatocyte 
cultures collected in 96-well plates (see above) and bioluminescence images were acquired 
with a 12,5 cm field of view (FOV), medium binning factor and an exposure time of 1 to 3 
minutes. For infected Huh7 cells, 70 µl of Luciferase Assay Substrate (Promega Luciferase Assay System Kit®) were added to 20 µl of lysed hepatocyte cultures in black 96-well plates. 
Bioluminescence images were acquired with a 12,5 cm FOV, medium binning factor and an exposure time of 5 minutes.                            
Bioluminescence measurements of in vitro cultured liver stages using a microplate 
reader (luminometer)        
For infected HepG2 cells, 100 µl of Luciferase Assay Substrate (Promega Luciferase Assay System Kit®) were added to 10 µl of lysed parasite samples in 96-well plates. Luminescence spectra of the samples were measured using a microplate reader (Wallac 1420 multilabel 
counter, PerkinElmer, NL) and the light reaction of each well was measured for 10 s. 
Measurements of luciferase activity are expressed as relative luminescence units (RLU). For 
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infected Huh7 cells, 75 µl of Luciferase Assay Substrate (Promega Luciferase Assay System Kit®) were added to 15 µl of lysed parasite samples in white 96-well plates. Luminescence 
intensity of the samples was measured using a microplate reader (Tecan, CH) and the light 
reaction of each well was measured for 5 seconds. Measurements of luciferase activity are 
expressed as relative luminescence units (RLU).               
In vivo development of liver stages in mice     
Mice were inoculated with sporozoites by i.v. injection of 1×103, 1×104, 5×104 or 1×105 
purified sporozoites or by mosquito bite (5–10 infected mosquitoes per mouse) at day 20–22 
after the infectious blood meal. Blood stage infections were monitored by analysis of Giemsa-
stained blood smears of tail blood collected on day 4–10 after inoculation of sporozoites or infection by mosquito bite.                  
Real-time in vivo imaging of liver stage development in whole bodies of live mice 
or in dissected livers        
Luciferase activity in animals was visualized through imaging of whole bodies or of dissected 
livers using the in vivo Imaging System (IVIS 100 and Spectrum; Caliper Life Sciences, USA) 
as described in Franke-Fayard et al. [37]. Animals were anesthetized using the isofluorane-
anesthesia system (XGI-8, Caliper Life Sciences, USA), their belly was shaved and D-luciferin 
dissolved in PBS (100 mg/kg; Synchem Laborgemeinschaft OHG, Germany) was injected subcutaneously (in the neck). Animals were kept anesthetized during the measurements, which were performed within 3 to 5 minutes after the injection of D-luciferin. Bioluminescence 
imaging was acquired with a 10 cm FOV, medium binning factor and an exposure time of 10 to 
180 seconds. Luciferase activity in individual livers was visualized in whole organs dissected 
44 h after sporozoite injection or mosquito bite. Livers were obtained by dissection of animals 
2 to 3 min after a second intravenous injection of D-luciferin (in the tail vein; 100 mg/kg). 
Livers were placed in Petri-dishes or on black tape to minimize light interference from plastic 
Petri-dishes. Dissected livers were imaged with a 10 cm FOV, medium binning factor and an 
exposure time of 60 to 180 seconds. Imaging data were analysed using the Living Image® 3.0 
(Caliper Life Sciences, USA) software. Quantitative analysis of bioluminescence of whole 
bodies or dissected livers was performed by measuring the luminescence signal intensity 
using the ROI settings of the Living Image® 3.0 software. The ROI was set to measure either 
the abdominal area at the location of the liver for whole body imaging or the complete livers in 
the case of dissected livers. ROI measurements are expressed in total flux of photons. 
For the 3D imaging of luciferase activity in live mice, the in vivo imaging system IVIS® 3D 
(Caliper Life Sciences, USA) was used as described [43-45]. The IVIS® 3D performs rotational 
axis imaging of the bioluminescent light sources within a living animal. The IVIS 3D acquires 
eight imaging views about the longitudinal axis of the animal at 3 different wavelengths: 580, 
600 and 620 nm. At each angle view, the animal height or surface topography is determined and stitched together to generate the whole 3D map of the animal. The 3D diffuse tomography 
software (Living Image TM) is used to reconstruct the eight bioluminescent images resulting in 
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data on in vivo source brightness, location, and size of the infection. Exposure time was of 60 
seconds for each angle of measurements. A digital female mouse atlas was overlaid onto the 3D diffuse tomography reconstruction to obtain anatomical reference points. This feature is 
included in the Living Image Software 3D Analysis Package. The liver was removed from the 3D 
reconstruction of the mouse organs to better visualize the bioluminescence signals.           
Analysis of in vitro development of liver stages in hepatocyte cultures and in 
extracted livers by qRT-PCR                                                                         
RNA was extracted from hepatocyte culture samples collected in 200 µl (HepG2) or 150 
µl (Huh7) of qRT-PCR buffer (see above) with Quiagen’s MicroRNeasy kit following the 
manufacturer’s instructions. The transcriptor first-strand cDNA synthesis kit (Roche) was 
used according to the manufacturer’s recommendations to make single-stranded cDNA. RNA 
was extracted from livers collected at 44 h after infection and homogenized in RLT buffer 
(DNA/RNA Quiagen extraction kit) supplemented with 0,07% β-mercaptoethanol and stored 
at −80°C till qRT-PCR analysis. The RNA samples were further processed as described above for the samples of the hepatocyte cultures.           
Real-time PCR analysis of specific P. berghei parasite 18S rRNA and β actin mouse (HepG2 
invasion) or Hypoxanthine Guanine Phosphoribosyl Transferase (HPRT; Huh7 invasion and 
whole infected livers) housekeeping genes was done according to [21,35]. Standardization 
was done by multiplying the value of each sample with a correction factor. This correction 
factor is the maximum value for the housekeeping genes found for all samples divided by the 
value of this gene obtained for the sample).               
Analysis of drug-inhibition of in vitro liver stage development   
For the analysis of inhibition of in vitro liver stage development by drugs, 3×104 sporozoites 
were added to monolayers of 7×104 Huh7 cells (400 µl/well) in 24 well plates as described 
above. Five drugs that are known to inhibit liver stage development were used to test the 
drug susceptibility: primaquine (primaquine diphosphate 98%, Aldrich, NL); tafenoquine 
(GlaxoSmithKline, UK); genistein [25]; lopinavir [24] and saquionovir [24]). Primaquine 
was dissolved in water to a final stock solution of 100 µM and serial dilutions with complete 
culture medium were prepared ranging from 1 µM to 100 µM. Tafenoquine was dissolved in 
ethanol to a final stock concentration of 100 µM and serial dilutions were prepared ranging 
from 0,3 to 30 µM. Genistein, lopinavir and saquinavir were dissolved in water to a final stock 
concentration of 100 µM, 100 µM and 25 µM, respectively. Serial dilutions with complete 
culture medium were prepared, ranging from 10 to 100 µM for genistein and 2,5 to 40 µM 
for lopinavir and saquinovir. Huh7 cells were incubated with different concentrations of the drugs in triplicate wells by replacing the culture medium with drug-containing medium prior 
to sporozoite addition. Forty-six hours after adding the sporozoites, the infected Huh7 cells 
were harvested and lysed with 100 µl of cell culture lysis reagent obtained from the Promega 
Luciferase Assay System Kit®. Seventy-five µl of Luciferase Assay Substrate (Promega 
Luciferase Assay System Kit®) were added to 15 µl of lysed parasite samples in white 96-well 
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plates. Luminescence spectra of the samples were measured using a microplate reader (Tecan, 
CH) and the light reaction of a sample of each well is measured for 5 seconds. Measurements 
of luciferase activity are expressed as relative luminescence units (RLU).           
Analysis of the inhibition of in vivo liver stage development by primaquine and 
tafenoquine                         
Mice were treated with primaquine (primaquine diphosphate 98%, Aldrich, NL) and 
tafenoquine (GlaxoSmithKline, UK) once at day −1, twice on the day of infection (day 0; 5 hours 
before and after infection) and once the following day (day +1; 19 h and 29 h after infection). 
Both primaquine and tafenoquine were dissolved in distilled water and administered 
subcutaneously with concentrations ranging from 1–40 mg/kg body weight and 10 and 20 
mg/kg body weight respectively. Mice were infected at day 0 by the bite of 5–10 mosquitoes, 
as described above. In vivo imaging was performed at 44 hours after infection as described 
above. At day 6 – 9 after infection, the same mice were analysed for blood stage infections by 
determination of the course of parasitemia in Giemsa stained thin blood films of tail blood. 
         
Growth inhibitory curves and statistical analysis     
The two tailed analysis using the Spearman’s rho test of the SPSS 16 software (SPSS Inc., 
USA) was used for statistical analysis. Correlation coefficients were determined using the 
two-tailed Spearman’s rho test for non-parametric analysis of small data set. qRT-PCR curves 
were drawn using the GraphPad Prism software (GraphPad Prism, Inc., US). p values were 
calculated using the same GraphPad Prism software. The non-linear regression function 
for sigmoidal dose-response (variable slope) of the GraphPad Prism software was used to 
calculate the (best-fit) effective concentration (EC50) values.              
Results
Analysis of PbGFP-Luccon liver stage development in vitro   
For the analysis of liver stage development we used a transgenic P. berghei parasite, 
PbGFP-Luccon (line 676m1cl1), which expresses a reporter fusion gene of gfp and luciferase, stably integrated in the 230p locus (PB000423.03.0) of the P. berghei genome. PbGFP-Luccon parasites do not contain a drug-resistance marker as they 
were selected by FACS sorting of transfected GFP-positive blood stages immediately 
after the transfection procedure [38]. The gfp-luciferase transgene in PbGFP-Luccon is under the control of the P. berghei eef1a promoter. Through the analysis of GFP 
expression we have previously demonstrated that the eef1a promoter drives 
constitutive and strong gene expression in all life cycle stages, including liver stage 
parasites [39]. The blood and mosquito stages of PbGFP-Luccon show similar growth characteristics as those of the parent reference line, cl15cy1 of P. berghei ANKA 
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(data not shown). Analysis of sporozoite motility, cell traversal and in vitro and in 
vivo infectivity demonstrated that all features of PbGFP-Luccon sporozoites were 
comparable to those of wildtype sporozoites (Figure S1).   
To determine the timing and level of luciferase expression of PbGFP-Luccon throughout 
development of liver stages in vitro, two hepatoma cell lines, HepG2 and Huh7, were infected with different numbers of sporozoites, ranging from 5×103 to 1.5×105, in 
24-well plates. The time course of luciferase expression during the first 48 hours 
of development is shown in Figures 1A&B and S2A&B. The luminescence intensity 
(luciferase activity) was measured by (a) direct imaging of the culture plates of live 
or lysed cells using the Lumina system (the luminescence intensity expressed as photons per second) or by (b) analysis of lysed cell samples in a microplate reader 
(luminescence intensity expressed as Relative Light Units, RLU). Both methods show 
a strong increase in luciferase activity throughout the 48 h period during which the 
invaded sporozoites develop into liver schizonts. The increase in reporter protein 
expression during trophozoite and schizont development is expected as a similar increase in eef1a based expression of luciferase or GFP is observed in blood stage 
trophozoites and schizonts [19,36]. Uninfected control cells showed low photon 
counts and luminescence values are significantly lower than those of infected cells at any of the time points assessed. The mean photon counts were 3×106 p/s (sd 2×106) and 5×104 p/s (sd 1×103) and the mean RLU values were 56 (sd 17) and 
30 (sd 15) for HepG2 and Huh7 cells respectively. Sporozoites contain low levels of 
the GFP-Luciferase protein as shown by analysis of GFP expression by fluorescence-
microscopy (data not shown) and therefore low bioluminescence levels at 4–5 h 
might be derived from invaded sporozoites. A strong increase in luminescence 
values is observed after 24–30 h which correlates with the development of the liver 
trophozoite into the schizont stage. For further quantitative analyses of liver stage 
development we compared luminescence levels of samples taken at time points 
between 30 and 48 h after sporozoite incubation.
Luminescence intensities at 30 and 48 h correlate well with the number of sporozoites added to the hepatocytes in the range of 5×103 to 1×105, using both the 
Lumina and the microplate reader (Figure 1C, S2A-C). When using as few as 5×103 
sporozoites a clear luminescent signal is obtained that is significantly higher than the background signal detected in uninfected wells (p=00,1). We then compared the 
relative luminescence intensities of cells infected with different sporozoite numbers 
with the relative amounts of parasite 18S ribosomal RNA using standard qRT-PCR 
methodologies (Figures 1D, S2D). A good correlation was observed between the
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Figure 1: Analysis of in vitro liver stage development by determination of luciferase expression.                     
A) Luminescence levels (photons/sec) during liver stage development of PbGFP-Luccon after infection of Huh7 cells with 
different numbers of sporozoites at 48 h (left panel) and at different time points after infection with 3×104 sporozoites 
(right panel) determined by direct imaging of samples using the Lumina system. Rainbow images show the relative 
levels of luminescence ranging from low (blue), to medium (green), to high (yellow/red). B) Luminescence levels 
during development of liver stages at different time points after invasion of Huh7 cells as measured by the Lumina 
system (Photons/sec) and a Tecan microplate reader (Relative light unit, RLU). C) Relationship between the numbers 
of sporozoites used to infect Huh7 hepatocyte cultures and the luminescence produced by the liver stages at 48 h after 
infection. Luminescence levels were determined by direct imaging of samples using the Lumina system (Photons/sec) 
and a Tecan microplate reader (RLU). D) Correlation between luminescence values as measured by the Lumina system and the Tecan microplate reader and of P. berghei 18S rRNA levels as determined by qRT-PCR of Huh7 cultures that 
are infected with different numbers of sporozoites. See Table S1 for the correlation coefficient data of the two-tailed Spearman’s rho test.
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relative luminescence intensities and the relative amounts of parasite 18S rRNA 
in the same cultures (Spearman correlation coefficient ranging from 0.61–0.94; Table S1).                   
Analysis of PbGFP-Luccon liver stage development in vivo   
To determine the timing and level of luminescence during PbGFP-Luccon development 
in the liver, groups of mice (n=4) were infected intravenously with different numbers of sporozoites ranging from 1×103 to 1×105. Luciferase activity in animals 
was visualized through the imaging of whole bodies at 5, 24, 35 and 44 hours after 
infection. In control, uninfected mice, luminescence values ranged between 1×107 and 4×107 p/s (sd 1×107). In mice infected with the highest dose of sporozoites (i.e. 1×105), 3 mice showed luminescence levels above background at 24 h (i.e. 1×108 
p/s (sd 3×107); see Figures 2A&B. Mice infected with 5×104 sporozoites showed a 
signal above background at 35 h. In all infected mice there was a strong increase 
in bioluminescence signal between 35 and 44 h (Figures 2C, S3), whereas between 
44 h and 52 h no further increase was observed and, indeed, in several mice the 
luminescence signal decreased between these time-points (Figure S4A). After 60 h, luminescence signals could be detected in the whole body, resulting from parasites 
that had invaded erythrocytes after the rupture of the liver schizonts (Figure S4A). 
The decrease in luminescence in the liver between 44 and 52 h may either be due 
to liver schizont rupture and the consequent reduction in the number of infected 
liver cells or is the results of decrease in luciferase expression in the final stages of 
schizont maturation. Such a decrease has been previously observed in erythrocytic 
schizonts where protein expression peaks in mature trophozoites/young schizonts and decreases in maturing schizont when the eef1a promoter is used to drive protein 
expression [36,39] and correlates with destruction of endogenous eef1a mRNA in 
schizonts [46]. Based on these observations, we decided to determine luminescence intensities at 44 h in subsequent experiments. At 44 h, a good correlation was 
observed between the luminescence intensity and the number of sporozoites 
initially injected  (Figures 2D&E). Specifically, the mean luminescence intensity ofmice infected with 1×103 sporozoites was 1×109 p/s (sd 4×108) and increased to 1×1010 p/s (sd 7×109) in mice infected with 1×104 sporozoites. 
After the whole body measurements, the livers of several of the mice from each group 
were dissected and imaged with the IVIS100 system. The luminescence intensity of 
the extracted livers was significantly lower than that of whole bodies (Figure 2C&D, 
S3). For example, livers from mice infected with 1×105 sporozoites had, on average, a 
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Figure 2: Analysis of in vivo liver stage development by determination of luciferase expression.  
A) Representative rainbow images of luminescence in livers of live mice at different time points after injection of 1×105 
sporozoites. Rainbow images show the relative levels of luminescence ranging from low (blue), to medium (green), 
to high (yellow/red). B) Luminescence levels (photons/sec) of livers in whole mice at different time points after infection with 1×105 sporozoites (n=4). Photon counts from whole body imaging are expressed as the percentage of 
the photon counts of mice at 44 h after infection (= RLU %). C) Distribution of luminescence signals in the livers of 
live mice and in extracted livers of the same mice at 44 h after infection with 1×103 (left) or 1×104 (right) sporozoites. 
D) Luminescence levels (photons/sec) of whole bodies and extracted livers of mice 44 h after inoculation of different numbers of sporozoites. Photon counts are expressed as the percentage of the photon counts of whole body of mice at 44 h infected with 105 sporozoites ( = RLU %). E) Correlation between luminescence values as measured by the Lumina 
system of whole body and dissected livers and of P. berghei 18S rRNA levels as determined by qRT-PCR of dissected livers that are infected with different numbers of sporozoites. The percentage of growth is normalized to the highest reading 
within each experiment. See Table S2 for the correlation coefficient data of the two-tailed Spearman’s rho test. F) The left panel shows the 3D-imaging of luminescence signals (3D tomography and source reconstruction) in a mouse at 44 
h after infection with 5 to 10 mosquito bites as measured with the IVIS 3D Series system. The brown/red spots (white 
arrows) indicate the origin of highest luminescence intensity in the body. These spots are located in the liver as shown by 
overlaying with a digital mouse atlas to obtain anatomical reference points. The right panel shows the same mouse and 
its extracted liver (imaged at both sides) imaged with the 2D-IVIS100 imaging system. Numbers in the images represent 
the number of luminescent spots identified. 
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ten-fold lower luminescence signal compared to whole body imaging (8×108 p/s, sd4×108; Figure 2D). The presence of clearly separated luminescent spots in dissected 
livers of mice infected with low numbers of sporozoites (1×103; Figure 2C,S3) 
indicates that these spots represent individual liver schizonts. Therefore, imaging of 
dissected livers may provide information on both the number and dissemination of 
parasites in the liver. When livers containing 3 to 13 individual spots were imaged, both sides often showed a comparable numbers of spots in a similar location 
(Figures S3B, S4B). However in each liver imaged, one or a few luminescent spots 
were only visible on one side of the liver, indicating that the imaging of these spots 
can be influenced by their localization, possibly due to a quenching effect of the liver. 
To better localize the origin of individual luminescent spots, we used the IVIS 3D 
Series system (Caliper Life Sciences, USA) to image luminescent signals in live mice 
in three dimensions. This instrument, in combination with the 3.1 Living Image® software, allows the precise localization of the origin of the luminescent signals in whole bodies in contrast to the more diffuse luminescence signals obtained with the 
IVIS100 2D-system. 3D-imaging of 4 infected mice in an anatomical context show the 
presence of clearly separated spots in the liver (Figures 2F and S5). The individual 
infected hepatocytes can be best visualized in the context of the whole liver when 
the mice are rotated as visualized in the Supplementary movies S1-S3 (online 
version of the paper). When the number of luminescent spots was determined 
by 2D-imaging in livers dissected after the 3D-imaging of the whole mice, a good correlation between the numbers of spots obtained with both methods was found. 
These observations indicate that 3D-imaging of whole bodies allows the detection of 
individual liver schizonts in live mice. However, like in 2D-imaging of isolated livers, some luminescent spots may be missed in the 3D-imaging, as shown in mouse 4 
Figure S5.       As described for the in vitro analysis of liver stage development, we compared the 
relative luminescence intensities of whole bodies and isolated livers measured at 44 
hpi with 18S ribosomal RNA qRT-PCR data derived from RNA extracted from the same 
livers. The relative luminescence intensities of whole bodies and dissected livers are 
in good agreement with the 18S rRNA qRT-PCR values (i.e. Spearman correlation 
coefficient ranging from 0.65 to 0.95; Figure 2E, Table S2). The best correlation is found between qRT-PCR and whole body imaging, possibly because of the decrease 
of luminescence during extraction of the livers as discussed above.   Rats (e.g. Sprague-Dawley, Wistar etc) as well as mice are frequently used to analyse 
liver stage development in the P. berghei model of malaria. We have performed a 
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limited number of experiments to investigate whether in vivo imaging of liver stage 
development in Wistar rats generates similar results to the in vivo imaging in mice 
(Figure S4B). In rats luminescence signals were detected at 24 h after infections had been initiated by mosquito bite with rapidly increasing luminescence intensities 
during the period of 24–30 h. Imaging of dissected livers from these rats also showed 
the same pattern of clearly separated luminescent spots (on both sides of the liver) 
as we had observed in extracted mouse livers (Figures 2C, S3).           
Analyses of drug-inhibition of PbGFP-Luccon liver stage development by 
luminescence measurements                                                                               
Having established that liver stage infection can be accurately and conveniently measured in vitro and in vivo by assessing the luminescence of PbGFP-Luccon-infected 
cells or mice livers, we decided to investigate the suitability of this method for the 
evaluation of anti-plasmodial drugs. The inhibition of in vitro development by drugs was determined by measurement of luminescence of PbGFP-Luccon-infected hepatoma cells maintained in 24-well plates and incubated with serial dilutions 
of five different drugs known to inhibit liver stage development (Figures 3A&B). 
Primaquine [47] tafenoquine [48] genistein [25], lopinavir [24] and saquinavir [24] were added to Huh7 cells 1 h before addition of Pb-GFP-Luccon sporozoites 
and luminescence was measured 44 h later with a microplate reader. In samples 
treated with the highest drug concentrations, known to completely block liver stage 
development, the luminescence values are low and almost identical to background 
ranging consistently from 20 to 350 RLU (mean of 104; sd 119). In contrast, in drug-
free control samples luminescence values ranged between 4×104 to 7×104 RLU (mean 5×104; sd 9×103) in the different experiments (Figures 3A&B). Primaquine’s 
IC50 value as determined by luminescence intensity correlated well with the 
value obtained by standard qRT-PCR methods (Figure 3A). Complete inhibition 
with primaquine and tafenoquine was observed at concentrations of 100 µM 
and 30 µM, respectively, which correspond to inhibitory concentrations reported in the literature for primaquine (2×10−7 to 5×10−5 M) and tafenoquine 3×10−7 M 
[23,47,49]. Genistein, lopinavir and saquinavir concentrations that inhibited liver 
stage development, quantified by the decrease in luminescence intensities are also 
in good agreement with previously reported inhibitory concentrations for these 
compounds that were determined by direct counting of liver stages or by qRT-PCR 
(Figure 3B)[24,25].
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Figure 3: Drug-inhibition of liver stage development determined by measurement of luciferase expression.            
A) Inhibition of in vitro liver stage development by primaquine (left panel) by measuring luminescence levels (RLU) 
in samples of Huh7 cells 44 h after infection of the cells with 3×104 PbGFP-Luccon sporozoites. The right panel shows 
the inhibition of liver stage development by primaquine as determined by both luminescence measurements and qRT-
qPCR analysis. The percentage of growth is defined by the RLU values and by the amounts of P. berghei 18S rRNA levels, 
respectively. Luminescence levels were measured using a Tecan microplate reader. B) Inhibition of in vitro liver stage 
development by tafenoquine, lopinavir, sanquinavir and genistein, as determined by measuring luciferase luminescence 
levels (RLU) in samples of Huh7-infected cells 44 h after infection of the cells with 3×104 PbGFP-Luccon sporozoites. 
Luminescence levels were measured using a microplate reader. C) Inhibition of in vivo liver stage development by 
primaquine and tafenoquine as determined by measuring luminescence levels (photons/sec) in live mice at 44 h after 
infection of the mice by the bite of 5 infected mosquitoes. Luminescence levels were determined by direct imaging of 
whole bodies using the IVIS100 system.
Analysis of in vivo inhibition of liver stage development by luminescence measurements was performed using primaquine and tafenoquine. Mice were treated 5 times with different doses of these drugs starting one day before infection 
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with PbGFP-Luccon and the last dose at 29 h after infection. Mice were infected by 
the bites of 5 infected mosquitoes and luminescence levels were determined 44 h 
later. Luminescence values of untreated, control mice, ranged between 2×108 and 2×109 p/s (mean 1×109; sd 5×108). No detectable luminescence signal was observed 
in mice treated with 10–40 mg/kg body weight of primaquine, indicating complete 
inhibition of parasite growth (Figure 3C). Indeed, analysis of these mice 5–9 days after infection showed no detectable parasites in peripheral blood, whereas control 
mice developed normal blood infections with parasitemias ranging between 0.1 
and 3% at day 4 post-infection. In mice treated with 1 and 5 mg/kg body weight of 
primaquine, 3 out of 6 mice showed a low level of luminescence ranging between 1×108 and 5×108 p/s (mean 3×108; sd 2×108) at 44 h while the remaining 3 mice 
were negative. Five of these mice developed a blood stage parasitemia that was 
delayed by two days compared to the control mice (parasitemia of 0,5 to 3% at day 
6 after infection), indicating a 100-fold inhibition of liver stage development. All 
mice treated with 10 or 20 mg/kg of tafenoquine were luminescence negative at 
44 h and did not develop blood stage infection (Figure 3C). The complete inhibition 
of liver stage development by primaquine and tafenoquine at doses of 10 mg/kg body weight and higher is in agreement with the inhibitory doses reported in the literature [25,50,51].         
Discussion 
         
Rodent malaria parasites are frequently used for the identification and 
characterization of new anti-malarial drugs [17-20,25,50,52-53]. These parasites 
are used in initial drug and small molecule inhibitor (SMI) screens in order to determine their in vivo anti-malarial activity in cultured cells and in mice. In 
comparison to the blood-stage parasite SMI screening assays [19] the screening 
and identification of agents that inhibit Plasmodium development in the liver is 
considerably more complex. Quantitative analysis of liver stage development both 
in cultured liver cells, in vitro, and in small laboratory animals, in vivo, is hampered 
by the low levels of parasite infection as well as the complicated, time consuming 
and expensive methods required to monitor parasite development, such as qRT-
PCR or direct counting of liver stages [21-23,26-27] and RNA hybridization [28-29] 
We have recently shown that transgenic rodent parasites expressing luciferase are 
useful reagents to determine parasite load and bio-distribution of blood stages in live mice using in vivo imaging [36,37]. We have also used these parasites to assess the 
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sensitivity of blood stages to drugs by measuring luminescence using a microplate 
reader based assay [19]. We now show that luminescence assays can also be used for 
the quantitative analysis of liver infection and that the results of these assays closely correlate to standard analysis methods (i.e. qRT-PCR). The transgenic parasite used in these assays, PbGFP-Luccon, expresses luciferase under the control of the strong 
and constitutive eef1a promoter. This promoter has previously been shown to drive 
expression of reporter proteins in growing and dividing stages throughout the 
parasite’s life-cycle [39]. The strong increase in reporter gene expression using this 
promoter from sporozoite-hepatocyte invasion to mature liver schizont is matched 
with reporter gene expression from merozoite-erythrocyte invasion to schizogony. 
The significant increase in luminescence 5–10 hours after sporozoite infection of hepatocytes, as compared to cultures incubated with sporozoites whose ability to 
invade liver cells is impaired (i.e. treated with cytochalasin-D), shows that luciferase 
production starts rapidly after invasion of the hepatocyte. We reproducibly observed 
a clear increase in luminescence 48 hours post infection in hepatocyte cultures infected with as few as 5×103 sporozoites, compared to uninfected control wells. This 
sensitivity of the luminescence assays with low sporozoite numbers in combination with the early detection of luciferase expression offers unique possibilities for large 
scale screenings of inhibitors of parasite liver stage development, with the potential for automation, using microplate assays. The use of such assays would confer the 
same advantage currently only available to drug screening against blood stage 
parasites [19].       
Despite the expression of luciferase during the early stages of parasite development 
within hepatocytes, we were not able to detect luminescence signals in live mice 
during the first 20 hours of infection, even at the highest infection dose of 1×105 
sporozoites. To investigate whether the sensitivity of detection of the young liver stages could be increased, we analysed a transgenic parasite line (mutant RMgm-152 in www.pberghei.eu) that expresses PbGFP-Luciferase under the control of the promoter of the circumsporozoite protein (CS; PB001026.00.0). The sporozoite stage of these reporter parasites strongly expresses the reporter fusion protein 
as visualised by GFP-fluorescence intensity; but we were still unable to detect 
sporozoites in the liver by in vivo imaging, although we were able to detect sporozoites in the skin at the site of biting when we measured mice directly after mosquito 
feeding (data not shown). Although we were not able to detect the young liver stages, 
the more mature liver stages were readily detected 30 h post infection of the mice, 
even after infection with a sporozoite dose as low as 1×103 sporozoites. The 30–48 
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h period corresponds to the phase of schizogony during which a single parasite can produce more than 1×104 daughter merozoites [54]. It is known that laboratory 
mice are relatively insensitive to infection with P. berghei sporozoites and therefore 
the sensitivity of in vivo imaging might even be higher if the reporter line were made in another rodent malaria parasite, P. yoelii, to which mice are more sensitive. When blood stage infections were analysed in mice that resulted from infections initiated with 1×103 sporozoites we calculated that the luminescence signal measured at 48 
h was the result of only 1–5 schizonts. This is based on the assumption that the 
parasite multiplication rate in erythrocytes is 10-fold every 24 hours [55] and that 
each liver schizont contains between 2×103 and 1×104 merozoites. The detection of 
localised spots of luminescence in dissected livers indicates that the in vivo imaging 
enables detection to the level of a single infected hepatocyte containing a mature 
liver schizont. However, the total luminescent intensity of extracted livers was lower 
than the luminescence intensity of livers determined by imaging of live mice. This was initially surprising because the expected quenching of luminescence by tissues 
in live mice would be absent when the isolated organ was examined. However, the 
lower values obtained from dissected livers are most likely the result of the rapid uptake and possibly metabolism of luciferin [56] during the time required to collect 
the liver.
It has recently been shown that mature liver schizonts produce so called merosomes, 
packets of 100–200 merozoites surrounded by the host cell membrane [57,58]. The 
possibility to detect bioluminescence signals of individual liver schizonts might also offer opportunities to analyse the process of merosome formation as well as merosome migration after their release from the infected hepatocyte. Merosomes 
are released in the blood circulating and appear to specifically accumulate in the 
lungs whereupon they burst open and merozoites are released and invade red blood 
cells [58]. It would therefore be interesting to see if the methodologies in this study 
can be adapted to also image the merosomes in the liver and then in isolated lungs or in lungs of whole bodies of animals to add to our understanding of merosome biology. 
The similar numbers of luminescence spots detected in dissected livers and in living mice (analysed by 3D imaging) also supports the notion that in vivo imaging can 
detect an individual mature liver schizont. However, in dissected livers there were 
several luminescence spots that were detected only on one side of the liver and by 
combining whole body imaging and imaging of dissected livers we found that a minor 
fraction of the schizonts was undetectable by either of the two methods. In addition, 
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a few mice treated with non-curative doses of primaquine showed no luminescence 
signals but developed a (delayed) blood stage infection. These observations indicate 
that small numbers of liver schizonts can be missed with whole body imaging, although in the case of primaquine treatment the absence of a luminescence signal 
might also be due to delayed development of the liver schizonts. To investigate 
whether we could increase the sensitivity of detection of mature liver schizonts we 
have separately analysed a different transgenic line which expresses luciferase under the control of the ama1 promoter (PB000821.01.0) [36]; mutant RMgm-30 in www.pberghei.eu). The ama1 gene encodes the micronemal protein, AMA1, in merozoites 
and it was our contention that since very large numbers of merozoites are produced 
in each liver schizont we could expect a high luciferase signal. Surprisingly, using similar sporozoite numbers as used with our eef1a promoter line, we measured a 
significantly lower luminescence signal, even in measurements that were taken at 
later time points (48–60 h) after infection (data not shown).
The analysis of drug-inhibition of parasite liver stage development by in vivo 
imaging offers clear advantages over standard qRT-PCR analysis of dissected livers 
or analysing the dynamics of the blood stage infection subsequent to liver infection. 
qRT-PCR analysis is both time consuming and expensive whereas the analysis of subsequent blood stage infections cannot easily discriminate the effect of the drugs 
on liver stage and/or resulting blood stage infections. In contrast, in vivo imaging is 
rapid and simple and allows, within the same animal, to measure both the specific 
inhibition of liver stage development by an inhibitor or drug and its subsequent effects on the blood stages. The analysis by in vivo imaging has the advantage in that 
analysis does not require sacrificing the experimental animal and thereby reduces the number of animals required for experimentation since multiple measurements 
can be made in the same animal over time. Moreover, it also has the advantage that 
it minimizes the biological variation within the study [59,60]. The in vivo analysis 
of drug sensitivity of liver stages to primaquine and tafenoquine was performed 
with mice that were infected by the bite of only five infected mosquitoes. All the control mice in these experiments (i.e. infections in the absence of drug) show a 
strong luminescence signal at 48 h after infection. These experiments demonstrate that in vivo drug-sensitivity assays are not dependent on the injection of mice with high numbers of sporozoites, which requires time-consuming manual dissection 
from mosquito salivary glands. The sensitivity of in vivo imaging therefore greatly 
simplifies the procedure of in vivo drug-sensitivity testing. An additional feature of 
the reporter protein luciferase that may be of great benefit is that it has a relatively 
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short half-life and therefore only allows the detection of live parasites, thereby 
avoiding errors potentially associated with the counting of dead liver parasites (as may occur with qRT-PCR experiments). The imaging assays described in this paper 
can also be used for the screening and analysis of parasite mutants for aberrant liver 
stage development. Moreover, these can be used to analyse liver stage development 
in challenge studies of mice that are immunized with either subunit vaccines against 
sporozoites/liver stage molecules or with genetically attenuated sporozoites. In 
conclusion, quantitative analysis of liver stage development by real-time imaging 
should greatly aid the validation of drugs and vaccines that act against the liver stages of the Plasmodium.          
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Supplementary Information
Supplementary Table S1
*   Correlation is significant at the 0,05 level (2-tailed)     
** Correlation is significant at the 0,01 level (2-tailed)
 
  RTqPCR Lumina Luminometer 
  HepG2, Ei: 25K, 50K, 75K spz at 24h 
RTqPCR ρ 1,00 0,80** 0,52 
 N 12 12 12 
Lumina  ρ 0,80** 1,00 0,61* 
 N 12 12 12 
Microplate reader ρ 0,52 0,61* 1,00 
 N 12 12 12 
  HepG2, Eii: 25K, 50K, 75K spz at 30h 
RTqPCR ρ 1,00 0,88** 0,92** 
 N 10 10 10 
Lumina  ρ 0,88** 1,00 0,85** 
 N 10 12 12 
Microplate reader ρ 0,92** 0,85** 1,00 
 N 10 12 12 
  HepG2, Eiii: 25K, 50K, 75K spz at 48h 
RTqPCR ρ 1,00 0,83* 0,78 
 N 6 6 6 
Lumina  ρ 0,83* 1,00 0,93* 
 N 6 6 6 
Microplate reader ρ 0,78 0,93* 1,00 
 N 6 6 6 
  Huh7: 5K, 30K, 75K spz at 48h 
RTqPCR ρ 1,00 0,83* 0,87** 
 N 11 8 11 
Lumina  ρ 0,83* 1,00 0,95** 
 N 8 9 9 
Microplate reader ρ 0,87** 0,95** 1,00 
 N 11 9 12 
  Huh7: 4, 18, 25, 42 hpi; 30K spz 
RTqPCR ρ 1,00 0,94* 0,98* 
 N 11 11 11 
Lumina  ρ 0,94* 1,00 0,93** 
 N 11 12 12 
Microplate reader ρ 0,93* 0,93** 1.00 
 N 11 12 12 
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Supplementary Table S2.       
Correlation coefficient data (ρ, two-tailed Spearman’s rho test) of the luminescence data (Lumina and 
Microplate reader) and the RT-qPCR data presented in Figure 2E.
*   Correlation is significant at the 0,05 level (2-tailed)     
** Correlation is significant at the 0,01 level (2-tailed)
 
  RTqPCR Lumina 
   Whole body Extracted liver 
RTqPCR ρ 1,00 0,95** 0,65* 
 N 16 15 11 
Lumina 
whole body 
ρ 0,95** 1,00 0,80** 
 N 15 15 11 
Lumina 
extracted liver  
ρ 0,65* 0,80** 1,00 
 N 11 11 11 
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Supplementary Figure S1                                                                
Analyis of sporozoite motility, cell traversal and infectivity of PbGFP-Luccon A) Representative 
immunofluorescence staining with anti-PbCSP [61] of the trails produced by PbGFP-Luccon (left) and 
wildtype sporozoites (right). Characteristic circles of gliding motility are observed in PbGFP-Luccon sporozoites. B) Cell traversal ability of wildtype and PbGFP-Luccon sporozoites as determined by FACS 
counting of Dextran positive Huh7 cells. FACS counting was performed 3 h after infection of Huh7 cells with 6×104 sporozoites. Uninfected: hepatocytes cultured in the presence of Dextran but without the addition of sporozoites. C) Infection of Huh7 cells on coverslips using 3×104 PbGFP-Luccon (left) and 
PbGFPcon [39] (right) sporozoites. After fixing and staining, similar numbers of exoerythrocytic forms 
are observed at 48 h post infection for both parasites. D) qRT-PCR quantification of in vitro invasion of 
HepG2 cells by wild type and PbGFP-Luccon at 24 h (black bars) and at 45 h post invasion (white bars). Cyto D: cultures with cytochalasin-D. E) qRT-PCR quantification of liver invasion in mice of wild type and 
PbGFP-Luccon sporozoites. qRT-PCR was performed on material from livers collected at 43 h after infection of the mice with 3×104 sporozoites. The pre-patent period, defined as the days between injection of 
sporozoites and a blood infection with a parasitemia of 0.5–2%, was 4.2 days (range 4–5 days) for PbGFP-
Luccon compared to 4.4 days (range 4–5) for wild type parasites after injection of 1×104 sporozoites. After injection of 1×104 sporozoites the pre-patent periods were 5.3 days (range 5–6) for PbGFP-Luccon and 5.5 
days (range 5–6) for wildtype parasites.
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Supplementary Figure S2       Analysis of in vitro liver stage development in HepG2 cells by determination of luciferase expression (luminescence). A) Relationship between the numbers of sporozoites used to infect hepatocyte cultures 
and the luminescence produced by the liver stages at 24, 30 and 48 h after infection. Luminescence 
levels were measured using the Lumina system (Photons/sec). B) Relationship between the numbers of 
sporozoites used to infect hepatocyte cultures and the luminescence produced by the liver stages at 24, 30 
h, 48 h after infection. Luminescence levels were measured using the Lumina system (Photons/sec) and 
a Wallac microplate reader (Relative light units, RLU), respectively. C) Relationship between the numbers 
of sporozoites used to infect hepatocyte cultures and the luminescence produced by the liver stages at 
30 after infection. Luminescence levels were measured using the Lumina system (Photons/sec) and a 
Wallac microplate reader (Relative light unit, RLU), respectively. D) Correlation between luminescence 
values and 18S rRNA levels. Luminescence values were determined using the Lumina system and the Wallac microplate reader (see C). P. berghei 18S rRNA levels were determined by qRT-PCR of hepatocyte cultures infected with different numbers of sporozoites. The percentage of growth is normalized to the 
highest reading within each experiment. See Table S1 for the correlation coefficient data of the two-tailed Spearman’s rho test.
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Supplementary Figure S3        
Imaging of whole bodies and dissected livers (IVIS100) of mice at 44 h after infection by 1×103 (A) or 1×104 sporozoites (B). Dissected livers were imaged at both sides. Numbers in the pictures of Panel A 
show the number of luminescent spots identified.
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Supplementary Figure S4    
A) Whole body imaging (IVIS100) of two representative mice during the period of 24–68 h after infection 
by bites of 20 infected mosquitoes, showing a strong increase of luminescence intensity of the liver during 
the period of 30–44 h after infection and a subsequent decrease after 52 h in the liver. The strong increase 
in luminescence of the whole body at 68 h is the result of the dissemination of the liver merozoites released 
into the bloodstream and subsequent invasion of erythrocytes. Rainbow images show the relative level 
of luminescence ranging from low (blue), to medium (green), to high (yellow/red). B) Imaging of whole 
bodies and extracted livers (IVIS100) of Wistar rats at 44 h after infection by bites of 1 or 5 infected 
mosquitoes. Extracted livers were measured at both sides (a, b) and lobes (c) and small sliced liver pieces 
(d) were analysed for additional luminescence spots. Numbers in the images represent the number of 
luminescent spots identified.
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Supplementary Figure S5                                              
A) Source reconstruction of 3D whole body imaging of three mice at 44 h after infection by bites of 5–10 
infected mosquitoes. Eleven luminescent sources are detected in mouse 3 (M3), one in mouse 5 (M5) and 
none in mouse 4 (M4). See also Supplementary Movies 2 and 3 (online version) corresponding to mouse 
3 and 5 respectively. B) 2D-imaging of the extracted livers of the mice shown in panel A. Livers were 
imaged at both sides using the IVIS Spectrum system. Numbers in the images represent the number of 
luminescent spots identified. Rainbow images show the relative level of luminescence ranging from low 
(blue), to medium (green), to high (yellow/red) 
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Abstract
Measurement of liver stage development is of key interest in malaria biology and 
vaccine studies. Parasite development in liver cells can be visualized in real-time, 
both in culture and in live mice, using a transgenic Plasmodium berghei parasite, 
PbGFP-Luccon, expressing the bioluminescent reporter luciferase. This study 
explores the benefit of using these parasites for the evaluation of immunity against malaria, compared to qRT-PCR techniques in vivo and in vitro. Mice were immunized with either radiation attenuated sporozoites (RAS) or wildtype sporozoites under chloroquine prophylaxis (CPS) and challenged with PbGFP-Luccon. The in vitro 
transgenic sporozoites neutralization assay (TSNA) was adapted by replacing 
PbCS(Pf) parasites for PbGFP-Luccon parasites. Application of PbGFP-Luccon transgenic 
parasites provides live quantitative visual information about the relation between 
parasite liver load and protection. Moreover, fast and reproducible results are obtained by using these parasites in the transgenic sporozoite neutralization assay, measuring functional antibody-mediated immune response. PbGFP-Luccon parasites 
are a straightforward and valuable tool for comprehension of the biological and immunological principles underlying protection against malaria. 
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Introduction
Transgenic organisms that express a bioluminescent reporter are increasingly used 
due to easy handling and visualization. Plasmodium berghei parasites, expressing the bioluminescent reporter luciferase (PbGFP-Luccon) have been used to visualize 
and quantify parasite development in vitro in hepatic cells and in vivo in mice using real-time luminescence imaging [1]. 
Measurement of liver stage development is of key interest in malaria biology and 
vaccine studies. Protection against the liver stage is one of the targets to abrogate the 
infection. Quantification of the number of parasites in hepatocytes is an important 
read-out to determine inhibitory activity. This quantification of in vitro [2] and 
in vivo [3] parasite liver load is usually performed by (qRT)-PCR. This technique, 
however, is time-consuming and costly, since mice need to be sacrificed at each time point for in vitro quantification. The use of in vivo and in vitro imaging of luciferase expressing parasites has some 
requisites. First, it requires that the luciferase expressing parasites are qualitative 
and quantitative biologically comparable to wildtype in terms of liver and blood 
infectivity. Second, the in vivo and in vitro parasite quantification by measurement of luminescence signaling needs to correlate to the established qRT-PCR methods. 
Previously we showed that the P. berghei line 676m1cl1 line (PbGFP-Luccon) and 
wildtype (WT) sporozoites have identical motility, cell traversal and in vitro and in 
vivo hepatocyte infectivity. Moreover, detailed examination revealed that luciferase 
expression correlated tightly with parasite 18S rRNA levels measured by qRT-PCR 
[1]. Therefore, this transgenic parasite seems suitable for a quantitative analysis of parasite load. This study aimed to explore the use of PbGFP-Luccon parasites in both in vivo and 
in vitro studies evaluating immunity against malaria. For the in vivo studies, mice were immunized with either radiation attenuated sporozoites (RAS) or wildtype sporozoites under chloroquine prophylaxis (CPS) and subsequently challenged with 
PbGFP-Luccon. For the in vitro studies, the transgenic sporozoites neutralization assay 
(TSNA) was adapted by replacing PbCS(Pf) parasites for PbGFP-Luccon parasites [2]. 
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Material and Methods
Mice         
Female C57BL6/J mice, eight weeks of age, were purchased from Elevage Janvier (France). 
All studies have been performed according to the regulations of the Dutch “Animal On 
Experimentation act” and the European guidelines 86/609/EEG. Approval was obtained 
from the Radboud University Experimental Animal Ethical Committee (RUDEC 2009-019). 
Mosquito infection and preparation of sporozoites   
The previously described, transgenic P. berghei line 676m1cl1 line (PbGFP-Luccon) [1] and 
its reference clone of ANKA strain cl15cy1, were used in this study. Anopheles stephensi mosquitoes were infected by feeding on infected mice using standard methods of mosquito 
infection [4]. On day 21 after infection, the salivary glands of the mosquitoes were collected by 
hand-dissection. Salivary glands were collected in DMEM (Dulbecco’s Modified Eagle Medium 
from GIBCO) and homogenized in a homemade glass grinder. The free sporozoites were counted in a Bürker-Türk counting chamber using phase-contrast microscopy. 
Immunization of mice with radiation attenuated sporozoites (RAS) or sporozoites 
under chloroquine prophylaxis (CPS) 
C57BL/6 mice were immunized with wildtype P. berghei radiation attenuated sporozoites 
(RAS) or sporozoites under chloroquine prophylaxis (CPS). Immunizations were performed 
by i.v injection with three doses of 1 × 104 (RAS and CPS) or 4 × 103 (CPS) sporozoites, with a 
7 day interval between the boosts. For CPS immunization, mice received 800 μg chloroquine base (cq-diphosphate Sigma) in PBS i.p, starting from sporozoite injection up to two weeks 
after the last immunization. Absence of blood stage parasites was confirmed by examination 
of Giemsa-stained blood smears of tail blood at the end of the chloroquine treatment period and approximately 1 day before challenge. Mice were challenged two weeks after ending 
choroquine treatment. Irradiation of sporozoites was performed by exposure of infected A. 
stephensi mosquitoes to 16,000 rad of γ-radiation (Cesium-137 Gammacel 1000). 
Challenge and real-time in vivo imaging of liver stage development in RAS and 
CPS immunized mice 
Immunized and control C57BL/6 mice were challenged by the bite of 5-11 infectious 
mosquitoes or by intravenous injection of 1 × 104 PbGFP-Luccon sporozoites in the tail (200 
ul). Control mice consisted of two groups, group 1 received chloroquine similar to the CPS 
immunized mice and group 2 did not receive chloroquine. Giemsa stained bloodsmears 
were prepared every other day starting from day 3 to day 21 after challenge, to monitor 
for blood stage parasitaemia. Parasite liver load in animals was visualized through imaging of whole bodies using the in vivo imaging system Lumina (Caliper Life Sciences, USA) as 
described [1], with some small adaptations. Briefly, animals were anesthetized using the 
isofluorane-anesthesia system, their belly was shaved and D-luciferin dissolved in PBS (100 
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mg/kg; Caliper Life Science, Belgium) was injected subcutaneously (in the neck). Animals were kept anesthetized during the measurements, performed within 3-5 minutes after the 
injection of D-luciferin. Bioluminescence imaging was performed with a 10 cm field of view, medium binning factor and an exposure time of 300 seconds. Bioluminescent intensities were 
expressed in total flux of photons. 
Real-time transgenic PbGFP-Luccon sporozoites neutralization assay 
The TSNA (transgenic sporozoites neutralization assay) protocol was adapted from Kumar et 
al. (Figure 1). Plasma was obtained from immunized (three doses of 1 × 104 ;RAS and CPS) and 
naive C57BL/6 mice, 21 days post challenge by mosquito bite; blood was collected by heart 
puncture after i.v. injection of 50 i.u. of heparin. Blood samples were centrifuged at 2000 rpm 
for 5 minutes (RT), plasma was collected and transferred to cryotubes (Nunc) and stored at 
-80°C for later use. Prior to the TSNA assay, plasma samples were thawed and centrifuged 
at 13,000 rpm for one minute (RT) to remove protein aggregates. PbGFP-Luccon sporozoites 
were pre-incubated for 30 minutes on ice with plasma of naive or immunized mice (1:1 ratio). Pre-incubated sporozoites were added to wells containing monolayers of 1 × 105 pre-seeded 
Huh-7 hepatocyte cultures (1 ml/well in 24 well plates). Huh-7 cells (human liver hepatoma 
cells) were preferred over standard HepG2 cells [2] since in these cells, luciferase expression 
correlated slightly better with parasite 18S rRNA levels measured by qRT-PCR [1]. Huh-7 
were suspended in 1 ml of ‘complete’ DMEM (DMEM, Gibco, supplemented with 10% FCS, 1% 
penicillin/streptomycin and 1% Glutamax) the day prior to infection, seeded in 24 well plates (105 cells/well) and incubated overnight. For each plasma sample, 3 × 104 sporozoites each 
were added to duplicate wells and plates were centrifuged 10 minutes at 1800 × g (Eppendorf 
centrifuge 5810 R). 40 hours after sporozoite addition, cells were washed once with PBS and 
lysed in 200 μl of cell culture lysis reagent obtained from the Promega Luciferase Assay System Kit® (Promega, PT). Samples in Promega lysis buffer were either stored at -80°C or processed 
immediately to measure luminescence intensity with the Lumina system. The in vivo imaging 
system Lumina (Caliper Life Sciences, USA) was used to measure luciferase activity of infected 
Huh-7 cells. Quantitative analysis was performed by measuring the luminescence signal 
intensity per well using the ROI settings of the Living Image® 3.0 software. ROI measurements 
are expressed in total flux of photons. 70 μl of Luciferase Assay Substrate (Promega Luciferase Assay System Kit®) was added to 20 μl of lysed hepatocyte cultures in a white 96-well plate 
(Dynex Technologies, USA). Bioluminescence images were acquired with a 7 cm FOV, medium binning factor and an exposure time of 10-30 seconds. Percent inhibition was calculated by 
the following formula; 1 - (average bioluminescence in immune plasma cultures/average 
bioluminescence in naive plasma cultures) × 100%. 
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Figure 1. Schematic representation of the adapted transgenic PbGFP-Luccon sporozoite 
neutralization assay. 
Neutralization of hepatocyte invasion by transgenic sporozoites was performed by incubation of naive or 
immune plasma obtained from (non-) immunized mice with the transgenic sporozoites. Neutralization 
was performed for 30 minutes on ice before the antibody/sporozoites mix was added to Huh-7 cells 
containing wells and incubated for 40 h at 37°C. This figure is adapted from figure 1 described by Kumar et al. [2]
Results
Challenge of immunized mice with PbGFP-Luccon sporozoites Mice immunized with CPS or RAS as well as control mice were challenged by PbGFP-
Luccon infected mosquitoes and protection against malaria was evaluated by blood smear reading and real-time in vivo imaging. All control challenged mice (n = 10) 
developed asexual parasitaemia and a positive bioluminescent liver signal by real-time in vivo imaging at 44 hours post challenge (Figure 2a). All mice immunized by CPS (n = 10) or RAS (n = 10) with a dose regimen of three times 104 sporozoites and challenged by infectious mosquito bites, neither became parasitaemic nor 
displayed any bioluminescent signal originating from the liver (Figure 2a). Next, 
the robustness of protective immunity was explored by increasing the challenge 
level in mice that were immunized with CPS by a lower dose regimen of three times
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Figure 2. Real-time in vivo parasite liver load upon challenge in mice immunized with CPS or 
RAS.          
A) Image (2 representative mice for each group) of the parasite liver load in control (n = 10), CPS (n = 
10) and RAS immunized (n = 10) C57BL/6 mice 44 hours post challenge. Mice were immunized i.v with 1 × 104 sporozoites followed by two boosts of 1 × 104 sporozoites. Challenge was performed by infectious 
mosquito bites. The rainbow image visible in the naive mice represents the total flux of photons (p/sec/cm2) in that area. B) Image (2 control mice and 3 immunized mice) of the parasite liver load in control 
(n = 3) and CPS immunized (n = 5) C57BL/6 mice 30-45 hours post challenge. Mice were immunized with 4 × 103 sporozoites by i.v injection followed by two boosts of 4 × 103 sporozoites. Challenge was performed by injection of 1 × 104 PbGFP-Luccon sporozoites i.v. The rainbow image visible in the control 
mice represents the total flux of photons (p/sec/cm2) in that area.
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4 × 103 sporozoites. Mice were challenged by i.v injection of 1 × 104 PbGFP-Luccon 
sporozoites and all immunized mice remained negative. These results are in line with the data obtained by in vivo imaging; mice immunized with CPS showed no 
bioluminescent signal, in contrast to control mice, with positive images at 30 to 45 
hours post challenge (Figure 2b). Therefore, the use of PbGFP-Luccon in a challenge 
model, combined with bioluminescent imaging permits determination of protective 
efficacy in the liver post-immunization.
Real-time transgenic PbGFP-Luccon sporozoites neutralization assay 
To evaluate the potential benefits of PbGFP-Luccon for assessment of protection 
in vitro, we adapted the transgenic sporozoite invasion inhibition assay (TSNA) as performed by Kumar et al. [2] by replacing the PbCS(Pf) sporozoites with 
PbGFP-Luccon sporozoites. The use of bioluminescent parasites in the TSNA has some requisites. Recently, Ploemen et al. described the highly significant 
quantitative correlation between parasite 18S rRNA levels measured by qRT-PCR and luminescence intensity for different numbers of PbGFP-Luccon sporozoites 
invaded into Huh-7 hepatocytes (Spearman rho = 0.83) [1]. As a follow-up of these results, a dose titration with 10 - 50.000 PbGFP-Luccon sporozoites, added 
to a Huh-7 hepatocyte culture was performed and bioluminescent intensity was 
measured 40 hrs post invasion (Figure 3a). Luminescent intensities increased linear (R2 = 0.97) with the number of PbGFP-Luccon sporozoites added to a Huh-7 
hepatocyte culture. These parasites, therefore, may be used in an adapted TSNA. 
Plasma from protected C57BL/6 mice was used in the adapted TSNA, after CPS or RAS 
immunization. Invasion of Huh-7 cells by PbGFP-Luccon sporozoites pre-incubated 
with plasma of protected mice was significantly inhibited compared to invasion 
by sporozoites pre-incubated with plasma of naive mice (p < 0.05) (Figure 3b). 
Further, 1:1 diluted plasma (in PBS), showed about half of the inhibition level of the 
original plasma (data not shown). Inhibition of sporozoites by purified plasma IgG 
of protected mice resulted in a similar inhibition level as non-purified plasma (data 
not shown). Although the % inhibition between individual plasma samples differs 
between mice, the duplicates of one plasma sample diverged at most on average 4% 
of the mean value of that sample (n = 21). These results show that this adapted TSNA 
is a more user friendly methodology, allowing identification of antibody-mediated 
inhibition of parasite liver invasion. 
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Figure 3. Transgenic PbGFP-Luccon sporozoite hepatocyte invasion inhibition assay. 
A) Huh-7 cells were seeded in 24 well plates and were grown to confluency as described in Materials 
and Methods. Graded numbers of PbGFP-Luccon sporozoites were added to the culture wells in duplicate 
and incubated for 40 h at 37 C in 5% CO2. Infectivity was quantified by analyzing the luminescent flux 
(p/sec/cm2) in each well. B) Invasion inhibition of sporozoites by plasma from CPS (n = 6) and RAS (n 
= 7) immunized mice. 30.000 PbGFP-Luccon sporozoites were incubated in plasma of naive or immune 
mice for 30 min on ice and subsequently added to Huh-7 cells. Infectivity was quantified by analyzing 
the luminescent flux (p/sec/cm2) in each well. The baseline represents the inhibition level of plasma 
from naive mice (approximately 4 × 10^7 p/sec/cm2). Percent inhibition was calculated by the following 
formula; 1 - (average bioluminescence in immune plasma sample/average bioluminescence in naive 
plasma sample) × 100%. The level of invasion inhibition in the immunized mice was significantly higher 
compared to the inhibition from the plasma of naive mice (95% CI CPS 36-79%; 95% CI RAS 58-81%). 
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Discussion
This study shows that PbGFP-Luccon parasites, can provide real-time quantitative information on the relation between in vivo parasite liver load and immunity against malaria. In vitro use of these parasites in the adapted TSNA allows for an easy and 
fast assessment of the functional sporozoite invasion inhibition by antibodies. 
Previously, Mwakingwe et al. applied bioluminescent imaging and qRT-PCR to analyse 
parasite prevalence in the liver of immunized mice, using luciferase expressing P. 
yoelii [5]. They did not, however, report on the direct quantitative relation between 
bioluminescent imaging and parasite (liver) load determined by qRT-PCR and the extent to which the transgenic parasite had similar characteristics as the WT parasite 
throughout the whole life cycle [5]. In the future, a Py-Luc parasite that meets these 
requisites for assessment of the liver load upon challenge, can be used beside PbGFP-
Luccon parasites, allowing for a direct comparison of the characteristics of P. yoelii and 
P. berghei in vivo. 
Evaluation of immunity against malaria by bioluminescent imaging offers many 
advantages over conventional qRT-PCR analysis. This analysis technique is more 
simple, rapid and reduces the amount of mice needed. As an added value, expression 
of the reporter protein luciferase is restricted to live parasites and therefore allows 
specific detection of live parasites. This avoids detection of dead liver parasites, 
as may occur by the qRT-PCR assay [1]. Measurement of parasite liver load upon challenge can be performed in vivo without the need for any invasive liver resection 
or biopsy. It does not require sacrificing animals and thereby reduces the number of 
animals and costs required for experimentation. Moreover, multiple measurements 
can be carried out in the same animal over time, linking the parasite liver load 
with protection and minimizing the effect of biological variation [6,7]. While the use of PbGFP-Luccon over qRT-PCR has its clear benefits, there are limitations. The 
expression of luciferase in the parasite is relatively low and cannot be visualized 
earlier than 20 hours post-infection [1]. Moreover, due to limitations in sensitivity, 
a low number of developing liver parasites may be missed which might mature into 
asexual parasites [1]. Negative results of in vivo imaging of liver stage development 
can therefore not be used to claim sterile protection, which eventually requires 
sub-inoculation of blood from challenged mice into naive mice [3]. Nonetheless, challenge of mice with a high number of PbGFP-Luccon sporozoites administered i.v 
does offer information on the parasite liver load in real-time without sacrifying the 
mice. In the CPS model the overwhelming majority of the parasites do not develop 
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in the liver beyond 30 hours. The presence of effector mechanisms that target early 
developing parasite stages can however, not formally be excluded. At least in this 
model with complete liver stage development, a high degree of immunity to late liver stage parasites can clearly be inferred. 
Finally, the application of PbGFP-Luccon parasites is not restricted to the described 
assays. In a recent publication describing the host mediated factors regulating 
the inhibition of liver stage infection upon superinfection, luciferase expressing parasites were used to enable distinction between the parasites from the original 
infection and the superinfection [8]. 
Conclusions
With clear benefits over conventional RT-qPCR techniques, PbGFP-Luccon parasites 
can function as an easy and valuable tool contributing to the comprehension of the immunological principles underlying immunity against malaria. As such, these 
parasites can be helpful in future studies evaluating protection against malaria. 
List of abbreviations
PbGFP-Luccon: Plasmodium berghei that constitutively express firefly Luciferase and the Green 
fluorescent protein; PbCS(pf): Plasmodium berghei that bears the Plasmodium falciparum 
CS repeats; TSNA: Transgenic sporozoite neutralization assay; RAS: Radiation attenuated 
sporozoites; CPS: Sporozoites under chloroquine prophylaxis; ROI: Region of interest; 
q-RTPCR: quantitative real-time polymerase chain reaction; IVIS: in vivo imaging system. 
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Abstract
The critical first step in the clinical development of a malaria vaccine, based on 
live-attenuated Plasmodium falciparum sporozoites, is the guarantee of complete 
arrest in the liver. We report an approach for assessing adequacy of attenuation of genetically attenuated sporozoites in vivo using the P. berghei model of malaria and 
P. falciparum sporozoites cultured in primary human hepatocytes. We show that 
two genetically attenuated sporozoite vaccine candidates, Δp52+p36 and Δfabb/f, are not adequately attenuated. Sporozoites infection of mice with both P. berghei 
candidates can result in blood infections. We also provide evidence that P. falciparum 
sporozoites of the leading vaccine candidate that is similarly attenuated through 
the deletion of the genes encoding the proteins P52 and P36, can develop into 
replicating liver stages. Therefore, we propose a minimal set of screening criteria to 
assess adequacy of sporozoite attenuation necessary before advancing into further 
clinical development and studies in humans.
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Introduction    
    
Immunization with live sporozoites that are attenuated by radiation (IrrSpz) 
induces strong protective immunity both in rodent models of malaria and in humans in experimental clinical studies [1;2]. Recently, the interest in a whole-organism 
vaccine consisting of live attenuated parasites has been renewed as efforts using 
recombinant subunit vaccines have still been unable to demonstrate sustained, high 
level sterile immunity [3-6]. In rodent models of malaria it has been shown that 
attenuation of sporozoites can also be achieved by reverse-genetic methodologies 
(genetically attenuated parasites, GAP; [7-9]) or by chemical treatment (chemically 
attenuated parasites; CAS [10;11]). Importantly, immunization of mice with GAP 
results in protective immune responses that are similar to those induced by IrrSpz, 
specifically cell mediated responses, critically involving CD8+ T-cells, which provide 
a long lasting and sterile protection against infection [12-14]. The use of GAP 
sporozoites that were shown to be safe (no breakthrough infections) and protective 
as a whole-organism vaccine could have several advantages over IrrSpz and CAS as they would be a homogeneous population of parasites with the potential for a 
defined attenuation phenotype. This could remove issues related to the delivery of 
correct doses of either irradiation or drugs in order to ensure sufficient attenuation 
without killing the parasites. The conceptual basis of vaccines consisting of IrrSpz 
or GAP is that after inoculation, sporozoites invade but only partially develop in the 
liver, as it has been shown that only sporozoites that are able to invade hepatocytes 
induce protective immune responses [15-17]. This sporozoite growth arrest in 
the liver needs to be complete, as the appearance of ‘breakthrough’ parasites in 
the bloodstream can lead to clinical disease and death [18]. As P. falciparum only 
efficiently infects humans, adequacy of attenuation of P. falciparum sporozoites cannot be assessed in vivo prior to initiating clinical trials. The murine malaria models P. berghei and P. yoelii are consequently not only used to identify suitable 
genes for generating GAPs but also to assess the safety and immunogenicity of GAPs. Thereby, these studies establish a road-map for designing P. falciparum GAPs and 
provide information critical in the decision to proceed with trials in humans.  
Several different GAPs have been generated in the rodent malaria parasites P. berghei and P. yoelii that abort development in the liver [7-9;19;20]. These include GAPs that 
lack genes essential for the formation and maintenance of a parasitophorous vacuole (p52, p36, uis3 and uis4; [7-9;21]), genes involved in type II fatty acid synthesis (i.e. 
fabb/f and fabz; [22;23] and a gene involved in (post-)transcriptional regulation of 
sporozoite/early liver stage genes (sap1/slarp; [19;20;24]). Immunization of mice 
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with sporozoites of all these GAPs induces, to varying degrees, protection against 
challenge with wild type (WT) parasites. Some of these GAPs confer protection 
against WT challenge after a single dose immunization with as few as 1000–10000 
attenuated sporozoites [21;25]. Since unequivocal orthologs for the two rodent uis-genes are absent in the P. falciparum genome (www.PlasmoDB.org) and P. berghei 
GAP lacking SLARP has been reported to induce limited protective immune responses 
[20], GAPs lacking p52 and p36 or genes involved in type II fatty acid synthesis (FAS 
II) are considered GAP vaccine candidates for translation into the human malaria parasite, P. falciparum [18;22;26]. 
Occasional breakthrough blood infections in mice after immunization with rodent 
GAPs lacking uis4 and p52 [7;9] emphasize the importance of removing multiple 
genes in the generation of GAPs that are completely attenuated. Infection of mice with high doses of P. yoelii sporozoites of a ‘double gene deletion’ GAP lacking two genes, p52 and p36, showed no breakthrough blood infections in the P. yoelii rodent 
model [21]. Generation of equivalent P. falciparum GAPs lacking these genes [27] 
have provided evidence that these P. falciparum GAPs show a comparable attenuation 
phenotype to the GAPs of rodent malaria parasites. In cultured human hepatocytes and in mice carrying human hepatocytes, these P. falciparum GAP abort development 
in hepatocytes soon after sporozoite invasion. The observations of the growth arrest of P. yoelii and P. falciparum GAP has led to the production of a P. falciparum GAP 
lacking expression of both P52 and P36 for use in human clinical trials [18;27].
In this study we have analysed the adequacy of attenuation of two GAPs in the rodent model, P. berghei, one lacking expression of both P52 and P36 (Δp52+p36) 
and the other lacking expression of FabB/F (Δfabb/f). In addition, we have analysed 
the development of P. falciparum Δp52+p36 parasites in cultured primary human 
hepatocytes. The presence of developing liver stages and the development of breakthrough blood infections in mice immunized with both P. berghei GAP show 
that the sporozoites of these GAP are not completely attenuated. Moreover, we 
provide evidence that the P. falciparum Δp52+p36 GAP can produce replicating liver 
stages, indicating that this GAP is also not adequately attenuated. These results 
clearly indicate that these GAP vaccine candidates require additional refinement 
before advancing into clinical studies in humans. The high costs and long time 
frames associated with clinical trials makes them inefficient methods to screen 
potential whole-organism vaccines against malaria. We therefore propose a robust and stringent screening approach, using multiple rodent malaria parasites and 
multiple mice strains, to determine the adequacy of GAP attenuation, as the best 
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available and providing a stringent safety criterion before advancing with further 
clinical development and studies in humans.
Material and Methods
Attenuated P. berghei and P. falciparum parasites were generated using standard genetic 
modification technologies. Adequacy of attenuation of P. berghei sporozoites was determined 
in vivo by infecting Swiss OF1, BALB/c and C57BL/6 mice with live attenuated sporozoites collected from infected Anopheles stephensi. Development of attenuated parasites was analysed 
in vitro in either cultured Huh7 hepatocytes (P. berghei) or in primary human hepatocytes (P. 
falciparum). Liver stage development in mice was determined by real-time in vivo imaging of luciferase-expressing parasites. Details of the generation of attenuated parasite lines, analysis of adequacy of attenuation, in vivo imaging of liver stage development and in vitro analysis of 
liver stages can be found in Supplementary Material and Methods.
Results
Generation and characterization of two P. berghei GAPs, Δfabb/f and Δp52+p36 Two P. berghei gene-deletion mutants (GAP), Δfabb/f and Δp52+p36, were generated 
using standard methods of gene targeting by double cross-over integration and 
for each mutant two independent parasite clones were produced (Fig. S1-3; Table 
S1). For each GAP, one mutant was generated in the P. berghei reference reporter line, PbGFP-Luccon, which allows for visualisation and counting of GFP-expressing parasites in hepatocytes, in vitro, and analysis of liver-stage development in live mice by real-time in vivo imaging [38]. The Δfabb/f mutant lacks expression of 
elongation condensing enzyme 3-oxoacyl-acyl-carrier protein synthase I/II, FabB/F 
(Fig. 1B), an enzyme of the bacterial-like type II fatty acid biosynthesis (FAS-II) 
pathway [39]. For P. yoelii it has been demonstrated that enzymes of this pathway 
are highly expressed in sporozoites and liver-stages and FabB/F was shown to be 
essential for complete development of liver stages [23;26]. The Δp52+p36 mutants 
lack expression of two 6-cys protein family members [21;40-42], P52 and P36 (Fig. 
1A). These genes are expressed in sporozoites and liver stages and appear to be 
important to the formation and/or maintenance of the parasitophorous vacuole 
membrane in the infected hepatocyte [9;21;42].
The Δfabb/f and Δp52+p36 mutants showed normal blood-stage development 
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(Table S2) and produced oocyst and sporozoite numbers comparable to those of 
WT parasites (Fig. 1C). Salivary gland sporozoites demonstrated normal gliding 
motility, hepatocyte traversal and sporozoites of all mutants were able to invade 
hepatocytes at WT levels (Fig. 1C and 1D). After in vitro invasion of hepatocytes, the 
Δp52+p36 mutants showed a greater than 90% reduction in liver stage development 
at 24 hours after sporozoite invasion as determined by qRT-PCR analysis of parasite 
ribosomal RNA (Fig. 1E). The early growth-arrest of Δp52+p36 parasites was 
confirmed by analysis of infected hepatocytes by immuno-fluorescence microscopy 
after staining with Hoechst and antibodies against the parasite protein HSP70 (Fig. 
2A and 2B). The early arrest of Δp52+p36 parasites after hepatocyte invasion is similar to the phenotype reported for P. berghei mutants lacking expression of only P52 and P. yoelii mutants lacking both P52 and P36 [21]. In addition, immunization 
of BALB/c and C57BL/6 mice with the Δp52+p36 mutants showed comparable 
levels of protection against challenge with WT parasites (Table S3) as observed with P. berghei mutants lacking p52  or P. yoelii mutants lacking p52 and p36 [21]. 
Full protection was induced in BALB/c mice with a single dose with as few as 1000 
sporozoites inoculated intravenously (IV) whereas protection in C57BL/6 mice required 3 immunizations (Table S3). 
In contrast to the early growth-arrest phenotype of Δp52+p36, liver stages of 
Δfabb/f developed into mature forms as shown by qRT-PCR analysis and immuno-
fluorescence microscopy (Fig. 1E, Fig. 2A). During in vitro liver stage development, 
the Δfabb/f parasites were morphologically similar to WT parasites as judged 
by immuno-fluorescence microscopy (Fig. 2A). However, schizonts showed a 
significantly lower level of expression of the merozoite surface protein 1 (MSP1); at 
48 hours post infection (hpi) only 18% of the Δfabb/f schizonts strongly expressed 
MSP1 whereas 39% of WT parasites were MSP1-positive (p<0.001) and this 
increased to 54% in WT and 37% in Δfabb/f at 54hpi (p=0.01) as shown in Fig. 
2C (and Fig. S5A/B). The normal morphology of maturing Δfabb/f liver stages and expression of MSP1 parasites is different from the phenotype reported for P. yoelii 
parasites lacking expression of FabB/F, where schizonts show clear signs of aberrant nuclear morphology and a complete absence of MSP1 expression [22].
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Figure 1: Characterisation of P. berghei Δp52+p36 and Δfabb/f mutant parasites  
A) qRT-PCR analysis showing absence of p52 and p36 transcripts in sporozoites of ∆p52+p36-b. PCR 
amplification using purified sporozoite RNA was performed either in the presence or absence of reverse 
transcriptase (RT+ or RT-, respectively) using the primers as shown in the left panel (see Table S1 for the sequence of the primers). The P. berghei circumsporozoite protein gene (cs) was used as a positive control. 
B) qRT-PCR analysis showing absence of fabb/f transcripts in sporozoites mutant of ∆p52+p36-b. PCR 
amplification using purified sporozoite RNA was performed either in the presence or absence of reverse 
transcriptase (RT+ or RT-, respectively) using the primers 6312 and 6313 (see Table S1 for the sequence of the primers). The P. berghei circumsporozoite protein gene (cs) was used as a positive control. C) Table of oocyst and sporozoite production in A. stephensi mosquitoes (given as numbers), sporozoite motility 
(as numbers of anti-CS ‘circle’ trails) and cell traversal capacity (mean number of cultured hepatocytes, 
Huh7, traversed) of P. berghei wildtype (WT) and mutant parasites. D) In vitro development 3 hours after 
sporozoites invasion of hepatocytes (Huh7) by P. berghei GAPs is represented as the ratio of extra- and 
intra-hepatic sporozoites; determined after 3 wash steps to remove sporozoites in suspension (see C).  E) 
Growth of P. berghei GAPs intra-hepatic stages in culture (in Huh7 cells) at different hours post invasion 
(hpi) of sporozoites. Growth is determined by qRT-PCR of 18s P. berghei rRNA. RNA levels shown are 
relative to RNA levels of WT liver-stages.
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Sporozoites of the P. berghei GAPs, Δfabb/f and Δp52+p36, are not completely 
attenuated
To examine the adequacy of attenuation of the Δfabb/f and Δp52+p36 mutants in 
vivo, we infected mice of two different strains, BALB/c and C57BL/6, with high 
sporozoite doses. An IV dose of 50K sporozoites did not result in blood infections 
in BALB/c mice in the two independent Δp52+p36 mutants (Table 1). In contrast, IV injection of 50K sporozoites of the two Δfabb/f mutants resulted in breakthrough 
blood infections in the majority (80-100%) of BALB/c mice (Table 1). Moreover, all 
C57BL/6 mice developed a blood stage infection when infected with 50K sporozoites 
of both independent Δfabb/f mutants (Table 1). Genotyping of the breakthrough 
blood parasites (Δfabb/fbr) by PCR and Southern analysis of chromosomes showed 
that these parasites had the Δfabb/f genotype (data not shown). The blood infections show a prolonged prepatency period of 1-2 days as compared to WT parasites. Assuming a P. berghei blood stage multiplication rate of 10x per 24 hour this delay 
to patency indicates a 90-99% reduction in the production and/or infectivity of the 
Δfabb/f exo-erythrocytic merozoites. Despite the significant reduction in production of infectious merozoites, our results show that P. berghei Δfabb/f sporozoites are only weakly attenuated compared to P. yoelii sporozoites lacking expression of FabB/F [22]. 
As infection of BALB/c mice with 50K sporozoites of the Δp52+p36 mutants did not result in breakthrough blood infections it was surprising that a low 
percentage of C57BL/6 mice (10-20%) produced breakthrough blood infections after inoculation with 50K sporozoites (Table 1). The prepatent period of these 
‘breakthrough’ infections was prolonged by 1-2 days compared to WT. Genotyping 
of the breakthrough blood parasites (Δp52+p36br) by PCR and Southern analysis of 
chromosomes confirmed that these parasites had the Δp52+p36 genotype (Fig. S1D). 
To examine the possibility that parasites can stably switch to an alternative, P52/P36 
independent, mechanism of liver stage development we analysed infections in mice 
after inoculation of 50K sporozoites derived from the Δp52+p36br parasites. Five out 
of 12 mice did not produce blood infections and those mice that developed a blood infection had a prolonged prepatent period of 1-2 days. Although the percentage 
of mice with breakthrough blood infections after infection with Δp52+p36br 
sporozoites is higher (58%) then after infection with Δp52+p36 sporozoites (10-
20%), these results indicate that the Δp52+p36br are not derived from parasites that 
had permanently switched to an efficient and P52/P36 independent mechanism of 
liver stage development. 
75
Assessing attenuation of Plasmodium GAPs
54 hpi48 hpi
αEXP1αMSP1 / 
40 hpi24 hpi
αEXP1αHSP70/ 
WT
Δf
ab
b/
f
WT
Δf
ab
b/
f
48hpi 54hpi
0
20
40
60
80
100
MSP++
MSP+
MSP-
(%)
WT
Δfabb/f
10µm
Δp52+p36
0
500
1000
1500
WT
Δfabb/f
Δp52+p36
24 hpi 48hpi
#L
iv
er
 st
ag
es
A
B C
Figure 2: Development of P. berghei Δp52+p36 and Δfabb/f parasites in vitro   
A) Development of liver-stage parasites of P. berghei GAPs in culture as shown by immuno-fluorescence 
analysis of parasites at different hpi. Staining with anti-PbCSP-antibodies at 3hpi in the invasion assay 
(see A) distinguishes extracellular (green) from intracellular (yellow/orange) sporozoites; anti-PbEXP1 
and anti-HSP70 antibodies recognize the parasitophorous vacuole (green) and the parasite cytoplasm 
(red), respectively; anti-PbMSP1 antibodies (red) is a marker of PbMSP1 expression during merozoite 
formation in mature liver-stage parasites. Nuclei are stained with Hoechst-33342. In the Δfabb/f 
parasites PbMSP1 expression is strongly reduced (see D). While >99% of Δp52+p36 liver-stage parasites 
abort development soon after invasion a few, PbEXP1-negative, parasites do mature and are detectable at 54hpi. B) Mean number of intra-hepatic (liver stage) WT and P. berghei mutant parasites at 24hpi and 
48hpi per in vitro culture well (4 wells counted per time point for each mutant sporozoite infection). C) 
Relative PbMSP1 expression in P. berghei liver-stages at 48hpi and 54hpi as determined by staining with 
anti-PbMSP1 antibodies of cultured liver-stages (see A). MSP++: intense staining; MSP+: weak staining; 
MSP-: MSP negative. See Figure S3 for the relative MSP1 staining of Δfabb/f liver stage parasites.
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Table 1. Breakthrough blood infections after intravenous injection of different doses of 
sporozoites of P. berghei GAPs
Animals Parasites Dose breakthrough/infected animals a
Pre-patency 
(days)
BALB/C WT 1x104 5/5 5-6
Δfabb/f-a 5 x104 12/15 6-7
Δfabb/f-b 5 x104 10/10 7-8
Δp52+p36-a 5 x104 0/10 n/a
Δp52+p36-b 5 x104 0/10 n/a
C57BL6 WT 1 x104 5/5 5-6
Δfabb/f-a 5 x104 15/15 6-7
Δfabb/f-b 5 x104 10/10 7-9
Δp52+p36-a 5 x104 1/10 6
Δp52+p36-b 5 x104 2/10 6-7
Δp52+p36-a
‘breakthrough’ b 5 x10
4 7/12 6-8
a Number of mice showing breakthrough infections of the total number of infected mice.                               
b Δp52+p36 ‘breakthrough’ are parasites that were derived from a blood infection in mice after infection 
with sporozoites of mutant Δp52+p36.
Evidence for complete development of P. berghei Δp52+36 parasites in 
hepatocytes in vitro and in vivo
For P. berghei it has been reported that WT sporozoites are not completely restricted 
to hepatocytes for development but can also develop into infectious merozoites in 
skin cells, albeit at a very low frequency [43;44]. The Δp52+36 breakthrough blood 
infections may therefore result from development of a low number of sporozoites in 
cells of other organs where the establishment of a PVM is less critical. To investigate whether Δp52+36 sporozoites could develop in hepatocytes into maturing liver 
stages we analysed development of Δp52+36 sporozoites in cultured hepatocytes and in mice using real-time in vivo imaging of liver stage development. Most 
Δp52+p36 parasites rapidly disappear from in vitro hepatocyte cultures as shown by 
quantitative analyses of infected hepatocytes by fluorescence microscopy. However, in-depth analyses whereby all hepatocytes present in the culture wells were analysed 
by fluorescence microscopy at 48h and 54h after adding sporozoites, showed very 
low numbers of Δp52+p36 liver-schizonts, 1 to 4 per well, that were comparable 
in size to WT schizonts (Fig. 2A). These liver-schizonts expressed MSP1 as shown 
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Figure 3: Development of P. berghei Δp52+p36 
and Δfabb/f parasites in vivo  
A) Development P. berghei GAPs in C57BL/6 mice as shown by real-time in vivo imaging of luciferase-
expressing liver-stage parasites at 40hpi. The upper panels show that all mice infected with 103 
(10K) WT sporozoites developed a breakthrough infection in the blood (i.e. 5 out of 5 mice), and all 
mice (10/10) infected with 50K Δfabb/f parasites 
numbers also developed a breakthrough 
infection. When 10 C57BL/6 mice were infected with 50K Δp52+p36 sporozoites only 2 produced a breakthrough blood infection, the 2 mice that 
developed a blood stage infection are shown and 
individual spots (possibly individual infected 
hepatocytes) localizing to the liver are clearly 
visible (see white arrows). 8 of the 10 C57BL/6 mice infected with 50K Δp52+p36 sporozoites did 
not develop a blood infection, in 7 of these mice 
no luciferase expressing parasites were visible. 
However, 1 mouse did show an individual spot 
(white arrow) in the liver but did not generate a blood infection. All mice were infected with 
hand dissected sporozoites injected IV. B) Graph 
showing the measured relative light intensity of 
C57BL/6 mice infected with 103 (10K) WT and 5x105 (50K) Δp52+p36 and Δfabb/f sporozoites IV 
at 40hpi; as shown in (A) and depicted as relative 
light units (RLU). 
by staining with anti-MSP1 antibodies and contained large numbers of distinct 
nuclei comparable to mature WT schizonts (Fig. 2A). Interestingly, in contrast to 
schizonts of WT and Δfabb/f, the Δp52+p36 schizonts were negative for staining 
with antibodies recognizing the PVM-resident protein EXP1, suggesting that the 
WT Δfabb/f
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PVM of these parasites is compromised (Fig. 2A, Fig. S4A). We next examined 
development of Δp52+p36 sporozoites in live mice using real-time in vivo imaging of 
luciferase-expressing parasites [38]. In the liver of mice infected with sporozoites of the reference WT line expressing luciferase, PbGFP-Luccon, liver stage luminescence signals can be detected at 24h after infection with sporozoites and imaging between 
40h and 60h allows the detection of individual liver schizonts [38]. As expected, 
based on the Δfabb/f breakthrough blood infections and in vitro maturation of 
Δfabb/f liver schizonts, infected hepatocytes were clearly visible in all mice infected 
with 50K Δfabb/f sporozoites at 42hpi (Fig. 3A). In contrast, imaging of mice infected 
with 50K Δp52+p36 sporozoites, did not show luminescence signals at 42hpi in 7 
out of 10 mice. None of the luminescence-negative mice developed a breakthrough 
blood stage infection, indicating the absence of developing Δp52+p36 sporozoites. 
Interestingly, in 3 mice we observed a clear luminescence signal in the liver although 
luciferase signals were confined to a few (1-3) individual spots as compared to the 
strong luminescence signals of whole livers that were observed in mice infected 
with WT or Δfabb/f sporozoites (Fig. 3A). Two of the 3 luminescence-positive 
mice developed a breakthrough blood infection and genotyping of the progeny 
of the blood parasites confirmed the Δp52+p36 genotype (Fig. S1D). Combined these results indicate that the breakthrough blood infections in these mice are 
associated with the presence of developing Δp52+p36 parasites in the liver. The 
one mouse that was luminescence-positive but did not develop a blood infection 
may indicate that certain cases Δp52+p36 liver sporozoites develop into maturing 
liver stages but abort development before production of infectious merozoites. 
Some P. falciparum Δp52+36 sporozoites are able to develop into replicating 
liver stage forms
We next examined if the ability of low numbers of Δp52+p36 sporozoites to develop 
into maturing liver stages was specific for P. berghei or that a similar phenotype could 
also be observed for P. falciparum Δp52+p36 parasites. Recently it has been reported that P. falciparum Δp52+p36 sporozoites invaded but did not mature in hepatocytes in 
culture or in a chimeric mouse harboring human hepatocytes [27]. Using sporozoites 
derived from two P. falciparum Δp52+p36 mutants, PfΔp52+p36 and PfΔp52+p36gfp 
[45] we examined their development in cultures of primary human hepatocytes. These P. falciparum mutants show normal in vitro blood stage development [45] as 
well as oocyst and sporozoite production (Fig. 4A) and we confirmed by RT-PCR that sporozoites of these mutants are unable to express either p52 or p36 (Fig. 4B). 
In culture, sporozoites showed cell traversal (Fig. 4C) and hepatocyte invasion (Fig. 
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4D) comparable to WT sporozoites but 24h after invasion the vast majority (>99%) 
of parasites became arrested as observed by HSP70 antibody-staining on days 2-7 
post invasion (Fig. 4D). However, after in-depth analyses whereby all hepatocytes 
present in the culture wells were analyzed by fluorescence microscopy, we detected 
very low numbers of PfΔp52+p36 parasites (occasionally 1 per well) at day 2, 3 and 
4 after sporozoite invasion that were comparable in size to WT parasites. These parasites could be detected in both the PfΔp52+p36 and PfΔp52+p36gfp mutant and 
the parasites present at day 4 clearly demonstrated nuclear division as shown by 
the presence of multiple, DAPI-stained nuclei (Fig. 4E). Since the p52 and p36 genes 
of both mutants had been deleted by double cross-over homologous recombination, 
the replicating parasites present at day 4 cannot be due to parasites that have a WT 
genotype as a result of a ‘reversion’ event that can occur when genes are deleted by 
a single cross-over homologous recombination [34]. These observations therefore 
provide evidence that P. falciparum sporozoites can progress into replicating liver stages in the absence of P52 and P36, comparable to P. berghei Δp52+p36 sporozoites.
Discussion 
In this study we report an assessment of the adequacy of attenuation using the P. 
berghei rodent model of two GAPs for which a complete liver stage growth arrest has 
been previously reported in BALB/c mice infected with the rodent parasite P. yoelii. 
For both P. berghei and P. yoelii it has been shown that the bacterial like type II fatty 
acid synthesis (FAS II) pathway plays an important role for liver stage development [22;46]. Deletion of 3 of the 4 genes that encode the key enzymes of this pathway, 
FabB/F, FabZ and FabI, have no effect on blood stage development but severely affect 
late liver stage development [22;46]. In P. yoelii deletion of either FabB/F or FabZ 
resulted in a complete growth arrest of liver stages. Moreover, it has been recently reported that P. yoelii parasites lacking FabB/F give rise to broader and larger 
protective CD8 responses in mice, than either IrrSpz or early arresting GAPs, making 
them promising ‘second-generation’ GAPs [23].  In contrast to the observations in P. 
yoelii, we found that P. berghei GAP lacking expression of FabB/F is not attenuated, in 
either BALB/c or C57BL/6 mice, although the prolonged prepatent period to a blood 
infection indicates a significant reduction in the generation of infectious merozoites. This phenotype of partial attenuation is comparable to the phenotype of P. berghei 
mutants lacking expression of FabI [46], which also showed a severe delay in the 
onset of blood stage patency. Liver schizonts of P. yoelii mutants lacking expression 
of FASII pathway enzymes showed clear features of aberrant nuclear division and
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Figure 4: Characterisation of P. falciparum Δp52+p36 (PfΔp52+p36 and PfΔp52+p36gfp) parasites 
A) Oocyst and sporozoite production in A. stephensi mosquitoes infected with P. falciparum wildtype (WT), PfΔp52+p36 and PfΔp52+p36gfp parasites. B) RT-PCR analysis showing absence of p52 and p36 transcripts in P. falciparum mutant sporozoites. PCR amplification using purified sporozoite RNA was 
performed either in the presence or absence of reverse transcriptase (RT+ or RT-, respectively), the 
positive control was performed by PCR of 18S rRNA using primers 18Sf/18Sr (for primer sequences see Methods). C) Cell traversal ability of P. falciparum WT (NF54) and mutant sporozoites as determined by 
FACS counting of Dextran positive hepG2 cells. Dextran: hepatocytes cultured in the presence of Dextran but without the addition of sporozoites. D) In vitro invasion of P. falciparum Δp52+p36 sporozoites 
and development of liver-stages in primary human hepatocytes. Invasion is represented as the ratio of extra- and intracellular sporozoites by double staining at 3 and 24 hpi, determined after 3 wash steps to 
remove sporozoites in suspension. From day 2 to 7 the number of parasites per 96-well was determined by counting parasites stained with anti-P. falciparum HSP70 antibodies. * Total number of liver stages 
observed in 6 wells, where infected cells were not identified they are indicated as not detected (nd). E) At 
day 4 low numbers of liver stages were detected, possessing multiple nuclei (i.e. replicating) as shown by 
DAPI staining of their nuclei (white arrows).
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an absence of the merozoite specific protein, MSP1, expression. In contrast, the 
liver schizonts of the P. berghei mutants expressed MSP1 although the level of MSP1 
expression was clearly delayed in comparison to WT parasites. These observations 
indicate that differences exist as to the essential nature of the FAS II pathway for 
P. berghei and P. yoelii liver stages. To which extent P. falciparum liver stages are 
dependent on the FASII pathways is as yet unknown and awaits investigations on mutant P. falciparum liver stages in primary hepatocytes. 
P. yoelii and P. berghei GAP lacking expression of P52 and P36 show a developmental 
arrest early after invasion of the hepatocyte [9;21]. These proteins belong to the 6-cys protein family consisting of 10 members, most of which are expressed in a 
discrete stage-specific manner; in gametocytes, sporozoites or merozoites [41]. 
P52, a putative GPI-anchored protein and P36, a putative secreted protein, are both 
expressed in sporozoites and early liver stages [41;42;47]. Despite the early growth-
arrest phenotype, C57BL/6 mice inoculated with sporozoites of ‘single gene deletion’ mutants lacking either P52 or P36 result in breakthrough blood infections in a low 
number of mice [9]. Since both proteins belong to the same family of proteins and their genes form a paralogous pair in the genome it has been reasoned that they may 
perform partly redundant functions and that removal of both genes might result in 
parasites that show a complete growth arrest during development in the liver. Indeed, complete attenuation has been reported for P. yoelii sporozoites that lack expression 
of both P52 and P36 [21] and this attenuation of the ‘double gene deletion’ mutants 
was demonstrated by the absence of breakthrough blood infections in BALB/c mice 
or Wistar rats after IV injection of up to 105 sporozoites. In agreement with these studies we found no breakthrough blood infections with P. berghei sporozoites 
lacking both P52 and P36 when tested in BALB/c mice. However, when C57BL/6 mice were injected with similar doses of sporozoites of the P. berghei ‘double gene 
deletion’ mutants, we observed breakthrough blood infections in a low percentage 
of mice, showing that these mutants did not completely abort development in the 
liver. These results indicate that differences may exist between P. yoelii and P. berghei 
on their dependence on P36 and P52 for liver stage development comparable to 
the differences in dependence on the FAS II pathway. For P52 evidence has been 
presented for a role in establishment and/or maintenance of the parasitophorous 
vacuole [9;21;42] and the early growth-arrest of sporozoites lacking P52 would 
suggest that liver stage parasites cannot develop in the absence of a competent PVM. 
For both P. berghei and P. yoelii it has recently been reported that WT sporozoites 
are not completely restricted to hepatocytes for development but can also develop 
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into infectious merozoites in skin cells, albeit at a very low frequency [43;44]. It 
may therefore be that the Δp52+36 breakthrough blood infections in the C57BL/6 
mice arise from sporozoites that have invaded and undergone development in cells 
other than the liver. However, our observations on maturation of P. berghei Δp52+36 
liver stages both in cultured hepatocytes and as in living mice using in vivo imaging 
provide evidence that breakthrough infections result from merozoites derived from 
schizonts developing in hepatocytes. Apart from a possible difference in attenuation between P. yoelii and P. berghei sporozoites lacking P52 and P36, the observed P. 
berghei breakthrough blood infections may also be explained by differences in 
intracellular survival of attenuated sporozoites inside cells from different mouse 
strains. Breakthrough blood infections were only observed in C57BL/6 mice and like in P. yoelii, infection of BALB/c mice with high doses of P. berghei Δp52+p36 
did not result in ‘breakthrough’ blood infections. It is known that large difference 
exist in the dose of sporozoites that is needed to obtain full protective immunity in 
C57BL/6 and BALB/c mice, where C57BL/6 mice are the more difficult to protect 
requiring multiple boosting immunizations. It has been suggested that differences 
in the protective immune responses may be partly attributed to the presence of an 
immunodominant CD8 +T cell epitope present in the circumsporozoite protein that 
is H2Kd -restricted [48-50]. Our observations that all Δp52+36 infected liver cells 
are removed in BALB/c mice whereas low numbers of Δp52+36 sporozoites are able 
to complete full liver development in C57BL/6 mice indicate that differences exist between these mouse strains in both the innate and acquired immune responses that 
are responsible for the recognition and removal of infected hepatocytes. Studies with 
IrrSpz of P. yoelii inoculated into both BALB/c and immunocompromised mice have 
shown that sufficiently irradiated sporozoites are unable to create breakthrough 
blood infections, indicating that abortion of development is due to the failure of the 
parasite to multiply and not the host to eliminate the infection [51]. Interestingly, 
our observations of breakthrough blood infections of the two rodent GAP provide 
evidence that the adequacy of sporozoite attenuation is not only dependent on the Plasmodium species studied, as in the case of genes encoding enzymes of the 
FASII pathway, but can also be influenced by host factors. Our results demonstrate that P. berghei in C57BL/6 mice is a more stringent model for preclinical testing of 
these GAPs than P. yoelii in BALB/c mice. This observation is emphasized by our analysis of P. falciparum Δp52+36 GAP in cultured primary human hepatocytes. The 
observations of low numbers of replicating liver stages demonstrates that maturation 
of Δp52+36 liver stages is not specific for P. berghei but can also occur in P. falciparum and underscores the incomplete attenuation of Plasmodium GAP lacking both P52 
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and P36. While we were not able to observe replicating P. falciparum Δp52+p36 
liver stages after day 4, we believe that this may result from the drop of 30-40% we 
observe in cultured primary human hepatocytes between day 5 and day 7, as can 
be observed with WT infected hepatocytes. Therefore the few Δp52+p36 replicating 
parasites may be below the level of detection in this assay. In a recent clinical trial, 
where human volunteers were immunized with P. falciparum Δp52+p36 GAP a 
breakthrough blood infection was confirmed in one volunteer [52]. Approaches such 
as the co-administration of anti-Plasmodium drugs with GAP vaccine formulations 
and/or the creation of genetically modified parasites that have genes introduced 
into their genome, which when expressed (i.e. in the liver stages) result in the 
destruction of the parasites, may mitigate the possibility of ‘breakthrough’ parasites. 
However, while we are currently exploring these potential solutions, they also raise 
additional questions both with respect to practical administration of a vaccine requiring prophylactic drugs in an endemic setting, and additional safety concerns 
related to parasites that ‘self-destruct’.
In conclusion, our combined data based on P. berghei and P. falciparum provides a 
strong indication that Δp52+p36 and Δfabb/f GAP are not sufficiently attenuated 
to move forward for further clinical development. Multiple genes governing 
independent cellular process, vital to liver stage development, must be removed 
such that abortion of liver stage development is complete. Our data underline the 
need for stringent preclinical testing of GAP before advancing into human vaccine 
trials. We therefore propose that GAP attenuation evaluation should preferably 
include, but not be limited to: (i) generation and analysis of equivalent GAPs in both P. yoelii and P. berghei; (ii) these GAPs should be tested for breakthrough blood 
infections in different mice strains (e.g. BALB/c, C57BL/6 and outbred mice) with escalating doses of sporozoites; and (iii) analysis of the corresponding P. falciparum 
GAP should be tested for liver stage development in cultured human hepatocytes.
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Supplementary Information
Material and Methods
Animals and parasites        
Female C57BL/6, BALB/c and Swiss OF1 mice (6-8 weeks old; Charles River/Janvier) were 
used. All animal experiments were performed after a positive recommendation of the Animal 
Experiments Committee of the LUMC (ADEC) and RUNMC (RUDEC 2008-123, RUDEC 2008-
148) was issued to the licensee. The Animal Experiment Committees are governed by sec-
tion 18 of the Experiments on Animals Act and are registered by the Dutch Inspectorate for 
Health, Protection and Veterinary Public Health, which is part of the Ministry of Health, Wel-
fare and Sport. The Dutch Experiments on Animal Act is established under European guide-
lines (EU directive no. 86/609/EEC regarding the Protection of Animals used for Experimen-
tal and Other Scientific Purposes).       
The following reference lines of the ANKA strain of P. berghei were used: line cl15cy1[1]; line 
676m1cl1 (PbGFP-Luccon; see RMgm-29 in www.pberghei.eu) and 507cl1 (PbGFPcon; for de-
tails see RMgm-7 in www.pberghei.eu). PbGFPcon expresses GFP from the constitutive eef1a promoter and PbGFP-Luccon expresses a fusion protein of GFP and Luciferase from the eef1a 
promoter [2;3]. For P. falciparum the lines NF54 (wild type; wt) and mutant lines PfΔ52+36 and PfΔ52+36gfp [4] were used. In these mutant lines of the NF54 line the p52 (PFD0215c) and p36 (PFD0210c) genes have been disrupted by double cross-over homologous integra-tion [4]. Blood stages were cultured in a semi-automated culture system using standard in 
vitro culture conditions for P. falciparum and induction of gametocyte production in these 
cultures was performed as previously described[5;6].
Generation of P. falciparum ∆p52+p36 mutantsThe generation of two independent P. falciparum Pf∆52+p36 mutants, Pf∆52+36 and 
Pf∆52+36gfp, has been previously described in van Schaijk et al [4]. For this study we char-acterized oocyst and sporozoite production of both clones and the sporozoites were subse-
quently used for analysis of liver stage development (see below). 
RT-PCR analysis of P. falciparum WT and ∆p52+p36 mutant sporozoites
Absence of transcripts of the targeted genes in sporozoites was analysed by reverse transcrip-
tase-PCR. Total RNA was isolated using the RNeasy mini Kit (Qiagen) from 106 salivary gland 
sporozoites collected by mosquito dissection of mosquitoes 16 days post feeding with NF54 or PfΔp52+36 parasites. Remaining DNA was degraded using DNAseI (Invitrogen). cDNA was 
subsequently synthesized using the First Strand cDNA synthesis Kit for RT-PCR AMV (Roche) 
(RT+) and as a negative control for the presence of genomic DNA, reactions were also pre-
formed without reverse transcriptase (RT-). PCR amplification was performed for regions of 
p52 or p36 using primers BVS139 (5’ gaatgtaaattcagatgaagctcaagaatgc) and BVS140 (5’ ag-
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gtatattatcaccaaaatcacaaccc) or BVS141 (5’ tcataatgtgtatccagttgtgac) and BVS142 (5’ catagaat-
ggcatgtaaattcccac) respectively. Positive control was performed by PCR of 18S rRNA using 
primers 18Sf (5’gtaattggaatgataggaatttacaaggt) and 18Sr (5’tcaactacgaacgttttaactgcaac). PCR 
products were size fractionated on a 2.0% agarose gel.
Generation of P. berghei ∆p52+p36 and ∆fabb/f mutantsTo disrupt the genes p36 (PBANKA_100210) and p52 (PBANKA_100220) a single gene dele-
tion construct was constructed using the standard targeting DNA construct, pL0001 (www.MR4.org) which contains the pyrimethamine resistant (pyrr) cassette derived from the Toxo-
plasma gondii (tg) gene, tgdhfr/ts, as a selectable-marker cassette (SM). Target sequences for 
integration of the construct by double cross-over homologous recombination were PCR am-
plified from P. berghei genomic DNA (cl15cy1) using primers (Table S1) specific for the 5’ and 3’ end of p52 and p36 respectively. The PCR–amplified target sequences were cloned either 
upstream or downstream of the SM of plasmid pL0001 (Fig. S1). The linear DNA construct, 
pL1164, used for transfection was obtained after digestion of plasmids with the appropriate restriction enzymes (Table S1). Two independent mutants (∆p52+p36-a, -b) were generated 
that lack expression of both P36 and P52. One mutant (∆p52+p36-a; 795cl1) was generated in reference line PbGFPcon (Fig. S1) and the other (∆p52+p36-b; 1409cl1) in the PbGFP-Luccon 
line (Fig. S2) using standard methods of transfection, drug-selection and parasite cloning [1]. To disrupt the gene fabb/f two different DNA constructs were generated. For the first con-
struct, pL1454, the same approach was used as described above for ∆p52+p36 using standard 
plasmid pL0037 [7]. This plasmid contains the hdhfr::yfcu selectable marker which is a fusion of the human dhfr (hdhfr) gene and the negative selection marker yfcu that confers suscepti-
bility to the pro-drug 5-FC [7]. Target sequences were PCR amplified from P. berghei genomic 
DNA (cl15cy1) using primers (Table S1) specific for the 5’ and 3’ end of fabb/f and cloned 
either upstream or downstream of the SM (Fig. S3). Using this construct the mutant ∆fabb/f-a (1345cl1) was generated in the cl15cy1 reference line using standard methods of transfection 
(Fig. S3). For the second construct, pL1662, we adapted a previously described ‘Anchor-tag-
ging’ PCR-based method for generation of gene deletion constructs[8]. This method employs 
a 2-step PCR reaction shown in Figure S4. In the first PCR reaction two-flanking fragments 
(5’or 3’; 0.8 kb each) of fabb/f were amplified using genomic DNA (cl15cy1) as template with 
the primer pairs 5804/5805 (5’target sequence) and 5806/5807 (3’target sequence). Both 
primer 5805 and 5806 (Table S1) have 5’-terminal extensions homologues to the hdhfr select-able marker cassette. This cassette contains the hdfr under control of the eef1a promoter re-
gion and the 3’UTR pbdhfr/ts and is obtained from plasmid pL0040 by digestion with restric-tion enzymes XhoI and NotI (pL0040 is available from The Leiden Malaria Research Group). 
Primers 5804 and 5807 (Table S1) have 5’-terminal overhang with an anchor-tag suitable for 
the second PCR reaction. In the second PCR reaction the fragments were annealed to either side of the hdhfr selectable marker cassette with anchor-tag primers 4661/4662, resulting in the second PCR fragment with the expected size, i.e. 3.2 kb (1.6 kb of the selectable marker 
cassette + two targeting fragments of 0.8Kb). To remove the anchor-tag from the final DNA 
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construct, the second PCR fragment was digested with Asp718 and ScaI as primer 5804 con-tained an Asp718 restriction enzyme site and 5807 contained a ScaI site. Following ethanol 
precipitation, the PCR fragment was re-suspended in water at 1µg/µl and used for transfec-
tion. Using this PCR-based targeting construct the mutant ∆fabb/f-b (1704cl1) was generated in the PbGFP-Luccon reference line using standard methods of transfection (Fig. S4). Correct integration of the constructs into the genome of mutant parasites was analysed by 
diagnostic PCR-analysis and Southern analysis of PFG-separated chromosomes[9] as shown 
in Fig. S1-3. PFG-separated chromosomes were hybridized with a probe recognizing the 3’-
UTR dhfr/ts of P. berghei[1]. Absence of transcripts of the targeted genes in sporozoites was 
analysed by reverse transcriptase-PCR. Total RNA was purified from salivary gland sporozo-
ites (see below) using TRIzol reagent (Invitrogen) and prepared according to manufactures 
specifications. Purified RNA was then treated with RQ1 DNase (Promega). Reverse transcrip-
tion was performed using the Super Script III RT (Invitrogen) as previously described in van Dijk et al (2005)[10]. cDNA was used as template for PCR amplification with control and gene 
specific primers that are listed in Table S1.
Analysis of blood stage and oocyst development of P. falciparum and P. berghei mu-
tant parasites                     
P. falciparum blood stages were cultured in a semi-automated culture system using standard 
in vitro culture conditions for P. falciparum and induction of gametocyte production in these 
cultures was performed as previously described [5;6]. Blood stage development and produc-tion of gametocytes of Pf∆p52+p36 and Pf∆p52+p36gfp were analyzed as described [4] and 
were similar to parasites of the parent line NF54. Feeding of A. stephensi mosquitoes and 
determination of oocyst production was performed as described [11]. Oocyst production of both pfΔp52+p36 and pfΔp52+p36gfp were comparable to the parent line NF54 (Fig. 4A). The P. berghei mutants, ∆p52+p36 and ∆fabb/f, were maintained in Swiss OF1 mice. The multi-plication rate of blood stages and gametocyte production were determined during the cloning 
procedure [1] and were not different from parasites of the reference ANKA lines. Feeding of 
A. stephensi mosquitoes and determination of oocyst production was performed as described [12]. 
Analysis of P. falciparum and P. berghei sporozoite production, motility and he-
patocyte traversal        
P. berghei sporozoites were collected at day 21 after infection by hand-dissection of the sal-
ivary glands. Salivary glands were collected in DMEM (Dulbecco’s Modified Eagle Medium 
from GIBCO) and homogenized in a homemade glass grinder. The number of sporozoites was 
determined by counting the numbers of sporozoites of 10 salivary glands in duplicate in a Bürker-Türk counting chamber using phase-contrast microscopy.    P. falci-
parum sporozoites were collected at day 14-16 after infection by hand-dissection of the sali-
vary glands. These salivary glands were collected in William’s E medium supplemented with 
10% FCS, 2% penicillin-streptomycin, 1% sodium-pyruvate, 1% L-glutamine, 1% insulin-
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transferin-selenium (Gibco) and 10-7M dexamethasone (Sigma) and homogenized in a home made glass grinder. The free sporozoites were counted in a Bürker-Türk counting chamber using phase-contrast microscopy. Sporozoite production of Pf∆52+36 and Pf∆52+36gfp were 
comparable to the parent line NF54 (Fig. 4A).
Gliding motility of P. berghei sporozoites was determined in assays that were performed on anti-P. berghei circumsporozoite antibody (3D11, monoclonal mouse antibody 10 µg/ml) 
pre-coated Labtek slides (Nunc, NL) to which 2×104 sporozoites were added [10]. After 30 
minutes of incubation at 37°C sporozoites were fixed with 4% PFA and after washing with 
PBS, the sporozoites and the trails (‘gliding circles’) were stained with anti-CSP-antibody 
(3D11[13]) conjugated to Alexa 488 (Dylight 488 antibody labeling kit; Thermo Scientific, 
NL). Slides were mounted with Fluoromount-G (SouthernBiotech, NL) and ‘gliding circles’ 
were analyzed using a Leica DMR fluorescence microscope at 1000X magnification. 
P. berghei sporozoite hepatocyte traversal was determined in assays as described previ-
ously[14]. Briefly, human liver hepatoma cells (Huh7) were suspended in 1ml of ‘complete’ 
DMEM (DMEM from Gibco, supplemented with 10% FCS, 1% penicillin/streptomycin and 
1% Glutamax) and were plated in 24 well plates (105 cells/ml). After the Huh7 monolayers 
were >80% confluent, 105 sporozoites were added with the addition of FITC- or Alexa-647-
labeled dextran (Invitrogen, NL). No sporozoites were added to the negative control wells. 
FACS analysis of dextran-positive cells was performed on a total 25x103 cells per well (each 
experiment was performed in triplicate wells) using a FACScalibur flow cytometer (Becton 
Dickinson, NL). P. falciparum sporozoite hepatocyte traversal was determined in assays previ-ously described [11].
Analysis of P. falciparum and P. berghei sporozoite infectivity and development in 
hepatocytes in immuno-fluorescence assays     
Infectivity of P. falciparum sporozoites and development in hepatocytes was analysed in pri-mary human hepatocytes. Primary human hepatocytes were isolated from healthy parts of 
human liver fragments which were collected during unrelated surgery in agreement with 
French national ethical regulations as described[15]. Cells were seeded into 96-well plates or 
8-chamber Lab-Tec slides (Nalge Nunc) coated with rat tail collagen I (Becton Dickinson, Le 
Pont de Claix, France) at a density of 8x104 or 21x104 cells per well, respectively. These cells 
were cultured at 37°C in 5% CO2 in complete William’s E culture medium supplemented with 
10% FCS, 2% penicillin-streptomycin, 1% sodium-pyruvate, 1% L-glutamine and 1% insulin-
transferin-selenium (reagents for cell culture Gibco, Invitrogen) and 10-7M dexamethasone 
(Sigma, Saint Quentin Fallavier, France). Sporozoites (5 x104) were added to the hepatocyte cultures, and 3 hours after addition of sporozoites, the cultures were washed with culture 
medium to remove mosquito salivary gland material as well as non-invaded and unattached 
sporozoites, culture medium was added and cultures were incubated overnight at 37°C. The 
culture medium was replaced with fresh culture medium at 24h and 72h after infection[16]. 
Cultures were fixed at different time points after adding sporozoites with cold methanol and 
developing liver schizonts were stained with anti- HSP70 antibodies [17] followed by stain-
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ing with goat anti-mouse ALEXA-488 (green, fluorescence; Molecular probes). Nuclei were 
stained with 1µg/ml diamidino-phenylindole (DAPI). 
Invasion of primary human hepatocytes by P. falciparum sporozoites was determined as de-
scribed[18]. Cultures were fixed with 4% paraformaldehyde (PFA) for 20 min at room temper-
ature and extracellular (non-invaded) parasites were stained with anti-CSP antibody (3SP2) 
followed by staining anti-mouse-ALEXA594 (red fluorescence; Molecular probes). To detect 
intracellular parasites, the hepatocytes were subsequently permeabilised with 1% Triton-
X-100 in PBS for 4 min and stained with with anti-CSP antibody (3SP2) and these were then 
identified using anti-mouse-ALEXA488 (i.e. green fluorescence; Molecular probes). Nuclei 
were stained with 1µg/ml DAPI. Analysis and counting of stained intracellular and extracel-
lular parasites were performed using a DM-IRBE Flu Leica fluorescence microscope. 
Infectivity of P. berghei sporozoites and development was determined in cultures of Huh7 
cells (see above). Sporozoites (5 × 104) were added to a monolayer of Huh7 cells on cover-
slips in 24 well plates (with a confluency of 80-90%) in ‘complete’ DMEM (see above). At 
different time points after infection, cells were fixed with paraformaldehyde 4%, permeabi-
lized with Triton-X-100 0.1%, blocked with 10% FCS in PBS, and subsequently stained with 
a primary and secondary antibody, for 2h and 1h respectively. Primary antibodies used were 
anti-PbEXP1 (raised in chicken [19]), detecting the PVM-resident protein (PBANKA_092670); 
anti-PbHSP70 (raised in mouse[10]), detecting the cytoplasmic heat shock protein 70 
(PBANKA_081890);, and anti-MSP-1 (mouse; MRA-78 from MR4; www.MR4.org) detecting MSP1 of P. yoelii and P. berghei. Anti-mouse, -chicken and -rabbit secondary antibodies, con-
jugated to Alexa-488 and Alexa-594, were used for visualization (Invitrogen). Nuclei were 
stained with Hoechst-33342. Cells were mounted in Vectashield (Vector Laboratories) and 
examined using a DM-IRBE Flu Leica fluorescence microscope.    
Invasion of hepatocytes in vitro by P. berghei sporozoites was determined, as described for P. 
falciparum above, specifically by addition of 5×104 sporozoites to a monolayer of Huh7 cells. 
After the addition of sporozoites, cultures were centrifuged for 10 minutes at 1800G (Ep-
pendorf centrifuge 5810 R) and then returned to the 37°C incubator. After 2-3 hours wells 
were washed 3 times with PBS to remove uninvaded sporozoites. Cells were fixed with 4% 
paraformaldehyde (PFA) for 10 min and extracellular (non-invaded) parasites were stained 
with anti-CS-antibody (3D11) and conjugated with Alexa 594 antibody (Dylight 594 antibody 
labeling kit; Thermo Scientific, NL). After permeabilization with 0.1 % Triton-X-100 for 10 
minutes and blocking with 10% FCS in PBS for 20 minutes, intracellular sporozoites were 
with anti-CS-antibody (3D11) and conjugated with Alexa 488 antibody (Dylight 488 antibody 
labeling kit; Thermo Scientific, NL). Nuclei were stained with Hoechst-33342. Analysis and 
counting of stained intracellular and extracellular parasites were performed using a Zeiss 
Axiophot Fluorescence microscope with Axiocam MRm CCD camera.
Analysis of P. berghei sporozoite development in hepatocytes by qRT-PCR  Sporozoites (5×104) were added to a monolayer of Huh7 cells, in 24 well plates (seeded the day before with 105 hepatocytes) in ‘complete’ DMEM (see above). At different time points 
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after adding the sporozoites, culture medium was removed, cells washed once with PBS, 
and cells were resuspended in 200 µl of RLT buffer (Quiagen’s MicroRNeasy kit). RNA from these samples was extracted following the manufacturer’s instructions. The transcriptor 
first-strand cDNA synthesis kit (Roche) was used according to the manufacturer’s recom-
mendations to make single-stranded cDNA. Real-time PCR analysis of P. berghei 18S rRNA 
and human β-actin was performed as described [20]. qRT-PCR curves were drawn using the 
GraphPad Prism software (GraphPad Prism, Inc., US)
Analysis of P. berghei sporozoite infectivity in mice and in vivo imaging of liver 
stage development in mice       
C57BL/6 mice were inoculated with sporozoites by intravenous injection of different sporo-zoite numbers, ranging from 1x104 - 5x105. Blood stage infections were monitored by analysis 
of Giemsa-stained thin smears of tail blood collected on day 4-14 after inoculation of sporozo-
ites. Pre-patency (measured in days after sporozoite inoculation) is defined as the day when 
parasitemia of 0.5-2%.in the blood is observed.      
Liver stage development in live mice was monitored by real-time in vivo imaging of liver stag-es as described [20;21]. Liver stages were visualized by measuring luciferase activity of para-sites (expressing luciferase under the eef1a promoter) in whole bodies of mice or in dissected 
livers using the IVIS100 Imaging System (Caliper Life Sciences, USA). Animals were anesthe-
tized using the isofluorane-anesthesia system (XGI-8, Caliper Life Sciences, USA), their belly 
was shaved and D-luciferin dissolved in PBS (100 mg/kg; Synchem Laborgemeinschaft OHG, 
Germany) was injected subcutaneously (in the neck). Animals were kept anesthetized during the measurements, which were performed within 3 to 5 minutes after the injection of D-lucif-
erin. Bioluminescence imaging was acquired with a 10 cm FOV, medium binning factor and an 
exposure time of 10 to 180 seconds. Quantitative analysis of bioluminescence of whole bodies 
was performed by measuring the luminescence signal intensity using the ROI settings of the 
Living Image® 3.0 software. The ROI was set to measure the abdominal area at the location of 
the liver and ROI measurements are expressed in total flux of photons. 
Immunizations of mice with P. berghei sporozoites    
BALB/C and C57BL6 mice were immunized by intravenous injection using different numbers of ∆p52+p36 and ∆fabb/f sporozoites collected as described above. Immunized mice were 
monitored for blood infections by analysis of Giemsa stained films of tail blood at day 4-16 
after immunization. Immunized mice were challenged at different time points after immuni-
zation by intravenous injection of 1x104 sporozoites from the P. berghei ANKA reference lines cl15cy1 or the PbGFP-Luccon. In each experiment, naïve mice were included to verify infectiv-ity of the sporozoite used for challenge. After challenge, mice were monitored for blood infec-
tions by analysis of Giemsa stained films. Pre-patent period is defined as the period (days) 
between sporozoite challenge and the day that mice showed a blood parasitemia of 0.5-2%.
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Figure S1: Generation of P. berghei mutants ∆p52+p36-a and ∆p52+p36-b and genotype analyses 
of ∆p52+p36-a         
A) Schematic showing the generation of mutants ∆p52+p36-a (759cl1) and ∆p52+p36-b (1409cl1).
The DNA-construct pL1164 is aimed at disruption of target genes, p52 and p36, by double cross-over homologous recombination. The sequence of the primers to amplify the 5’- and 3’-target regions of the 
genes are shown in Table S1. Primers for diagnostic PCR (table S1) and size of the PCR DNA fragments are shown. B) Diagnostic PCR for confirmation of correct disruption of p52 and p36 in mutant ∆p52+p36-a and ∆p52+p36-b. SM: selectable marker (primers 4501/4502); 5’-integration event (primers L1389/
L313); 3’-integration event (primers 4239/47020); ORF (primers L775/L121). See Table S1 for the sequence of the primers. C) Southern analysis of Pulse Field Gel (PFG)-separated chromosomes of mutant ∆p52+p36-a and ∆p52+p36-b. Mutant ∆p52+p36-a has been generated in the reference P. berghei 
ANKA line PbGFPcon which has a gfp gene integrated into the silent 230p locus (PBANKA_030600) on 
chromosome 3 (i.e. RMgm-7; http://pberghei.eu/index.php?rmgm=7). Mutant ∆p52+p36-b has been generated in the reference P. berghei ANKA line PbGFP-Luccon which has a gfp-luciferase gene integrated 
into the silent 230p locus (PBANKA_030600) on chromosome 3 (i.e. RMgm-29; http://pberghei.eu/
index.php?rmgm=29) . Hybridization with the 3’-UTR dhfr/ts probe recognizes the integrated construct 
on chromosome 9, the reporter GFP-Luccon construct on chromosome 3, and the endogenous dhfr/ts gene 
located on chromosome 7. D) PCR and FIGE confirmation that the ∆p52+p36-b parasites that produced a 
breakthrough blood infections in BALB/c mice had the correct, mutant, genotype (see Figure 3).
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Figure S2: Generation and genotype analyses of P. berghei mutant; ∆fabb/f-a 
A) Schematic showing the generation of mutant ∆fabb/f-a (1345cl1). The DNA-construct pL1454 is aimed 
at disruption of target gene by double cross-over homologous recombination. The sequence of the primers to amplify the 5’- and 3’-target regions of the genes are shown in Table S1. Primers for diagnostic PCR 
(Table S1) and size of the PCR DNA fragments are shown. B) Diagnostic PCR for confirmation of correct 
disruption of fabb/f in mutant ∆fabb/f-a. SM: selectable marker (primers L379/L1511); 5’-integration 
event (primers 4253/L1858); 3’-interation event (primers 4239/4254); ORF (primers 4255/4256). See Table S1 for the sequence of the primers. C) Southern analysis of PFG-separated chromosomes of mutant 
∆fabb/f-a. This mutant has been generated in the reference P. berghei ANKA line cl15cy1. Hybridization 
with the 3’-UTR dhfr/ts probe recognizes the integrated construct on chromosome 9 and the endogenous 
dhfr/ts gene located on chromosome 7. 
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Figure S3: Generation and genotype analyses of P. berghei mutant; ∆fabb/f-b    
A) Schematic showing the generation of mutant ∆fabb/f-b (1704cl1). The DNA-construct pL1662 is 
aimed at disruption of target gene by double cross-over homologous recombination. The construct was 
generated by an adapted ‘Anchor-tagging’ PCR-based method employing a 2-step PCR reaction. In the 
first PCR step two-flanking fragments of fabb/f were amplified from genomic DNA with the primers 
5804/5805 (5’) and 5806/5807 (3’). Both primer 5805 and 5806 have 5’-terminal extensions homologues 
to the hdhfr selectable marker cassette (SM) obtained from plasmid pL0040 by digestion with restriction 
enzymes XhoI and NotI. Primers 5804 and 5807 have 5’-terminal overhang with an anchor-tag suitable 
for the second PCR step. In this step the fragments were annealed to either side of the SM with anchor-
tag primers 4661/4662, resulting in the second PCR fragment. To remove the ‘anchor’, the second PCR 
fragment was digested with Asp718 and ScaI as primer 5804 contained an Asp718 restriction enzyme 
site and 5807 contained a ScaI site. See Table S1 for the sequence of the primers. B) Diagnostic PCR 
for confirmation of correct disruption of fabb/f in mutant ∆fabb/f-b. SM: selectable marker (primers 
L307C/3187); 5’-integration event (primers 5808/4470); 3’-interation event (primers 4471/5809); ORF 
(primers 4255/4256). See Table S1 for the sequence of the primers. C) Southern analysis of PFG-separated chromosomes of mutant ∆fabb/f-b. This mutant has been generated in the reference P. berghei ANKA 
PbGFP-Luccon which has a gfp-luciferase gene integrated into the silent 230p locus (PBANKA_030600) 
on chromosome 3. Hybridization with the 3’-UTR dhfr/ts probe recognizes the integrated construct on 
chromosome 9, the reporter GFP-Luccon construct on chromosome 3, and the endogenous dhfr/ts gene 
located on chromosome 7. 
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Figure S4: IFA analysis of the few ∆p52+p36 infected hepatocytes (Huh7) visible at 48hpi  Three ∆p52+p36 infected hepatocytes are compared with a control WT infected hepatocytes. Staining 
with anti-MSP1 antibodies (red) identifies maturing merozoites inside the liver schizont; anti-PbEXP1 
recognize the parasitophorous vacuole (green) and is clearly visible around only WT parasites and is absent in all ∆p52+p36 infected cells. Nuclei are stained with Hoechst-33342. 
BF Hoechst MergeαEXP1αMSP1
10µm
WT
Δp52+p36
Δp52+p36
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Figure S5
A) MSP1 IFA expression criteria of liver stage parasites at 54hpi. Parasites are stained with anti-MSP1 
(red) and anti-EXP1 (green)-antibodies. Nuclei are stained with Hoechst-33342. MSP1++: MSP1 staining 
visible after short exposure (0.5 sec); MSP +: MSP1 staining only visible after long exposure (4 sec); MSP-: 
MSP1 staining not visible even after long exposure (4 sec), using a Leica DFC 420C camera and ebq 100 lamp, see Material and Methods for details. B) The percentage of (strongly; i.e. MSP++) MSP1 expressing 
liver stage parasites was determined at 48hpi and 54hpi (see Figure 2C). There are significantly more 
MSP1++ positive WT infected hepatocytes than MSP++ Δfabb/f infected hepatocytes at both 48 and 54hpi 
(using a paired student t-test; p<0.001 at 48hpi and p=0.01 at 54hpi; GraphPad Prism 5® software).
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Table S1
List of primers and primer sequences used in this study
Table S1: Primers used in this study
Name Sequence Restriction site Description Gene models
Primers for generation of the ∆p52+p36 target regions (for pL1164) (restriction sites are shown in red)
∆p52+p36   L903 CGATCGATGAATAATAGTAAATGATGAAACGTCG ClaI ∆p52+p36  5' target F PBANKA_100220 and PBANKA_100210
∆p52+p36   L904 CCCAAGCTTAATTACGTCCCCTGGATATGC HindIII ∆p52+p36   5'target R PBANKA_100220 and PBANKA_100210
∆p52+p36   L864 GGATATCCGATTTAGCATCTCATCATGG EcoRV ∆p52+p36   3' target F PBANKA_100220 and PBANKA_100210
∆p52+p36   L865 CGGGGTACCTGGTACTGCGAAAATCACACC KpnI ∆p52+p36   3' target R PBANKA_100220 and PBANKA_100210
Primers for confirmation PCR of the integration event in ∆p52+p36
∆p52+p36 L1389 ATTTTGCAACAATTTTATTCTTGG ∆p52+p36   5' integration F PBANKA_100220 and PBANKA_100210
∆p52+p36 L313 ACGCATTATATGAGTTCATTTTAC ∆p52+p36   5' integration R from KO construct pL1164
∆p52+p36 4239 GATTTTTAAAATGTTTATAATATGATTAGC ∆p52+p36   3' integration F from KO construct pL1164
∆p52+p36 4702 TATTTGGGTATGCCGTGAGG ∆p52+p36   3' integration R  PBANKA_100220 and PBANKA_100210
∆p52+p36 L775 GAAACAATATGAGTTCGCACGC ∆p52+p36   intergenic region F PBANKA_100220 and PBANKA_100210
∆p52+p36 L1212 TATATTGCTAGTCCTTTGTTCC ∆p52+p36  p36  orf R PBANKA_100220 and PBANKA_100210
∆p52+p36 4501 GGACAGATTGAACATCGTCG tgdhfr/ts F
∆p52+p36 4502 GATCACATTCTTCAGCTGGTC tgdhfr/ts R
Primers for generation of the ∆fabb/f  target regions (for pL1454) (restriction sites are shown in red)
∆fabb/f 4194 GCGCGGTACCACATAAATTTGTACAAAACTTAAATGA KpnI ∆fabb/f   5' target F PBANKA_112510
∆fabb/f 4195 GCGCGGATCCGATATGTATTTATTTCACACACTTTAT BamHI ∆fabb/f    5'target R PBANKA_112510
∆fabb/f 4196 GCGCGAATTCATTTATTAGTTGATATTATTATTTATA EcoRI ∆fabb/f   3' target F PBANKA_112510
∆fabb/f 4197 GCGCCCCGGGTTTATATGTATATCTCATATAAATGGT XmaI ∆fabb/f   3' target R PBANKA_112510
Primers for confirmation PCR of the intergration even in ∆fabb/f
∆fabb/f 4253 ATTTCCTCTTTTTCTGCTTTTTGGTTCACC ∆fabb/f   5' integration F  PBANKA_112510
∆fabb/f L1858 ATGCACAAAAAAAAATATGCACAC ∆fabb/f   5' integration R from KO construct
∆fabb/f 4239 GATTTTTAAAATGTTTATAATATGATTAGC ∆fabb/f   3' integration F from KO construct
∆fabb/f 4254 TATATGTATATATGATTAATCCATAACCC ∆fabb/f   3' integration R  PBANKA_112510
∆fabb/f 4255 GAGGAATTTCTATTGGTATGTTAAGTGCATGCG ∆fabb/f  orf F PBANKA_112510
∆fabb/f 4256 ATTTAATGAAAAATCAATATTCTGTTCTGAGGG ∆fabb/f  orf R PBANKA_112510
∆fabb/f L379 GGCAAGAACGGGGACCTG hdhfr  F
∆fabb/f L1511 CGATTCACCAGCTCTGAC yfcu  R
Primers for the Anchor‐tagging PCR‐based method: Generation of ∆fabb/f  target regions (for pL1662) (restriction sites are shown in red; Anchor tags are shown in blue)
∆fabb/f 5804 GAACTCGTACTCCTTGGTGACGGTACCGGTAATGGATGTGTACACAAAAG Asp718 ∆fabb/f   5' target F PBANKA_112510
∆fabb/f 5805 CATCTACAAGCATCGTCGACCTCCACACTGTATACAGGACACTTG ∆fabb/f    5'target R PBANKA_112510
∆fabb/f 5806 CCTTCAATTTCGGATCCACTAGCATGGCATCTTTCTCGCACAC ∆fabb/f   3' target F PBANKA_112510
∆fabb/f 5807 AGGTTGGTCATTGACACTCAGCAGTACTTGATAACCTATGCACTCAAGG ScaI ∆fabb/f   3' target R PBANKA_112510
∆fabb/f 4661 GAACTCGTACTCCTTGGTGACG for 2nd PCR
∆fabb/f 4662 AGGTTGGTCATTGACACTCAGC for 2nd PCR
Primers for confirmation PCR of the integration event in ∆fabb/f  (Anchor tags are shown in blue)
∆fabb/f 5808 ACTAATGCACACTGCAGTTAC ∆fabb/f   5' integration F  PBANKA_112510
∆fabb/f 4770 CATCTACAAGCATCGTCGACCTC ∆fabb/f   5' integration R from KO construct PBANKA_112510
∆fabb/f 5809 GGGTTGTATAATACCTTCTTCG ∆fabb/f   3' integration F from KO construct PBANKA_112510
∆fabb/f 4771 CCTTCAATTTCGGATCCACTAG ∆fabb/f   3' integration R  PBANKA_112510
∆fabb/f L307C GCTTAATTCTTTTCGAGCTC hdhfr F
∆fabb/f 3187 GTGTCACTTTCAAAGTCTTGC hdhfr R
Primers for RT‐PCR
RT‐PCR 6301 ATACCAGAACCACATGTTACG CS for RT primer PBANKA_040320
RT‐PCR 6302 CTCTACTTCCAGGATATGGAC CS F for RT‐PCR PBANKA_040320
RT‐PCR 6303 CATTGAGACCATTCCTCTGTG CS R for RT‐PCR PBANKA_040320
RT‐PCR 6304 CATTTCTTTTGCATGAGCAAC p52 for RT primer PBANKA_100220
RT‐PCR 6305 CCTAATACGACCTTAGGACAC p52 F for RT‐PCR PBANKA_100220
RT‐PCR 6306 AACATCATTACTCGGATCTGG p52 R for RT‐PCR PBANKA_100220
RT‐PCR 6140 TATTGCTAGTCCTTTGTTCCC p36 for RT primer PBANKA_100210
RT‐PCR 6310 TCCAACGGGGAATTGTAGTG p36 F for RT‐PCR PBANKA_100210
RT‐PCR 6139 GTCCCTTTCTATCTCATTAGG p36 R for RT‐PCR PBANKA_100210
RT‐PCR 6311 GCTCCTATGCAATGACCTGTC fabb/f  for RT primer PBANKA_112510
RT‐PCR 6312 GACTTCCAGAGTTGTATGCAC fabb/f F for RT‐PCR PBANKA_112510
RT‐PCR 6313 ATCGGATACACTTATGTTGGC fabb/f  R for RT‐PCR PBANKA_112510
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Table S2Multiplication rate of asexual blood stages and gametocyte production of different P. berghei
Animals Line number in vivo multiplication rate1
Gametocyte 
production2 
(% Mean ± SD)
Δp52+p36-a 795cl1 10 (0) n=3 18.4 (1.9)
Δp52+p36-b 1409cl1 10 (0) n=6 19.0 (3.0)
Δfabb/f-a 1354cl1 10 (0) n=3 20.3 (2.3)
Δfabb/f-b 1704cl1 10 (0) n=2 17.9 (2.8)
WT 10 (0) n=10 Range: 15-25
The mean values and standard deviations (between brackets) are shown for the mutant lines. For the 
wild type parasites the range is shown of values obtained with 10 infections.   1The multiplication rate of asexual blood stages per 24h was determined in mice infected with a single parasite; n is the number of mice infected. 2Gametocyte production is the percentage of blood stage 
parasites that develop into gametocytes under standardized in vivo conditions.
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Table S3 
Protection of BALB/c and C57BL/6 mice after immunization with Δp52+p36 GAPs 
Mice GAP Imm. dose
Challenge 
after imma.
days
(re-challenge)
Protected/ 
infected No. 
mice 
(re-challenge)
Pre-patency 
days
Balb/c
Δp52+p36 50K 10d
90d
(180d)
10/10
(10/10)
(10/10)
n/a
Δp52+p36 25K 10d
90d
(180d)
10/10
(10/10)
(10/10)
n/a
Δp52+p36 10K 10d
90d
(180d)
10/10
(10/10)
(10/10)
n/a
Δp52+p36
gfp::luc
10K 10d
90d
(180d)
10/10
(10/10)
(10/10)
n/a
Δp52+p36 5K 10d
90d
(180d)
10/10
(10/10)
(10/10)
n/a
Δp52+p36
gfp::luc
5K 10d
(180d)
10/10
(10/10)
n/a
Δp52+p36
gfp::luc
1K 10d
(180d)
8/9 
(5/5)
6
C57BL/6 Δp52+p36 50K 10d 0/5 6
Δp52+p36
gfp::luc
50K 10d 0/5 6
Δp52+p36 50/20/20Kb 180d 6/7c 7c
aWt challenge constitutes 10K sporozoites delivered i.v. b50K sporozoites i.v. day 0 followed by a boost 
of 20K sporozoites i.v. at day 7 and day 14. c40 mice were exposed to the 50/20/20K immunization 
regiment, only 7 mice remained blood stage negative and these mice then received their first challenge 
with WT parasites 6 months later (10K sporozoites i.v), 6/7 mice were protected and 1 mouse developed 
a patent blood stage infection at day 7.
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Abstract
The proteins P52 and P36 are expressed in the sporozoite stage of the murine ma-laria parasite Plasmodium berghei. Δp52&p36 sporozoites lacking expression of both 
proteins are severely compromised in their capability to develop into liver stage par-
asites and abort development soon after invasion; presumably due to the absence 
of a parasitophorous vacuole membrane (PVM). However, a small proportion of P. 
berghei Δp52&p36 parasites is capable to fully mature in hepatocytes causing break-through blood stage infections.
We have studied the maturation of replicating Δp52&p36 parasites in cultured Huh-
7 hepatocytes. Approximately 50% of Δp52&p36 parasites developed inside the nucleus of the hepatocyte but did not complete maturation and failed to produce 
merosomes. In contrast cytosolic Δp52&p36 parasites were able to fully mature and produced infectious merozoites. These Δp52&p36 parasites developed into mature 
schizonts in the absence of an apparent parasitophorous vacuole membrane as 
shown by immunofluorescence and electron microscopy. Merozoites derived from these maturing Δp52&p36 liver stages were infectious for C57BL/6 mice. 
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Introduction
Plasmodium sporozoites are transmitted to the mammalian host by the bites of in-fected Anopheline mosquitoes. The parasites leave the injection site and make their 
way to the liver where they invade hepatocytes before commencing the erythrocytic cycle. There are two distinct pathways by which Plasmodium sporozoites enter he-patocytes: they either migrate through cells disrupting the host cell membrane, or 
they invaginate the host cell membrane forming a parasitophorous vacuole (PV) and 
a parasitophorous vacuole membrane (PVM) [1]. Proper formation and subsequent 
modification of the PV and PVM are considered crucial for development and sur-
vival of intrahepatic parasites [2]. Nonetheless, a small proportion of Plasmodium 
parasites is capable of (partial) intranuclear development [3,4] in the absence of a 
PVM [4]. After invasion of the hepatocyte the sporozoites multiply and form tens of thousands of merozoites, which are released into the bloodstream as merosomes.  Both the Plasmodium genes p52, encoding a putative GPI-anchored protein [5,6] and its paralogous gene p36, encoding a putative secreted protein [6] are upregulated in 
sporozoite stages [7] with a putative function in hepatocyte invasion. P. berghei and 
P. yoelii parasites, genetically attenuated by the deletion of the p52 gene or the p36 
gene, lack a PVM upon hepatocyte invasion [5,8]. These mutant parasites are severe-
ly compromised in their capability to develop into liver cells and abort development 
soon after invasion. The developmental arrest of these Δp52&p36 mutant parasites 
was confirmed in P. falciparum [7].  Infection of mice with high numbers of P. yoelii 
Δp52&p36 sporozoites, does not result in a blood stage infection [8]. The develop-mental arrest of these knock-out  parasites is thought to be related to the lack of a 
PVM, considered  critical for intracellular survival in hepatocytes.
Despite the apparent full developmental arrest, we previously showed that a low percentage of Δp52 [5] and Δp52&p36 [9]parasites are able to generate a blood stage infection in the P. berghei murine model. Moreover, we provided evidence that low numbers of Δp52&p36 P. falciparum sporozoites, develop into replicating liver stages 
[9]. In this study we followed replicating  Δp52&p36 parasites in the course of he-
patic maturation and more specifically in relation to intranuclear location and PVM 
development.
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Materials and Methods
Mice and parasites
Female C57BL/6J, eight weeks of age, were purchased from Elevage Janvier (France). All stud-
ies in which animals were involved have been performed according to the regulations of the 
Dutch “Animal On Experimentation act” and the European Directive 2010/63/EU.The P. berghei Δp52&p36 and wildtype (P. berghei ANKA) parasites used are described else-
where [9].
Analysis of in vitro P. berghei liver stage development by immunofluorescence.
P. berghei sporozoites were collected at day 21 after mosquito infection by hand-dissection 
of salivary glands. Salivary glands were collected in DMEM (Dulbecco’s Modified Eagle Medi-
um from GIBCO) and homogenized in a homemade glass grinder. The number of sporozoites was determined by counting samples in duplicate in a Bürker-Türk counting chamber using phase-contrast microscopy.
Liver stage development of the P. berghei mutants and wildtype parasites was determined 
in vitro as described previously [9].Briefly, human liver hepatoma cells (Huh-7 [10]) were 
suspended in 1 ml of ‘complete’ DMEM (DMEM, Gibco, supplemented with 10% FCS, 1% peni-
cillin/streptomycin and 1% Glutamax) and were seeded on coverslips in 24-well plates (105 
cells/well). After Huh-7 monolayers were >80% confluent, 5x104 sporozoites were added per 
well, and  centrifuged 10 minutes at 1800xG (eppendorf centrifuge 5810 R). At different time 
points after infection, cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% 
Triton-X-100, blocked with 10% FCS in PBS, and subsequently stained with a primary and 
secondary antibody at room temperature for 45 and 30 min respectively. Primary antibodies used were anti-PbUIS-4 (raised in rabbit; [11](Mueller et al., 2005), detecting a PVM-resident protein); anti-PbHSP70 (raised in mouse;[5], detecting the parasite cytoplasmic heat-shock 
protein 70 and anti-PbMSP-1 (raised in mouse; MRA-667 from MR4; www.MR4.org), detect-ing the merozoite surface protein 1 of P. berghei. The anti-UIS-4 antibody were preferred over 
the earlier described anti-EXP-1 antibody [9]detecting another PVM resident protein because 
of the intensity and the constitutive expression. Anti-mouse and anti-rabbit secondary an-
tibodies, conjugated to Alexa-488 and Alexa-594, were used for visualization (Invitrogen). 
Nuclei were stained with DAPI. Analysis of infected hepatocytes was performed using a Zeiss 
Axiophot Fluorescence microscope with Axiocam MRm CCD camera (Fig. 1C and Fig. S1) or a 
Olympus FV1000 Confocal Laser Scanning Microscope. 
TEM analysis of infected Huh-7 cells
For ultrathin-section transmission electron microscopy, 2x105 wt and 5x105  p52/p36-defi-cient sporozoites were used to infect 3.5x105 sub-confluent Huh-7 cells, seeded the day prior 
in 35 mm petridishes.  Sporozoites were centrifuged for 10 minutes at 1800xG and 32 hours 
post infection cells were fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences) in 0.1 
M sodium cacodylate buffer (pH 7.4) for 1 h at room temperature and subsequently washed 
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three times for 10 minutes in 0.1 M sodium cacodylate buffer and then post-fixed for 1 h in 1% 
osmium tetroxide (Electron Microscopy Sciences, Gibbstown, NY) in  sodium cacodylate buf-fer at room temperature. Samples were washed three times 20 minutes in 0.1 M sodium caco-dylate buffer and subsequently dehydrated in a graded series (10-50-70-96-100%) of ethanol. 
Cells were resin infiltrated in a 100% ethanol/EPON (Sigma) mixture (2:1) for 3 hours and 
subsequently in a 100% ethanol/EPON mixture (1:1) for 5 hours and subsequently in pure 
EPON overnight. Beem capsules were placed onto the cells perpendicular, filled with EPON, 
and polymerized overnight at 60 °C. Ultrathin (50–100nm) sections were cut parallel to the 
cell surface using an Ultracut ultramicrotome (Leica, Germany) and contrasted with 2% ura-nyl acetate and lead citrate before examination with a JEOL 1010 microscope under 60 kV.
Analysis of infectivity of Huh-7 hepatocyte-derived merozoites.
Assessment of the infectivity of hepatocyte derived merozoites has previously been de-scribed for Pb∆lisp1 mutants [12]. The protocol was adapted and Huh-7 cells were seeded in a 24-wells plate at 106 cells/ well, overnight. Sporozoites were added to the wells (>80% 
confluent) at 8x104 sporozoites per well, and centrifuged 10 minutes at 1800xG (eppendorf 
centrifuge 5810 R). 65 hours post infection 100 µl supernatants were collected from each well, centrifuged for 3 minutes at 12.000 rpm and the cell pellet was re-suspended in 100 
µl RPMI. A total of 200 µl re-suspended culture supernatant (from 2 wells) was injected i.v 
per C57BL/6 mice. Approval was obtained from the Radboud University Experimental Ani-
mal Ethical Committee (RUDEC 2009-225). Blood stage infections were monitored by Giemsa 
staining of blood smears from day 2 up to day 14 post injection. Genotype confirmation of 
Δp52&p36 and wildtype parasites was performed as described  [9]. The pre-patent period 
was defined as the period of time (days) between injection and the day that mice showed a 
blood stage parasitemia of 0.5-2%.
Results
P. berghei ∆p52&p36 parasites can partially develop inside the nucleus of the 
hepatocyte.
In vitro analysis of P. berghei infected Huh-7 hepatocyte cultures showed that com-
pared to wildtype (100%), a low proportion of ∆p52&p36 sporozoites, (2±0.6 % 
(p<0.01)) was able to develop into replicating intra-hepatic parasites (Fig. 1a, Table 
S1).  Most knockout parasites (98%) abort development soon after invasion and do not start nuclear replication.
Remarkably, a relatively large proportion of the replicating ∆p52&p36 parasites, 45% 
(±0.7%) resided inside the nucleus of hepatocytes, compared to 1.25% (±0.35%) of 
intranuclear wildtype parasites (p<0.01) at 24 hours post invasion (Fig. 1a, Table S1). The absolute number of intranuclear mutant parasites matched the number
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Figure 1: Intranuclear development of Δp52&p36 P. berghei parasites.         
A)Pie diagrams of intranuclear and cytosolic wildtype and mutant replicating parasites at 24, 36 and 48 
hours post invasion in Huh-7 cells. The diameter of the circles represents the relative number of  replicat-
ing parasites observed per coverslip, where the wildtype circle at 24 hour represent 100% and all other circles are deduced (wildtype = 1300-1500 and Δp52&p36 = 20-40 replicating parasites per coverslip at 24 hours post infection. Absolute numbers are depicted in Table S1 B) UIS-4 and HSP70 expression on an intranuclear P. berghei parasite 44 hours post infection (Bar = 10µm). C) MSP-1 expression on intra-nuclear (Δp52&p36) and cytocolic (wildtype) P. berghei parasites 52 hours post infection (Bar = 10µm).
of wildtype parasites. For both wildtype and mutant parasites, there was a slight 
decrease in the percentage of intranuclear developing parasites during the course 
of parasite maturation. At any time point, however, while the absolute number re-
mained the same, the percentage of intranuclear mutant parasites was significantly 
higher than the percentage of intranuclear wildtype parasites (p<0.05) (Fig. 1a). 
Intranuclear developing P. berghei wildtype and ∆p52&p36 parasites were nega-
tive for UIS-4 peripheral staining, a marker for the presence of a PVM (Fig. 1b) and did not express MSP-1 at 52 hours post infection, as depicted by an intranuclear 
Δp52&p36 parasite (Fig. 1c). At time points up to 72 hours post infection, these para-
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sites remained negative (data not shown) indicating that the absence of MSP1 stain-ing is not the results of a delay in maturation period . Based on MSP-1 expression, 
intranuclear parasites are unlikely the cause of ∆p52&p36 parasite breakthrough in mice.
Cytosolic ∆p52&p36 parasites can produce mature merozoites in the absence 
of an apparent PVM.More than half of the replicating ∆p52&p36 parasites resided in the cytosol of Huh-7 
hepatocytes (Fig. 1a) expressing MSP-1 and transforming into mature merozoites 
from 52 hours post invasion onwards. These cytosolic ∆p52&p36 parasites did not show the typical round shape of wildtype parasites, but were instead characterized 
by an irregular morphology (Fig. 2a, Fig S1). Individual merosomes were clearly 
visible budding of from the infected hepatocyte (Fig S1 right box). Replicating cy-
tosolic ∆p52&p36 parasites (n=498) were negative for peripheral UIS-4 staining at 
any time point starting from early liver infection onwards (6-52 hour post invasion) 
(Fig. 2b). Using transmission electron microscopy at 32 hours post infection, we ob-
served cytosolic wildtype parasites demarked by a surrounding PV and PVM, while, 
in contrast, both PV and PVM could not be detected in ∆p52&p36 parasites (Fig. 2c). 
Thus, ∆p52&p36 parasites replicating in the cytosol expressed MSP-1, but lacked an 
apparent PVM.
Table 1: Δp52&p36 merozoites are capable of inducing a blood stage infection
Experiment
No.
No. Asexual positive/ No.injected
(mean ± sd pre-patency)
∆p52&p36 WT
1 4/4 
(6 ± 0 days)
2/2 
(3 ± 0 days)
2 5/5 
(5.8 ± 0.4 days)
3/3 
(2 ± 0 days)
Huh-7 cells were infected with Δp52&p36 and WT parasites and cultured for 65 hours. After 65 hours, cul-
ture supernatant containing merozoites was collected and injected i.v in C57BL/6 mice. Regular Giemsa 
staining was performed in all groups, 2-14 days post  i.v injection in mice, to control for asexual parasites.
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Figure 2: Cytosolic developing Δp52&p36 P. 
berghei parasites lack an apparent PVM.
A) MSP-1 expression on cytosolic wildtype and 
Δp52&p36 P. berghei parasites 52 hours post 
infection (Bar = 10µm). B) UIS-4 and HSP70 ex-pression on cytosolic Δp52&p36 and wildtype P. 
berghei parasites at 6-52 hours post infection 
(Bar = 10µm). C) Electron microscopic analysis of cytosolic wildtype (upper row) and Δp52&p36 (lower row) parasites, 32 hours post hepatocyte 
infection. The inset boxes show higher magnifi-
cations of the boxed areas within the overview 
images. IMC, inner membrane complex; Ly ly-
sosome; NE, Nuclear envelope; PPM, parasite 
plasma membrane; PV, parasitophorous vacuole 
; PVM, parasitophorous vacuole membrane; Rh, 
rhoptry (Bar = 10µm).
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Hepatocyte derived ∆p52&p36 merozoites are able to induce a blood stage in-
fection.
We next tested whether ∆p52&p36 parasites developing into merozoites were ca-
pable of infecting erythrocytes. Therefore, supernatants of ∆p52&p36 and wildtype 
infected Huh-7 cells, collected 65 hours post infection, were injected i.v in C57BL/6 mice (Table 1). All mice injected with culture supernatant became patent with blood 
stage parasitemia as determined by thick smear. Genotyping of blood parasites con-
firmed the ∆p52&p36 genotype (Fig. S2). The mean difference in day of patency 
between ∆p52&p36 and wildtype parasites i.e. 5.9 versus 2.4 days post injection 
respectively, likely reflects the difference in number of viable merozoites injected. 
These data show that ∆p52&p36 parasites, developing in Huh-7 hepatocytes in the 
absence of an apparent PVM, are capable of maturing into infectious merozoites.
Discussion 
Here we show that a proportion of P. berghei ∆p52&p36 parasites can develop in 
Huh-7 hepatocytes in the apparent absence of a PVM and fully mature into mero-
zoites. Merozoites derived from an in vitro ∆p52&p36 hepatocyte culture were in-
fectious and lead to a blood stage infection in mice. Our data question the absolute 
necessity for the presence of a PVM for intrahepatic P. berghei development. 
Although all observed replicating ∆p52&p36 parasites herein (approximately 900 
by immunofluorescence) develop free of PVM inside the hepatocytes, one cannot formally exclude the possibility that a small proportion of the P. berghei mutants de-
velop with a PVM into infectious merozoites. Nonetheless, the breakthrough blood stage parasites were infectious for mosquitoes and upon re-infection of a hepato-
cyte culture with sporozoites, all replicating mutants lacked UIS-4 staining (data not shown). This indicates that the infectious merozoites did not arise from a subset of 
mutant parasites that stably switched to a phenotype of forming a PVM in the ab-sence of P52 or P36. 
The relatively high percentage of mutant parasites replicating in the hepatocyte 
nucleus seems remarkable. However, despite an apparent preference of the mutant parasites to replicate in the nucleus, the absolute number of intranuclear replicating mutants does not differ from wildtype. Thus, mutant parasites do not preferentially 
invade the nucleus of hepatocytes. 
The seemingly preference for intranuclear development merely arises from the de-
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velopmental arrest of a major part of the cytosolic mutant parasites. Intranuclear 
mutants have a developmental advantage over cytosolic mutant parasites and their 
numbers seem untouched by the absence of a PVM. Possibly, the nuclear envelope 
acts as a substitute for the PVM.The intranuclear mutant and wildtype P. berghei parasites likely halt inside the nu-cleus of the hepatocyte upon transmigration, similar to P. yoelii and P. falciparum [4]. 
These parasites do probably not play a role in the observed breakthrough infections in mice. Based on MSP-1 expression, cytosolic and not intranuclear parasites are  the likely source of infectious merozoites. Nevertheless, we cannot exclude that merozo-
ites may arise from intranuclear developing parasites.Whereas Plasmodium parasites replicating in the nucleus in the apparent absence 
of a PVM have previously been reported, cytosolic parasites have not. Interestingly, 
upon close examination of wildtype parasites, a small percentage (± 1.5 %  n=27) 
of the cytosolic wildtype parasites lack peripheral UIS-4 staining at 30 hour post 
infection, similar to the cytosolic ∆p52&p36 parasites (data not shown). These data 
support the possibility of a non-conventional intra-hepatic pathway for P. berghei 
development. 
In the absence of an encompassing membrane cytosolic parasites are likely more 
vulnerable to host defense mechanisms. Genes involved in the evasion of host cell 
apoptosis [13,14] might be less effective to avert cell death. Possibly, replicating mu-
tant parasites survive in an equilibrium of anti-apoptotic gene expression and host defense mechanism.
It remains to be seen whether these findings in P. berghei are representative for oth-er Plasmodium species. Fully developing cytosolic parasites absent of a PVM have, 
to our knowledge, never been reported for any of the other Plasmodium species. While P. yoelii ∆p52&p36 breakthrough has not been reported, Labaied et al. previ-ously described a multi-nucleated P. yoelii ‘growth arrested’ ∆p52&p36 parasite  in 
a Hepg2-CD81 cell [4], a human hepatoma cell line that promotes the formation of a 
PVM by P. yoelii [4]. This particular parasite lacked a peripheral UIS-4 expression [8]. 
Apparently, very low numbers of the mutant P. yoelii parasites still replicate inside 
Hepg2-CD81 cells in the absence of a PVM. Furthermore, it will be interesting to see 
whether the low numbers of mutant ∆p52&p36 P. falciparum parasites that repli-
cate in primary human hepatocytes [9] have a similar phenotype as the P. berghei mutants. 
Our findings are confined to an in vitro Huh-7 P. berghei model and the in vivo rel-
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evance of these findings remains elusive. In vivo characterization is hampered by the extremely low number of replicating parasites. Similarly, P. yoelii and P. falciparum 
replicating ∆p52&p36 parasites are extremely rare and at present their mechanism 
of breakthrough remains unclear. Nevertheless, once confirmed in P. falciparum, our 
findings may have implications for the development of a genetically attenuated ma-
laria vaccine. Based on protective efficacy conferred in mice and apparent full arrest in P. yoelii and P. falciparum models, genetically attenuated Δp52&p36 parasites have 
been considered eligible for clinical development as an attenuated sporozoite vac-
cine [7]. Given the break-through infections, our data suggest that for a sufficiently 
attenuated malaria vaccine, multiple genes need to be targeted. Such genes could 
not only include genes involved in the formation of the PVM, but preferably other 
Plasmodium gene targets with independent functions for liver stage development.
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Supllementary Table S1
a Average number of replicating liver stage parasites per coverslip. A total of 3 coverslips was counted per timepoint per parasite.
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Supplementary Figure S1: Late liver stage intracytosolar Δp52&p36p parasites have an irregular 
shape.
Four representative images of Δp52&p36p P. berghei parasites in culture 48 hours post invasion in Huh-
7 cells. Msp-1 expression is depicted in red, DAPI in blue (Bar= 10 µm). 
Supplementary Figure S2: Confirmation of Δp52+p36p and wildtype genotype after merosome 
injection assay.
A) Diagnostic PCR for confirmation of correct disruption of p52 and p36 in mutant Δp52+p36p (1409cl1). 
SM: selectable marker (primers 4501/4502; 1093bp); 5’-integration event (primers L1389/L313; 
1050bp); ORF (primers L775/L121; 1029bp). B) Sequence of the primers used. C) Southern analysis of 
pulse field gel (PFG)-separated chromosomes of mutant Δp52+p36p. Mutant Δp52+p36p has been gener-ated in the reference P. berghei ANKA line PbGFP-Luccon which has a gfp-luciferase gene integrated into 
the silent 230p locus (PBANKA_030600) on chromosome 3 (i.e. RMgm-29; http://pberghei.eu/index.
php?rmgm=29). Hybridization with the 3’-UTR dhfr/ts probe recognizes the integrated construct on 
chromosome 9, the reporter GFP-Luccon construct on chromosome 3, and the endogenous dhfr/ts gene 
located on chromosome 7. 
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Primers for confirmation PCR of the integration event in ∆p52+p36
∆p52+p36 L1389 ATTTTGCAACAATTTTATTCTTGG ∆p52+p36 5' integration F PBANKA_100220 and PBANKA_100210
∆p52+p36 L313 ACGCATTATATGAGTTCATTTTAC ∆p52+p36 5' integration R from KO construct pL1164
∆p52+p36 L775 GAAACAATATGAGTTCGCACGC ∆p52+p36  intergenic region F PBANKA_100220 and PBANKA_100210
∆p52+p36 L1212 TATATTGCTAGTCCTTTGTTCC ∆p52+p36  p36 orf R PBANKA_100220 and PBANKA_100210
∆p52+p36 4501 GGACAGATTGAACATCGTCG tgdhfr/ts F
∆p52+p36 4502 GATCACATTCTTCAGCTGGTC tgdhfr/ts R
A. B.
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P. berghei ∆b9∆slarp parasites are completely ar-
rested in liver stage development and can confer 
long-lasting protection against malaria in mice.  
Ivo Ploemen
 
These studies are part of two papers (in preparation); the first paper describes in de-
tail the biology of the B9 protein of P. berghei and P. falciparum (its relationship with 
other members of the Plasmodium 6-Cys family of proteins, the timing of expression 
and its cellular location); the second paper reports the generation and characteriza-
tion of P. berghei and P. falciparum parasites lacking expression of both B9 and SLARP.
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Ben van Schaijk, Robert Sauerwein
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Takeshi Annoura, Severine Chevalley-Maurel, Blandine M.D. Franke-Fayard, Shahid 
Khan, Chris Janse
The Leiden Malaria Research Group (Parasitology), Leiden University Medical Center, Leiden, The Nether-
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Abstract
Over the past decades, many attempts have been made to develop an efficacious 
malaria vaccine. Protection conferred by the immunization with live whole 
sporozoites is unequaled by any malaria vaccine attempt, in both animal models 
and human volunteers. For obvious safety reasons, it is essential to immunize 
with sporozoites that are 100% unable to develop into the pathogenic blood stage. 
Genetically attenuated parasites (GAP) that arrest in the liver stage form a high 
ranked live sporozoite vaccine approach. Both GAP safety (i.e no breakthrough 
blood infections) and protective efficacy are essential characteristics of a future P. 
falciparum GAP. Here, we report on the generation and characterization of a P. berghei 
GAP consisting of multiple gene deletions: ∆b9∆slarp. Safety and protective efficacy 
were assessed by adopting a robust and stringent screening approach. First, single gene deleted ∆b9 GAP were generated and characterized. P. berghei ∆b9 sporozoites 
abort development soon after hepatocyte invasion. Immunization of mice with ∆b9 
parasites confers long-lasting sterile protection. Nonetheless, very low numbers of 
P. berghei ∆b9 are capable of developing inside the hepatocyte resulting in a blood 
stage parasitemia. This GAP is therefore not a safe GAP candidate, ready for further 
clinical development. We subsequently generated a multiply attenuated ∆b9∆slarp 
GAP, which was fully safe in our P. berghei model. None of the parasites was capable 
of full liver stage maturation. Moreover, we show that immunization of BALB/c 
and C57BL/6 mice with low doses of ∆b9∆slarp confers sterile and long-lasting protection. The ∆b9∆slarp GAP is now the leading GAP vaccine candidate for further 
development in P. falciparum. 
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Introduction
Over 40 percent of the world’s population is at risk for exposure to malaria. More 
than 250.000 new clinical malaria cases occur annually resulting in 800.000 to 1.2 million deaths, most of which are children in sub-Saharan Africa suffering from a 
severe P. falciparum infection [1]. Malaria remains a global health crisis and there is 
a dire need for an effective and potent malaria vaccine.
Preliminary results of a Phase III trial with the most advanced malaria vaccine, a 
subunit vaccine named RTS,S, show an approximate 55% reduction in the acquisition 
of clinical malaria and a 35% reduction in the progression into severe malaria for up 
to 11 months post immunization [2]. While promising, a whole sporozoite vaccine approach might be much more potent in conferring protection, thereby forming the 
next generation of malaria vaccines. Vaccination with whole life sporozoites is only 
safe when parasite development is halted before the pathogenic blood stage. For this end, sporozoite immunizations can be performed with, radiation attenuated 
sporozoites (RAS), genetically attenuated parasites (GAP) and sporozoites administered concomitantly with anti-malarial drugs [chemoprofylactic sporozoites 
(CPS)]. RAS immunization has a long standing track record of proven efficacy 
in rodents [3], monkeys [4] and man [5,6,7]. CPS immunization leads to sterile 
protection in mice [8,9,10] and high (>90%) and sustained (at least 28 months) levels of protection against a controlled homologous human malaria infection in humans 
[11,12]. At present, the efficacy of the GAP vaccine has not been assessed in human 
volunteers but in rodent models the protective efficacy conferred by most GAPs is similar to RAS. Both vaccination strategies rely on the complete developmental arrest of the attenuated parasite in the host hepatocyte and subsequent (mainly cellular) immune responses. 
There are clear advantages of a GAP vaccine over RAS and CPS in that it is comprised 
of a homogenous parasite population and its attenuation is not influenced by external 
(e.g radiation, host drug metabolism) factors. GAPs go into developmental arrest in 
the hepatocyte at the time point predestined by the specific gene deletion. Most GAPs like ∆p52, ∆p36, ∆uis3, ∆uis4 and ∆slarp/∆sap1 arrest at early liver stage. Other GAPs, like ∆fabb/f arrest in the late liver stage. Despite this apparent abundance of GAP 
vaccine candidates it has proved challenging to generate a safe and protective GAP in 
P. falciparum. For instance, unequivocal orthologs of the P. berghei and P. yoelii  uis3 and uis4 genes are absent in the P. falciparum genome (www.PlasmoDB.org) and can 
therefore not be made into a vaccine product. In the P. berghei model the arrest of 
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the ∆p52 [13], the ∆p52&p36 and the ∆fabb/f [14] parasites was not complete in that 
they were capable of maturing in the liver in low numbers, resulting in a blood stage 
infection in mice. Moreover, we observed very low numbers of replicating ∆p52&p36 
P. falciparum parasites in primary human hepatocyte cultures [14]. 
Based on these low levels of breakthrough GAP parasites, we previously described a 
set of safety criteria that have to be met by a P. berghei GAP prior to further clinical 
development of the GAP candidate in P. falciparum [14]. Adequacy of GAP attenuation can be assessed by testing for breakthrough blood stage infections in different mice 
strains inoculated with a high number of GAP sporozoites. Moreover, in vivo imaging 
of parasites can be used to further attest the absence of GAP developing in the liver.
In order to find a GAP that completely arrests in the liver stage and following 
immunization, confers long-lasting protection, one can i) combine known GAP 
candidates to one multiple attenuated GAP or ii) pursue new GAP candidates. In 
this study we generate and characterize a new GAP candidate, ∆b9, which we subsequently multiply attenuate by additional deletion of the slarp gene. Both P. 
berghei ∆slarp and its orthologue in P. yoelii ∆sap1 mutant parasites completely 
arrest in the liver and a clear orthologue of the gene is present in P. falciparum 
[15,16]. There is however controversy over the protective efficacy of these parasites 
upon immunization [17]. Contrary to immunization of mice with P. yoelii ∆sap1, immunization with P. berghei ∆slarp did not confer long-lasting sterile protection. 
Here we show in a P. berghei model, using a robust and stringent screening platform [14], the full arrest of the multiply attenuated ∆b9∆slarp parasite and moreover its 
potent and long-lived protective efficacy in mice upon immunization. 
Material and methods
Experimental animals and parasites
Female C57BL/6J and BALB/c (12 weeks old; Janvier France) and Swiss OF1 (8 weeks 
old Charles River) were used. All animal experiments were performed after a positive 
recommendation of the RUNMC (RUDEC 2008-123, RUDEC 2008-148, RUDEC 2010-250, 
RUDEC 2011-022, RUDEC 2011-208) or the LUMC (ADEC) was issued to the licensee. All 
studies were performed according to the regulations of the Dutch “Animal On Experimentation 
act” and the European Directive 2010/63/EU on the protection of animals used for scientific purposes. 
The following reference lines of the ANKA strain of P. berghei were used: line cl15cy1 [18] and 
line 676m1cl1 (PbGFP-Luccon; see RMgm-29 in www.pberghei.eu). PbGFP-Luccon expresses a 
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fusion protein of GFP and Luciferase from the eef1a promoter [19,20]. 
Generation of P. berghei mutantsTo disrupt the P. berghei b9 gene (PBANKA_080810) two different gene deletion constructs 
were constructed. The first construct used the standard targeting DNA construct, pL0037 
(MR4; www.MR4.org) which contains the positive/negative selectable marker cassette hdhfr/
yfcu. Target sequences for integration of the construct by double cross-over homologous 
recombination were PCR amplified from P. berghei genomic DNA (cl15cy1) using primers 
(Table S1) which are specific for the 5’ and 3’ end of b9, respectively. The PCR–amplified target 
sequences were cloned either upstream or downstream of the SM of plasmid pL0037 resulting 
in plasmid pL1439 (Fig. S1). Prior to transfection the DNA-construct pL1439 was linearized with Asp 718 and Xma I. Using this construct the mutant ∆b9-a (1309cl1) was generated in 
the cl15cy1 reference line using standard methods of transfection and positive selection with 
pyrimethamine [18] (Fig. S1).The second construct for disruption of the b9 gene, pL1499, was generated using the adapted 
‘Anchor-tagging’ PCR-based method as described [14] (Fig S1). The two targeting fragments 
(0.8 kb) of b9 were amplified using genomic DNA (parasite line cl15cy1) as template with 
the primer pairs 4667/4557 (5’target sequence) and 4558/4668 (3’target sequence). See 
Table S1 for the sequence of the primers. Using this PCR-based targeting construct the mutant 
∆b9-b (1481cl4) was generated in the PbGFP-Luccon reference line using standard methods of 
transfection and positive selection with pyrimethamine (Fig. S1).To disrupt the P. berghei slarp gene (PBANKA_090210) a construct was generated using the 
adapted ‘Anchor-tagging’ PCR-based method as described [14] (Fig. S3). The two targeting 
fragments (1195bp and 823bp) of slarp were amplified using genomic DNA (parasite line 
cl15cy1) as template with the primer pairs 5960/5961 (5’target sequence) and 5962/5963 
(3’target sequence). See Table S1 for the sequence of the primers. Using this PCR-based 
targeting construct (pL1740) the mutant ∆slarp-a (1839cl3) was generated in the PbGFP-
Luccon reference line using standard methods of transfection and positive selection with 
pyrimethamine (Fig. S3).
To generate a selectable marker-free mutant Pb∆b9∆sm we removed the drug-selectable 
marker cassette from mutant Pb∆b9-a using the standard procedure of negative selection [14] 
(Fig. S4).  The resulting cloned mutant (∆b9∆sm; 1309cl1m0cl2) which contains a disrupted 
b9 gene and is drug-selectable marker free was used for deleting the slarp (PBANKA_090210) gene. To delete the slarp gene the gene deletion construct pL1740 was used as described above. 
Using this construct the mutant PbΔb9Δslarp (line 1844cl1) was generated in the ∆b9∆sm line 
using standard methods of transfection and positive selection with pyrimethamine (Fig. S5).Correct integration of the constructs into the genome of mutant parasites was analysed by 
diagnostic PCR-analysis and Southern analysis of PFG-separated chromosomes as shown 
in Fig. S1+2-5. PFG-separated chromosomes were hybridized with a probe recognizing 
hdhfr or the 3’-UTR dhfr/ts of P. berghei [18]. Absence of transcripts of the targeted genes 
in sporozoites was analysed by reverse transcriptase-PCR. Total RNA was purified from 
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salivary gland sporozoites using TRIzol reagent (Invitrogen) and prepared according to 
manufactures specifications. Purified RNA was then treated with RQ1 DNase (Promega). 
Reverse transcription was performed using the Super Script III RT (Invitrogen) as previously 
described [13]. cDNA was used as template for PCR amplification with control and gene 
specific primers that are listed in Table S1.
Analysis of blood and mosquito stage development of P. berghei mutant parasitesThe P. berghei mutants were maintained in Swiss mice. The multiplication rate of blood stages 
and gametocyte production were determined during the cloning procedure [18] and were not 
different from parasites of the reference ANKA lines. Feeding of A. stephensi mosquitoes and determination of oocyst production was performed as described [21]. P. berghei sporozoite 
production was determined by collection of salivary glands at day 21 after infection by hand-
dissection. Salivary glands were collected in DMEM (Dulbecco’s Modified Eagle Medium from 
GIBCO) and homogenized in a homemade glass grinder. The number of sporozoites was 
determined by counting the numbers of sporozoites of 10 salivary glands in triplicate in a Bürker-Türk counting chamber using phase-contrast microscopy. 
Analysis of P. berghei  sporozoite motility, hepatocyte traversal, invasion and 
development
Gliding motility of P. berghei sporozoites was determined in assays that were performed on anti-P. berghei circumsporozoite antibody (3D11, monoclonal mouse antibody 10 µg/ml) 
pre-coated Labtek slides (Nunc, NL) to which 2×104 sporozoites were added [13]. After 30 
minutes of incubation at 37°C sporozoites were fixed with 4% PFA and after washing with 
PBS, the sporozoites and the trails (‘gliding circles’) were stained with anti-CSP-antibody 
(3D11[22]) conjugated to Alexa 488 (Dylight 488 antibody labeling kit; Thermo Scientific, 
NL). Slides were mounted with Fluoromount-G (SouthernBiotech, NL) and ‘gliding circles’ 
were analyzed using a Leica DMR fluorescence microscope at 1000X magnification.
P. berghei sporozoite hepatocyte traversal was determined in assays as described previously 
[23]. Briefly, human liver hepatoma cells (Huh7) were suspended in 1ml of ‘complete’ 
DMEM (DMEM from Gibco, supplemented with 10% FCS, 1% penicillin/streptomycin and 
1% Glutamax) and were plated in 24 well plates (105 cells/ml). After the Huh7 monolayers 
were >80% confluent, 105 sporozoites were added with the addition of FITC- or Alexa-647-
labeled dextran (Invitrogen, NL). No sporozoites were added to the negative control wells. 
FACS analysis of dextran-positive cells was performed on a total 25x103 cells per well (each 
experiment was performed in triplicate wells) using a FACScalibur flow cytometer (Becton 
Dickinson, NL).
Invasion of hepatocytes in vitro by P. berghei sporozoites was determined by addition of 5×104 sporozoites to a monolayer of Huh7 cells. After the addition of sporozoites, cultures 
were centrifuged for 10 minutes at 1800G (Eppendorf centrifuge 5810 R) and then returned 
to the 37°C incubator. After 2-3 hours wells were washed 3 times with PBS to remove 
uninvaded sporozoites. Cells were fixed with 4% paraformaldehyde (PFA) for 10 min and 
125
P. berghei Δb9Δslarp are completely arrested and confer long-lasting protection
extracellular (non-invaded) parasites were stained with anti-CS-antibody (3D11) and 
conjugated with Alexa 594 antibody (Dylight 594 antibody labeling kit; Thermo Scientific, 
NL). After permeabilization with 0.1 % Triton-X-100 for 10 minutes and blocking with 10% 
FCS in PBS for 20 minutes, intracellular sporozoites were stained with anti-CS-antibody 
(3D11) conjugated with Alexa 488 antibody (Dylight 488 antibody labeling kit; Thermo 
Scientific, NL). Nuclei were stained with DAPI. Analysis and counting of stained intracellular 
and extracellular parasites were performed using a Leica DMR fluorescence microscope at 
1000X magnification. All quantitative phenotypical assays with P. berghei parasite lines were performed in triplo. 
P. berghei sporozoites development was determined in cultures of Huh7 cells (see above). Sporozoites (5 × 104) were added to a monolayer of Huh7 cells on coverslips in 24 well plates 
(with a confluency of 80-90%) in ‘complete’ DMEM (see above). At different time points after 
infection, cells were fixed  with paraformaldehyde 4%, permeabilized with Triton-X-100 0.1%, 
blocked with 10% FCS in PBS, and subsequently stained with a primary (anti-PbEXP1 [24]; anti-PbHSP70 [13]; anti-PbUIS-4 and anti-MSP-1 (MRA-78 from MR4;www.MR4.org) and 
secondary antibody, for 2h and 1h respectively. Anti-mouse, -chicken and -rabbit secondary 
antibodies, conjugated to Alexa-488 and Alexa-594, were used for visualization (Invitrogen). 
Nuclei were stained with DAPI. Cells were mounted in Fluoromount-G and examined using a 
Leica DMR fluorescence microscope at 1000X magnification.
Analysis of P. berghei sporozoite infectivity and in vivo imaging of liver stage 
development in mice
C57BL/6 mice were inoculated with sporozoites by intravenous injection of different sporozoite numbers, ranging from 1x104 - 5x105. Blood stage infections were monitored by 
analysis of Giemsa-stained thin smears of tail blood collected on day 4-18 after inoculation of 
sporozoites. Pre-patency (measured in days after sporozoite inoculation) is defined as the day 
when a parasitemia of 0.5-2% is observed in the blood.
Liver stage development in live mice was monitored by real-time in vivo imaging of liver stages 
as described previously [25] with minor adaptations. Briefly, animals were anesthetized using 
the isoflurane-anesthesia system, their abdomens were shaved and D-luciferin dissolved in 
PBS (150 mg/kg; Caliper Life Science, Belgium) was injected SC (in the neck). Animals were kept anesthetized during the measurements, which were performed 4 minutes after the 
injection of D-luciferin. Bioluminescence imaging was acquired with a 10 cm field of view, 
medium binning factor and an exposure time of 180 seconds. The color scale limits were set 
automatically and the quantitative analysis of bioluminescence was performed by measuring 
the luminescence signal intensity using the region of interest (ROI) settings of the Living 
Image 3.2 software. The ROI was set to measure the abdominal area at the location of the 
liver. ROI measurements are expressed in total flux of photons. 
Immunizations of mice with P. berghei sporozoitesPrior to immunization, P. berghei sporozoites were collected at day 21-27 after mosquito 
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infection by hand-dissection. Salivary glands were collected in DMEM (Dulbecco’s 
Modified Eagle Medium from GIBCO) and homogenized in a homemade glass grinder. The number of sporozoites was determined by counting in triplicate in a Bürker-Türk counting 
chamber using phase-contrast microscopy. BALB/c and C57BL/6J mice were immunized by 
intravenous injection using different numbers of GAP and γ-irradiated sporozoites (infected 
mosquitoes were irradiated at 16,000 rad (Gammacel 1000 137Cs) prior to dissection). BALB/c 
mice received one immunization and C57BL/6 mice received three immunizations with 7 
day intervals. Immunized mice were monitored for blood infections by analysis of Giemsa 
stained films of tail blood at day 4-16 after immunization. Immunized mice were challenged 
at different time points after immunization by intravenous injection of 1x104 sporozoites from the P. berghei ANKA reference line cl15cy1. In each experiment, age matched naive mice 
were included to verify infectivity of the sporozoites used for challenge. After challenge, mice 
were monitored for blood infections by analysis of Giemsa stained films of tail blood at day 
4-21. Pre-patency (measured in days after sporozoite inoculation) is defined as the day when 
a parasitemia of 0.5-2% is observed in the blood. 
Mononuclear cell isolation from liver, ex vivo stimulation and phenotyping
Immunized C57BL/6 mice were euthanized by isoflurane inhalation after i.v. injection of 50 
i.u. of heparin. Livers were collected after perfusion with 10ml of PBS. Cell suspensions of 
livers were made by pressing the organs through a 70-µm nylon cell strainer (BD Labware). 
Liver cells were resuspended in 35% Percoll (GE Healthcare) and centrifuged at 800g for 20min. After erythrocyte lysis (5min on ice with ACK lying buffer), hepatic mononuclear 
cells (HMC) were washed and re-suspended in RPMI medium (Gibco, 1640) for counting. 
Subsequently, hepatic mononuclear cells were co-cultured in complete RPMI 1640 medium 
[26] in the presence of cryoconserved sporozoites (5x104) or salivary glands from uninfected 
mosquitoes. Cells were stimulated at 37°C/5%CO2 for 24 hours during which Brefeldin 
A (Sigma) was added for the last four hours (10µg/ml  final concentration). As a positive 
control to the stimulation, PMA and Ionomycin (Sigma) were added simultaneously with 
Brefeldin A at a final concentration of 100ng/ml and 1.25µg/ml respectively. Cells were 
harvested after 24-hours in vitro stimulation and stained for 30min at 4°C in cold assay 
buffer (PBS supplemented with 0.5% bovine serum albumin – Sigma-Aldrich ) containing 
labeled monoclonal antibodies against CD3, CD4 and CD8 (Pacific blue-conjugated anti CD3 
(17A2), Peridinin Chlorophyll Protein (PerCP)-conjugated anti CD4 (RM4.5), Alexa fluor 
700-conjugated anti CD8a (53-6.7); Biolegend (San Diego, CA)). Cells were fixed for 30min at 
4°C with Fix & Perm medium A (Invitrogen) and subsequently stained for 30min at 4°C Fix 
& Perm medium B (Invitrogen) containing APC-conjugated anti-IFNγ. Flow cytometry was 
performed on a 9-color Cyan ADP (Beckman Coulter) and data analysis using FlowJo software 
(version 9.1; Tree Star). Comparisons between groups were performed by a Mann-Whitney 
U test using PRISM software version 5.0 (Graphpad, San Diego, CA). p < 0.05 are considered 
statistically significant.
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Results 
Generation and characterization of P. berghei ∆b9 parasites.The b9 gene was selected as a potential GAP target based on the presence of b9 
transcripts in sporozoites and absence of protein expression in sporozoites. B9 was found to be a member of the 6-Cys family of Plasmodium proteins. This family includes 
P52 and P36, both of which leading GAP candidates. The lack of B9 protein expression 
in salivary gland sporozoites suggests that the b9 transcripts are translationally 
repressed and only translated after sporozoites invade hepatocytes (unpublished 
data). We found that B9 is not expressed during the blood and mosquito stage 
parasites but is only present as protein during liver stage development (unpublished data). 
P. berghei Δb9 mutants were generated, using standard methods of targeted 
gene-deletion by integrating constructs through double cross-over homologous 
recombination (Fig. S1). Two independent b9 mutants were generated in the P. 
berghei ANKA reference lines cl15cy1 and PbGFP-Luccon. The latter line is a reporter 
line which expresses the fusion protein of GFP-Luciferase from the constitutive 
eef1a promoter, thereby allowing analysis of liver stage development in live mice by 
in vivo imaging [25]. Correct deletion of the genes in cloned mutants was confirmed 
by Southern analysis of FIGE-separated chromosomes and diagnostic PCR (Fig. S1). 
The Δb9 mutants had normal blood-stage development, and the production of oocysts and sporozoites was comparable to those of wildtype parasites (Table S2). 
In addition, salivary gland sporozoites exhibited normal levels of gliding motility, 
hepatocyte traversal and wildtype levels of hepatocyte invasion (Table S2). In WT parasites b9 transcripts were clearly present in salivary gland sporozoites by RT-PCR analysis whereas b9 transcripts were, as expected, absent in PbΔb9 mutants 
(Fig. 1A). When Swiss or BALB/c mice were infected by intravenous inoculation of 1x104 or 5x104 Δb9 sporozoites none of these mice developed a blood stage 
infection (Table S3), indicating an important role of b9 in the liver. We next explored whether the Pb∆b9 GAP is capable of eliciting long lasting and sterile protection by 
immunizing mice with different dosages. Immunization of BALB/c and C57BL/6 mice with Pb∆b9 parasites induced sterile protection against challenge with wildtype 
parasites (Table 1). A single dose of as few as 1000 sporozoites was sufficient to 
induce immunity in BALB/c mice. Immunization of C57BL/6 mice by a prime and 
boost regimen (50K/20K/20K) resulted in sterile protection in approximately 50 
% of the mice for up to 1 year post immunization. A 1 year re-challenge of mice that 
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were already challenged at 6 months increased the level of  protection to 100%. The 
Pb∆b9 thereby elicits at least the same level of protection as observed for mutants lacking either p52 or p52&p36 [13,27,28]. 
Table 1: Protection in BALB/c and C57BL/6 mice following immunization with P. berghei Δb9
Mice
Immuniza-
tion dose 
Spz x 103
Challenge after 
immunizationa
(re-challenge)
No. protected/ no. challenged 
-pre-patency-b
Δb9 Control
Balb/c 50
d10
(d90 & d180 & d210 
& d365)
20/20
(15/15 & 10/10 & 5/5 
& 5/5)
25 d10(d90 & d180)
10/10
(5/5 & 5/5)
10 d10(d90 & d180)
10/10
(5/5 & 5/5)
5 d10(d90 & d180)
8/10
-7.5-
(3/3 & 3/3)
1 d10(d90 & d180)
8/10
-7-
(3/3 & 3/3)
None
d10 & d90 & d180 & 
d210 
& d365
0/5d
-4.5-
C57BL/6 50/20/20c d10(d90 & d180)
4/4
(4/4 & 4/4)
50/20/20c d90 5/5
50/10/20c d180 (d365)
9/9
(4/4)
50/20/20c d365 5/11-7-
None d10 & d90 & d180& d365
0/4d
-4-aChallenge was performed by a 104 wildtype sporozoite IV injection.bMean of pre-patent period in days post challenge.cImmunizations were performed with two 7 day intervals.dRepresentative for challenge of naïve mice at any time point post last immunization 
Despite this good protective efficacy, when we infected C57BL/6 mice with a sporozoite dose of  5x104 PbΔb9 sporozoites, 10-20%  of the mice developed 
breakthrough blood infections (Table S3). In these mice the pre-patent period was delayed with 2-3 days, indicating that blood infections arose from a few infected 
hepatocytes. Genotyping of parasites derived from the breakthrough blood infections 
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confirmed the PbΔb9 genotype of these parasites (data not shown). 
We next analysed the development of PbΔb9 parasites in more detail both in cultured 
hepatocytes and in the liver of infected C57BL/6 mice. Quantitative analyses of PbΔb9-
infected hepatocytes by fluorescence microscopy demonstrated that Δb9 parasites 
arrest early after invasion of hepatocytes. At 24hpi most parasites had disappeared 
from the cultures and a few small forms were observed with a size similar to that 
of liver stages 1-5hpi of hepatocytes (Fig. 1B,C). Analysis of PbΔb9 parasites in the 
liver, using real-time in vivo imaging of luciferase expressing parasites, confirmed 
the growth-arrest phenotype observed in cultured hepatocytes. In six out of ten 
C57BL/6 mice infected 5x104 PbΔb9 sporozoites we did not observe development 
of liver stages, as demonstrated by the complete absence of luminescence signals 
in the liver at 42hpi. At this time point all livers from all control mice infected with 
luciferase-expressing WT parasites were strongly luminescent (Fig. 1D). None of the 
luminescent-negative mice developed a blood stage infection. In four PbΔb9-infected 
mice a weak luminescent signal was detected which was confined to only a few (1–
2) small spots (Fig. 1D) but only two of these mice developed a blood infection with 
a pre-patent period of 8 to 9 days (Table S3). Combined, our analyses demonstrate that PbΔb9 has an important role during early liver stage development. However, 
in the absence of the B9 protein liver stage development can occur, as shown by 
the occurrence of breakthrough blood infections in 10-20% of the mice (albeit 
only after high intravenous  PbΔb9 sporozoite inoculation). On close examination of in vitro hepatocyte culture, we found that P. berghei Δb9 parasites were capable 
of developing into infectious merozoites in the absence of an apparent PVM, as 
indicated by the lack of a peripheral EXP-1 and UIS-4 staining (Fig. S2). 
Generation and characterization of P. berghei ∆b9∆slarp parasites.
In our pursued of a fully arresting GAP we next generated a P. berghei multiple attenuated Δb9Δslarp GAP using standard methods of gene targeting by double 
cross-over integration (Fig. S5; Table S1). Moreover a Δslarp mutant was generated in the P. berghei reference reporter line, PbGFP-Luccon (Fig. S3; Table S1). The 
PbΔslarp and PbΔb9Δslarp mutants showed normal blood stage development (data not shown) and produced oocyst and sporozoite numbers comparable to those of 
WT parasites (Table S4). Salivary gland sporozoites demonstrated normal gliding 
motility, hepatocyte traversal and sporozoites of all mutants were able to invade 
hepatocytes at WT levels (Table S4).  Pb∆b9Δslarp parasites had an early growth-
arrest in hepatocytes as determined by immunofluorescent microscopy of infected 
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Figure 1: Characterization of P. berghei ∆b9 liver stage development.     
A) qRT-PCR analysis showing absence of b9 transcripts in sporozoites of ∆b9 mutants and wildtype. 
PCR amplification using purified sporozoite RNA was performed either in the presence or absence of 
reverse transcriptase (RT+ or RT-, respectively) using the primers as shown in the left panel (see Table S1 for the sequence of the primers). The P. berghei circumsporozoite protein gene (cs) was used as a 
positive control. B) Number of ∆b9-a and  ∆b9-b mutant parasites in a Huh-7 infected culture at 24 hours post infection as compared to wildtype. C) IFA of wildtype and Δb9 infected huh-7 cells stained with 
Hoechst-33342 (upper panel) and anti-HSP70 (red: lower panel) at 24 hours post infection. D) Real-time 
in vivo imaging of luciferase-expressing liver stage parasites in C57BL/6 mice at 42hpi. C57BL/6 mice 
were injected IV with either 5 x104 Pb-GFPLuccon sporozoites (n=5) resulting in a full liver infection (left 
figure: representative image of WT infected mice), or with 5 x104 Pb ∆b9-b sporozoites (n=10) (right 
panel).  All mice infected with WT parasites became patent with a blood stage parasitemia. Out of the 10 
C57BL/6 mice that were infected with 50K Δb9-b sporozoites 6 remained negative for any luminescent 
signal and did not get infected by a blood stage parasitemia.  Out of the other 4 mice, which showed 
individual spots overlaying the liver  (possibly individual infected hepatocytes) 2 became patent with a delayed blood stage infection.
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Huh7 cells, similar to the previously reported Pb∆slarp [15] and that of Pb∆b9 GAP 
(data not shown). In contrast with P. berghei ∆p52p36 [14] and ∆b9 parasites, not a single ∆b9Δslarp  parasite developed and underwent multiple nuclear replications 
in the hepatocytes (data not shown). Infection of BALB/c and C57BL/6 mice with high numbers (5x104 and 5x105 respectively) of Pb∆slarp and ∆b9Δslarp sporozoites 
did not result in a breakthrough blood infection (Table S5). Moreover, infection of 
C57BL/6 mice with 5x105 ∆slarp sporozoites did not result in any detectable liver 
stage development as determined by in vivo real-time imaging (Fig. 2).
 
 
                  24 hr           35 hr                     45 hr  
    
 
 
 
 WT-luc  
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Figure 2: Real-time in vivo imaging of ∆slarp-luc parasite liver development. Real-time in vivo imaging of luciferase-expressing liver stage parasites in C57BL/6 mice at 30, 35 and 44 
hours post infection. C57BL/6 mice were injected IV with either 5x104 Pb-GFPLuccon sporozoites (n=5) 
(upper panel: representative image of WT infected mice), or with 5 x104 Pb ∆slarp-a sporozoites (n=5) 
(lower panel: representative image of ∆slarp-a infected mice).  
Immunization of mice with P. berghei ∆b9∆slarp induces sterile and long-
lasting protection.
Having verified that the Pb∆b9∆slarp GAP cannot develop in mature liver stage 
parasites we addressed its protective efficacy following immunization. Similar to immunization with Pb∆b9 parasites, Pb∆b9∆slarp induced sterile protection against 
challenge with wildtype parasites at low doses in BALB/c mice (Table 2). Moreover, low dose Pb∆b9∆slarp immunization of C57BL/6 mice resulted in a conferred level of 
protection, similar to that of γ-irradiated sporozoite immunization (Table 2). These 
data were affirmed by the cellular immune response in C57BL/6 mice immunized with ∆b9∆slarp or γ-irradiated sporozoites, at as late as 70 days post challenge 
(Figure S6). Stimulation of hepatic mononuclear cells from mice immunized with 
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Table 2: Protection in BALB/c and C57BL/6 mice following immunization with P. berghei 
Δb9Δslarp and irradiated sporozoites.
Mice
Immuniza-
tion dose 
Spz x 103
Challenge after 
immunizationa
(re-challenge)
No. protected/ no. challenged 
-pre-patency-b
Δb9Δslarp γ-irradiated Control
Balb/c 25 d10 10/10
10 d10 20/20
5 d10 10/10
1 d10 20/20
None d10 0/15 -4.5-
C57BL/6 10/10/10c d10(d180)
10/10 
(5)
10/10 
(4/5)
-8-
1/1/1c d10 6/10 -7-
7/10 
-7.3-
None d10 0/6 -4.5-
50/20/20c d180 6/6 10/10
50/10/20c d180 3/3
50/20d d180 1/1
None d180 0/4-4-aChallenge was performed by a 104 wildtype sporozoite IV injection.bMean of pre-patent period in days post challenge.cImmunizations were performed with two 7 day intervals.dImmunizations were performed with a 14 day interval.
a dose regimen of 10K/10K/10K and 1K/1K/1K resulted in significantly higher 
IFNγ responses of CD8+ T cells, (p < 0.02). Within each dose regimen, no significant 
difference could be observed between mice receiving a ∆b9∆slarp or γ-irradiated sporozoite immunization. 
The majority of mice receiving a low immunization dose (10K/10K/10K spz) were 
protected upon re-challenge after 180 days. More importantly, mice immunized with ∆b9∆slarp or with γ-irradiated sporozoites showed high levels of protection 
after a first time challenge at 180 days post immunization (Table 2). In summary, the multiple attenuated P. berghei GAP ∆b9∆slarp does not develop into mature 
liver stage parasites and induces long-lasting sterile protection against a wildtype challenge.
Immunization of BALB/c and C57BL/6 mice with the single gene deleted Pb∆slarp 
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parasite resulted in sterile and long-lasting protection, not significantly different from immunization with Pb∆b9∆slarp  (Table S6).
Discussion
Here we show that, in the P. berghei rodent model, genetic attenuation of the parasite by simultaneous deletion of the b9 and slarp genes, results in a fully arresting (i.e no 
breakthrough infection) GAP that can induce strong long-lasting immune responses.Deletion of the b9 gene leads to an arrest of the majority of P. berghei parasites early 
after invasion of hepatocytes by sporozoites. Immunization of mice with P. berghei 
∆b9, leads to long-lived sterile protection, but is not fully safe in that some parasites 
can develop into blood stage parasites. This early growth-arrested phenotype is 
very similar to the phenotype described for mutants lacking expression of the P52 
protein or lacking the proteins P52 and P36 [13,14]. We previously reported the lack 
of an apparent PVM in P. berghei Δp52Δp36 developing in the cytosol of a hepatocyte (Ploemen et al. in press). Low numbers of P. berghei ∆b9 parasites seem to avert an 
arrest in the hepatocyte in a similar fashion. These findings may indicate that B9, P52 
and P36 play a similar role in the development of a PVM. Indeed, when we inoculated 
C57Bl/6 mice with high doses of triple gene deleted P. berghei Δb9Δp52Δp36 GAP 
sporozoites, we observed that the multiple gene-deletion mutant Δb9Δp52Δp36 
shows the same high level of growth arrest as the single gene-deletion mutant Δb9 (data not shown). The multiple attenuated ∆b9∆slarp  GAP is absent of the safety 
concerns from these GAPs. 
By adopting a previously  proposed robust and stringent screening approach for 
GAP safety [14], we find that the ∆b9∆slarp  GAP does not induce breakthrough infections. We used amongst others in vivo imaging and multiple mice strains, to 
determine the adequacy of GAP attenuation, before advancement with further 
clinical development. In fact both P. berghei ∆slarp and ∆b9∆slarp  parasites meet the screening criteria. Both mutant parasites do not replicate in hepatocytes after 
invasion. Moreover, both BALB/c and C57BL/6 mice remained negative for blood stage parasitemia after inoculation with high numbers of mutant sporozoites. 
Although robust, these findings might not be so surprising since it was already 
observed that inoculation of high numbers of P. berghei ∆slarp [15] and its P. yoelii orthologue ∆sap1 [16] sporozoites, did not result in blood stage infection in mice, albeit in one mouse strain. Still, the multiple attenuated ∆b9∆slarp  GAP has a safety 
advantage over the single gene deleted ∆slarp GAP. The full arrest of ∆slarp/∆sap1 
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parasites likely results from a depletion of transcripts from a number of various so-
called UIS (up-regulated in sporozoites) genes [17]. The combined effect of all these 
down-regulated UIS genes might very well cause the subsequent full developmental 
arrest. However, as these UIS genes are down-regulated but not absent there might 
possibly be a safety concern, which is alleviated by the simultaneous deletion of another gene, b9, in one parasite. Thereby forming a multiple genetically attenuated 
fully arresting safe GAP.
Our results show that immunization of C57BL/6 mice with either ∆slarp or ∆b9∆slarp 
parasites induces long-lived protection. This is remarkable since others have shown that ∆slarp (SL22 cl3) parasites induce a decreased protective efficacy in C57BL/6 
mice from as early as 3 weeks post last immunization [15]. In our present study, we use this exact ∆slarp parasite and an independently generated mutant to show long-
lived protection. Moreover, we observed that a mere prime boost with a two week 
interval is sufficient to induce long-lived protection in C57BL/6 mice (Table S6). 
Two immunizations with a one week interval did previously not confer protection in 
∆p52 immunized C57BL/6 mice [13]. Possibly, the time interval between the prime 
and boost immunization is of influence on the conferred level of protection. The 
discrepancy between the herein and previously reported long-lived protection in 
∆slarp immunized C57BL/6 mice could result from a number of factors. Laboratory 
differences can possibly influence the outcome of the experiments. Also, the age of 
the sporozoites at the time of immunization could very well be of influence. When 
we immunized 10 BALB/c mice with 1000 30-day old ∆Slarp (Sl22 cl3) parasites 
we found a mere 10% protection whereas we observed 80% protection following 
immunization with 1000 21-day old mutant parasites (Table S6). Late ∆slarp parasites (30+ days post mosquito infection) showed a strong decrease in gliding motility compared to wildtype (data not shown). Possibly, down-regulation of the 
Pumilio-2 gene in the ∆slarp mutant influences the gliding motility and subsequently 
the protective efficacy of the sporozoites over time. Previously it was shown that the 
pumilio-2 gene is down-regulated in the P. yoelii ∆slarp orthologue ∆sap1 and in P. 
berghei ∆pumilio-2 parasites have an impaired gliding motility [17,29]. A possible similar effect on mutant P. falciparum parasites could not influence future vaccine 
efficacy since all parasites will be harvested at the same time early after sporozoite 
salivary gland infection.
It will be key to determine the phenotype of a P. falciparum ∆b9∆slarp  GAP. These 
parasites have now been generated (unpublished data Ben van Schaijk). If these multiply attenuated P. falciparum ∆b9∆slarp  parasites make viable sporozoites 
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which invade primary human hepatocytes prior to a full developmental arrest, 
these GAP might be ready to go into clinical testing. Subsequently, with the use 
of the cryopreservation techniques of sporozoites designed by Sanaria Inc. and 
recent insights in the effective administration of whole sporozoite malaria vaccines by needle and syringe (Ploemen et al. in press) the clinical development of a GAP 
vaccine candidate might be in grasp.
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Supplementary Information
Supplementary Table S1: List of primers used in this study.
Name Sequence Restriction site Description Gene models
Primers for generation of the ∆B9 target regions (for pL1439) (restriction sites are shown in red)
∆b9 4096 GGGGTACCTAAATAACATGATGAAACGTCAC Asp718 ∆b9  5' target F PBANKA_080810
∆b9 4097 CCCAAGCTTTCTATGCATTACTTCTACCCTC HIndIII ∆b9  5'target R PBANKA_080810
∆b9 4098 GGAATTCGATATGCTTGAAATTCCTAGAC EcoRI ∆b9   3' target F PBANKA_080810
∆b9 4099 TCCCCCCGGGCGCTTGTGGTTGCATACATC XmaI ∆b9   3' target R PBANKA_080810
Primers for confirmation PCR of the integration event in ∆B9
∆b9 4288 CAAATCCACAGACACTTACTC ∆b9  5' integration F PBANKA_080810
∆b9 L1858 ATGCACAAAAAAAAATATGCACAC ∆b9   5' integration R from KO construct pL1439 PBANKA_080810
∆b9 4239 GATTTTTAAAATGTTTATAATATGATTAGC ∆b9  3' integration F from KO construct pL1439 PBANKA_080810
∆b9 4289 CAACCTTTTGCCTTGCATG ∆b9  3' integration R PBANKA_080810
∆b9 4437 CGCATTATTCGAGGTAGACC ∆b9 orf  F PBANKA_080810
∆b9 4438 ACGGGTTTCACTTACATACTC ∆b9 orf  R PBANKA_080810
∆b9 4698 GTTCGCTAAACTGCATCGTC hdhfr F
∆b9 4699 GTTTGAGGTAGCAAGTAGACG yfcu R
∆b9 5441 ATGAGCATAAATGTGAGCATGG ∆b9 negative selection 5' target F PBANKA_080810
∆b9 5442 CTTGAACCTAGATTGGGTGTAG ∆b9 negative selection 3' target R PBANKA_080810
Primers for the Anchor-tagging PCR-based method: Generation of ∆B9 target regions (for pL1499) (restriction sites are shown in red; Anchor tags are shown in blue)
∆b9 4667 GAACTCGTACTCCTTGGTGACGGGTACCTAAATAACATGATGAAACGTCAC Asp718 ∆b9  5' target F PBANKA_080810
∆b9 4557 CATCTACAAGCATCGTCGACCTCTCTATGCATTACTTCTACCCTC ∆b9   5'target R PBANKA_080810
∆b9 4558 CCTTCAATTTCGGATCCACTAGGATATGCTTGAAATTCCTAGAC ∆b9  3' target F PBANKA_080810
∆b9 4668 AGGTTGGTCATTGACACTCAGCAGTACTCGCTTGTGGTTGCATACATC ScaI ∆b9   3' target R PBANKA_080810
∆b9 4661 GAACTCGTACTCCTTGGTGACG for 2nd PCR anchor tag
∆b9 4662 AGGTTGGTCATTGACACTCAGC for 2nd PCR anchor tag
Primers for confirmation PCR of the integration event in ∆B9 (Anchor tags are shown in blue)
∆b9 4288 CAAATCCACAGACACTTACTC ∆b9  5' integration F
∆b9 4770 CATCTACAAGCATCGTCGACCTC ∆b9  5' integration R from KO construct pL1499 anchor tag
∆b9 4771 CCTTCAATTTCGGATCCACTAG ∆b9  3' integration F from KO construct pL1499 anchor tag
∆b9 4289 CAACCTTTTGCCTTGCATG ∆b9  3' integration R 
∆b9 4437 CGCATTATTCGAGGTAGACC ∆b9 orf  F PBANKA_080810
∆b9 4438 ACGGGTTTCACTTACATACTC ∆b9 orf  R PBANKA_080810
∆b9 L307C GCTTAATTCTTTTCGAGCTC hdhfr F
∆b9 3187 GTGTCACTTTCAAAGTCTTGC hdhfr R
Primers for RT-PCR
RT-PCR 6301 ATACCAGAACCACATGTTACG CS  for RT primer PBANKA_040320
RT-PCR 6302 CTCTACTTCCAGGATATGGAC CS  F for RT-PCR PBANKA_040320
RT-PCR 6303 CATTGAGACCATTCCTCTGTG CS  R for RT-PCR PBANKA_040320
RT-PCR 7034 CCATTCTGGGTAGAACAAATGC b9  for RT primer PBANKA_080810
RT-PCR 7035 TATCCCATCACTCATACCTAG b9  F for RT-PCR PBANKA_080810
RT-PCR 7036 ACGGGTTTCACTTACATACTC b9  R for RT-PCR PBANKA_080810
Primers for the Anchor-tagging PCR-based method: Generation of ∆slarp target regions (for pL1740) (restriction sites are shown in red; Anchor tags are shown in blue)
∆slarp 5960 GAACTCGTACTCCTTGGTGACGGGTACCGGGAGTCAAAAACGGTATGC Asp718 ∆slarp  5' target F PBANKA_090210 
∆slarp 5961 CATCTACAAGCATCGTCGACCTCTCCTATAGTACATGCCCACG ∆slarp  5'target R PBANKA_090210 
∆slarp 5962 CCTTCAATTTCGGATCCACTAGCATGTTAGGAGCACGAAACC ∆slarp   3' target F PBANKA_090210
∆slarp 5963 AGGTTGGTCATTGACACTCAGCAGTACTCTAAAATTGTGGGAATCCACTTG ScaI ∆slarp   3' target R PBANKA_090210
4661 GAACTCGTACTCCTTGGTGACG for 2nd PCR
4662 AGGTTGGTCATTGACACTCAGC for 2nd PCR
Primers for confirmation PCR of the integration event in ∆slarp (Anchor tags are shown in blue)
∆slarp 6125 CATGTCTCTTTGCATGTGGC ∆slarp  5' integration F PBANKA_090210 
∆slarp 6349 CTCATCTACAAGCATCGTCG ∆slarp  5' integration R from KO construct
∆slarp 4771 CCTTCAATTTCGGATCCACTAG ∆slarp  3' integration F from KO construct
∆slarp 6126 GTCGTCCTATAGTAAGTTGAGC ∆slarp  3' integration R PBANKA_090210
∆slarp 6127 CCCAAATGATCAAGCACCAG slarp orf F PBANKA_090210
∆slarp 6128 CAATTTGAATCGGCACAAGGC slarp orf R PBANKA_090210
6346 TGGACATTGCCTATGAGGAG hdhfr-yfcu F
6347 AACACAGTAGTATCTGTCACC hdhfr-yfcu R
∆b9 4437 CGCATTATTCGAGGTAGACC b9 orf F PBANKA_080810
∆b9 4438 ACGGGTTTCACTTACATACTC b9 orf R PBANKA_080810
Chapter 6
138
Supplementary Table S2: Phenotypic analysis of P. berghei Δb9 mosquito and liver stages.
Parasite Oocyst No. 
Mean ± sd 
Spz No. 
(x 103)
Mean ± sd 
Sporozoite 
Motilitya
Cell 
Traversalb
Hepatocyte
invasionc
WT 85 ± 25 102 ± 28 1.00 ± 0.03 1.00 ± 0.14 1.00 ± 0.12
WT
(PbGFP-Luccon)
63 ± 15 86 ± 24 Nd 1.0 ± 0.1 0.92 ± 0.16
Δb9-a 89 ± 14 89 ± 28 1.01 ± 0.02 1.11 ± 0.03 1.08 ± 0.28
Δb9-b 55 ± 18 85 ± 25 Nd 0.9 ± 0.08 1.03 ± 0.07
aDetermined by counting CS protein sporozoite trails.bSporozoite Traversal through Huh-7 cells.cSporozoite invasion of Huh-7 cells. Number of intracellular parasites determined at 3h after infection.
Supplementary Table S3: Breakthrough blood infection in Swiss, BALB/c  and C57BL/6 after 
inoculation with P. berghei Δb9 mutants.
Mouse 
strain Parasites Dose
breakthrough/
infected animals 
Pre-patency 
(days)
Swiss WT 1x104                5/5             5
PbΔb9-a 1x104 0/3 n/a
PbΔb9-b 1x104 0/3 n/a
PbΔb9-b 5x104 0/3 n/a
BALB/c WT 1 x104 5/5 5
PbΔb9-a 5 x104 0/20 n/a
PbΔb9-b 5 x104 0/10 n/a
C57BL/6 WT 1 x104 5/5 5
PbΔb9-a 5 x104 2/10 8-9
PbΔb9-b 5 x104 1/10 9
PbΔb9-b 2 x105 2/10 8-9
aInoculation dose of sporozoites administered IV
139
P. berghei Δb9Δslarp are completely arrested and confer long-lasting protection
Supplementary Table S4: Phenotypic analysis of P. berghei Δslarp and Δb9Δslarp mosquito and 
liver stages.
Parasite Oocyst No. 
Mean ± sd 
Spz No. 
(x 103)
Mean ± sd 
Sporozoite 
Motilitya
Cell 
Traversalb
Hepatocyte
invasionc
WT 119 ± 40 108 ± 23 1.0 ± 0.1 1.00 ± 0.08 1.00 ± 0.06
Δslarp-a 154 ± 17 88 ± 41 1.01 ± 0.13 1.09 ± 0.06 0.97 ± 0.11
Δb9Δslarp 172 ± 5 43 ± 23 1.05 ± 0.03 1.21 ± 0.12 1.02 ± 0.03
aDetermined by counting CS protein sporozoite trails.bSporozoite Traversal through Huh-7 cells.cSporozoite invasion of Huh-7 cells. Number of intracellular parasites determined at 3h after infection.
Supplementary Table S5: No breakthrough blood infection in BALB/c and C57BL/6 after 
inoculation with P. berghei Δslarp and Δb9Δslarp sporozoites.
Mouse 
strain Parasites Dose
breakthrough/
infected animals 
Pre-patency 
(days)
BALB/c WT 1x104                5/5             4-5
Δslarp-a 5 x104 0/5 n/a
Δslarp-a 25 x103 0/10 n/a
Δb9Δslarp 25 x103 0/10 n/a
C57BL/6 WT 1 x104 5/5 4-5
Δslarp-a 5 x105 0/5 n/a
Δslarp-a 4 x105 0/5 n/a
Δslarp-a 2 x105 0/10 n/a
Δb9Δslarp 2 x105 0/10 n/a
Δb9Δslarp 15 x104 0/5 n/aaInoculation dose of sporozoites administered IV
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Supplementary Table S6: Protection in BALB/c and C57BL/6 mice following immunization with 
P. berghei Δslarp sporozoites.
Mice
Immuniza-
tion dose 
Spz x 103
Challenge after 
immunizationa
(re-challenge)
No. protected/ no. challenged 
-pre-patency-b
Δslarp 
(1839 cl3)
Δslarp 
(SL22 cl3)e
Controlf
Balb/c 50 d10 14/14
25 d10 10/10 14/14
10 d10 19/20-5- 10/10
5 d10 10/10 10/10
1 d10 20/20 8/10-8-
None d10 0/15 -4.5-
C57BL/6 10/10/10c d10(d180)
10/10 
(10/10)
10/10 
(9/10)
-8-
1/1/1c d10(d180)
5/10 
-7.2-
(4/5) 
-6-
5/10 
-7.8-
(5/5) 
None d10 0/6 -4.5-
50/20/20c d180 8/9 -9-
50/10/20c d180 6/7-7-
50/20d d180 3/3
None d180 0/4 -4-
aChallenge was performed by a 104 wildtype sporozoite IV injection.bMean of pre-patent period in days post challenge.cImmunizations were performed with two 7 day intervals.dImmunizations were performed with a 14 day interval.eThis Δslarp GAP was previously generated and published [15].f For each mouse strain, immunizations and challenges were conducted in one experiment. Immunizations  of mice presented in Table 2 were performed simultaneous with the immunization experiments   presented in Table S6; hence only one group of control mice were used per challenge time point.
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Supplementary Figure S1: Generation and genotype analyses of P. berghei mutant; Δb9-a and 
Δb9-b.
A) Generation of mutant ∆b9-a (1309cl1). For ∆b9-a the DNA-construct pL1439 was generated containing 
the positive/negative selectable marker cassette hdhfr/yfcy. This construct was subsequently used to generate the mutant ∆b9-a (1309cl1) in the cl15cy1 reference line. See Table S1 for the sequence of the primers. B) For the mutant ∆b9-b (1481cl4) the pL1499 construct was generated which was used for the generation of the mutant in the PbGFP-Luccon reference line. See Table S1 for the sequence of the primers. 
C+D) Diagnostic PCR (C) and Southern analysis (D) of Pulse Field Gel (PFG)-separated chromosomes of mutant ∆b9-a and ∆b9-b confirming correct disruption of the b9-locus. See Table S1 for the sequence 
of the primers used for the selectable marker gene (M); 5’-integration event (5’); 3’-integration event (3’) and the b9-ORF. Mutant ∆b9-a has been generated in the reference P. berghei ANKA line cl15cy1. Mutant ∆b9-b has been generated in the reference P. berghei ANKA line PbGFP-Luccon which has a gfp-
luciferase gene integrated into the silent 230p locus (PBANKA_030600) on chromosome 3 (i.e. RMgm-
29; http://pberghei.eu/index.php?rmgm=29). For Southern analysis, PFG-separated chromosome were 
hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into P. berghei b9 locus on 
chromosome 8, the endogenous locus of dhfr/ts on chromosome 7 and in mutant ∆b9-b the gfp-luciferase gene integrated into chromosome 3.
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Supplementary Figure S2: Characterization of the PVM in developing P. berghei Δb9 mutants. 
IFA of wildtype and Δb9 infected hepatocytes stained with anti-HSP70 or anti-MSP1 (red) and anti-
EXP1 and anti-UIS4 (green)-antibodies at various time points post infection. Nuclei are stained with 
Hoechst-33342. Bar represents 10µm.
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Supplementary Figure S3: Generation and genotype analyses of P. berghei mutant; Δslarp-a. 
A) Generation of mutant ∆slarp-a (1839cl3) mutant. For ∆slarp-a the DNA-construct pL1740 was 
generated containing the positive/negative selectable marker cassette hdhfr/yfcy. This construct was subsequently used to generate the mutant ∆slarp-a (1839cl3) in the PbGFP-Luccon reference line. See Table S1 for the sequence of the primers. B) Diagnostic PCR and southern analysis of Pulse Field Gel 
(PFG)-separated chromosomes of mutant ∆slarp-a confirming correct disruption of the slarp-locus.  See 
Table S1 for the sequence of the primers used for the selectable marker gene (SM); 5’-integration event 
(5’); 3’-integration event (3’) and the slarp ORF. Mutant ∆slarp has been generated in the reference P. 
berghei ANKA line PbGFP-Luccon which has a gfp-luciferase gene integrated into the silent 230p locus 
(PBANKA_030600) on chromosome 3 (i.e. RMgm-29; http://pberghei.eu/index.php?rmgm=29). For 
Southern analysis, PFG-separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into P. berghei slarp locus on chromosome 9, the endogenous locus of dhfr/ts on chromosome 7 and the gfp-luciferase gene integrated into chromosome 3. In addition, the chromosomes were hybridized with the hdhfr probe recognizing the integrated construct into the slarp 
locus on chromosome 9.
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Supplementary Figure S4: Generation and genotype analyses of P. berghei mutant; Δb9Δsm.  
A) Schematic representation of the generation of a  selectable marker free ∆b9 mutant using the marker-
recycling method. The b9 disruption construct containing the hdhfr::yfcu selectable marker (black 
arrows) flanked by the recombination sequences (3’pbdhfr, shaded boxes) targets the 230p locus by 
double cross-over homologous recombination at specific target regions (gray boxes). The ∆b9-a mutant is 
obtained after transfection, using positive selection with pyrimethamine and then cloning. Subsequently, the marker-free ∆b9(∆sm) mutant is selected by negative selection using 5-FC. Only mutant parasites 
that have ‘spontaneously’ lost the hdhfr::yfcu marker from their genome, achieved by a homologous 
recombination/excision, survive the negative selection. B) Southern blot analysis was hybridized with a 
5’ UTR b9 probe (i.e. 5’ targeting region). The localization of the restriction enzyme site (N; Nde I) and the expected size of the fragments are shown in Wt (wild type); ∆b9-a (b9 deletion mutant) and ∆b9∆sm (b9 deletion mutant free of selectable-marker).
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Supplementary Figure S5: Generation and genotype analyses of P. berghei mutant; Δb9Δslarp. 
A) Generation of mutant ∆b9∆slarp. For ∆b9∆slarp the DNA-construct pL1740 was generated containing 
the positive/negative selectable marker cassette hdhfr/yfcy. This construct was subsequently used to generate the mutant ∆b9∆slarp in the ∆b9∆sm mutant. See Table S1 for the sequence of the primers. 
B) Diagnostic PCR and southern analysis of Pulse Field Gel (PFG)-separated chromosomes of mutant 
∆b9∆slarp confirming correct disruption of the slarp-locus and the b9 locus.  See Table S1 for the sequence 
of the primers used for the selectable marker gene (SM); 5’-integration event (5’); 3’-integration event (3’) and the slarp and the b9 ORF. For Southern analysis, PFG-separated chromosomes were hybridized using a 
3’UTR pbdhfr probe that recognizes the construct integrated into P. berghei slarp locus on chromosome 9, the endogenous locus of dhfr/ts on chromosome 7 and a 3’UTR pbdhfr probe that recognizes the construct integrated into P. berghei b9 locus on chromosome 8. In addition, the chromosomes were hybridized with the hdhfr probe recognizing the integrated construct into the slarp locus on chromosome 9.
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Figure S6: Liver CD8+ T cells with IFNγ response after immunization with ∆b9∆slarp or γ-irradiated 
sporozoites. Sporozoite specific CD8+ T cell response in the liver of naïve or immunized C57BL/6j mice 
at C+70 post a ∆b9∆slarp or irradiated sporozoites immunization with a 10K/10K/10K or a 1K/1K/1K 
dose regimen. Intracellular IFNγ production was measured by flow cytometry before challenge in liver. 
Immunized groups and naive mice responded equally to a polyclonal (PMA/Ionomycine) stimulation 
(data not shown). *  P < 0.02; ** P < 0.001 compared to naïve mice.
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Abstract
Studies in animal models suggest that protection against malaria induced by 
intradermal (ID) administration of sporozoites is less effective compared to 
intravenous injection (IV). We investigated in a murine model the protective efficacy 
and immune responses after ID or IV immunization of sporozoites. Mice were 
immunized via either IV or ID route with P. berghei sporozoites in combination with 
chloroquine treatment (CPS)  (allowing full liver stage development) or by γ-radiation 
attenuated sporozoites (RAS) (early liver stage arrest). While IV immunization with 
both RAS and CPS generated 90-100% protection, ID immunization resulted in 
reduced levels of protection with either immunization strategy in both Balb/cByJ 
(50%) and C57BL/6j mice (7-13%). Lower protection by ID routing associated with 
a 30-fold lower parasite liver load (p<0.001 (χ2= 49.08, (df 1)) assessed by real-time 
in vivo imaging of bioluminescent P. berghei parasites. Unlike IV, ID immunization 
did not result in expansion of  CD8+ T-cells with effector memory phenotype 
and showed lower IFNγ responses irrespective of the immunization regime. In conclusion, protection against sporozoite infection is likely dependent on parasite 
liver infection and subsequently generated cellular immune responses.
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Introduction
Attenuated whole malaria parasites are considered eligible candidates for a 
potentially successful vaccine [1,2]. The approach is based on disruption of the 
Plasmodium parasite life cycle allowing the host to develop protective immunity 
in the absence of overt clinical disease [3]. Whole parasite immunizations with sporozoites attenuated by radiation (RAS), or with sporozoites in combination 
with chloroquine chemo-prophylaxis (CPS), have been successfully conducted in 
mice and men resulting in complete protection [4,5,6]. RAS arrest early in liver 
stage development [7] whereas CPS undergo full liver stage maturation releasing blood stage parasites that are subsequently killed by chloroquine [4]. While murine 
immunizations are generally performed by intravenous (IV) routing, alternative 
routes are required for sustainable clinical applications in humans. Immunity to 
malaria is known to comprise cellular and humoral responses [8]. Various studies 
have report antibody responses during sporozoite immunization in mice, including 
RAS and CPS [9,10,11]. Moreover, protective efficacy following IV immunizations 
in mice is attributed to liver CD8+ effector memory T cells and high levels of IFNγ 
production [12,13,14,15]. However lower levels of protection are induced following 
intradermal (ID) sporozoite immunization with either P. berghei genetically 
attenuated parasites (GAP) [16] or P. yoelii RAS [17]. In a recent clinical study, 
subcutaneous or ID immunization with irradiated P. falciparum sporozoites also 
showed suboptimal immune responses and protective efficacy in humans [18]. These 
data corroborated with findings in a murine model, showing that protective efficacy 
following ID immunization requires a higher sporozoite inoculation compared to IV 
immunization, and suggesting  that differences in protective efficacy may be related 
to the number of sporozoites reaching the liver.  
Using bioluminescent parasites, we studied the relation between parasite liver load 
following IV or ID sporozoite infection and protective immunity following  IV or ID immunizations by P. berghei RAS or CPS protocols.
Material and Methods
Mice and parasites
Female BALB/cByJ and C57BL/6J, eight weeks of age, were purchased from Elevage Janvier 
(France). All studies were performed according to the regulations of the Dutch “Animal On 
Experimentation act” and the European guidelines 86/609/EEG. Approval was obtained from 
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the Radboud University Experimental Animal Ethical Committee (RUDEC 2009-019, RUDEC 
2009-225). P. berghei (ANKA) sporozoites (spz) were obtained by dissection of the salivary glands of infected female Anopheles stephensi mosquitoes 21-28 days after infected blood 
meal. For radiation attenuated sporozoites (RAS), infected mosquitoes were irradiated at 
16,000 rad (Gammacel 1000 137Cs) prior to dissection.
Intravenous and intradermal immunization by RAS and CPS
All immunizations were performed with freshly isolated sporozoites. BALB/cByJ mice were immunized once with 50.000 P. berghei sporozoites. C57BL/6J mice received three injections 
of 10,000 sporozoites with 7 day intervals. Different immunization protocols were used 
given that in contrast to BALB/c mice, multiple sporozoite inoculations are required to 
induce protection in C57BL/6  mice [19,20]. In both mouse strains, the choice for specific 
immunization dose was made based on a suspected (sub)optimal level of conferred protection. 
All immunizations were performed by IV injection (200 μl in the tail vein) or ID injection 
(50 μl in the proximal part of each hind leg). For the chloroquine prophylactic sporozoites 
(CPS) immunizations, mice received a daily i.p. injection of 800µg of chloroquine base 
starting simultaneously with the first sporozoite inoculation up to two weeks after the last sporozoite inoculation. Chloroquine diphosphate (CQ, Sigma-aldrich) was diluted in PBS and administered  to mice. At the end of the chloroquine treatment and one day before challenge, 
absence of parasitemia was confirmed by examination of Giemsa-stained slides of tail blood.
Challenge of immunized mice by mosquito bite
Groups of BALB/cByJ and C57BL/6J mice, immunized with either irradiated sporozoites or 
sporozoites under chloroquine cover, were challenged by PbGFP-Luccon infectious mosquito 
bites (5-11 mosquitoes) two weeks after the chloroquine treatment. Salivary glands of all 
blood-engorged mosquitoes were dissected to confirm the presence of sporozoites. Giemsa 
stained bloodsmears were prepared every other day starting from day 3 to day 21 after mosquito bite challenge,  to monitor for blood stage parasitemia. The pre-patent period 
was defined as the period of time between challenge and the first appearance of blood stage 
parasites (0.5-2% blood smear positive).
Real-time in vivo imaging of liver stage development in C57BL/6 mice Since in vivo visualization of parasites during particularly RAS immunization is not possible, we performed a separate infection experiment with PbGFP-Luccon. PbGFP-Luccon sporozoites (50x103) were administered to C57BL/6 mice by IV injection in the tail (200 µl) or by ID 
injection in the proximal part of each hind leg (50 µl per leg). C57BL/6 mice were preferred 
over BALB/c mice based on a higher susceptibility for P. berghei infection [21], which 
enables a more sensitive visualization of the parasite load. Each group consisted of 5 mice. 
Luciferase activity in animals was visualized through imaging of whole bodies using the in 
vivo imaging system Lumina (Caliper Life Sciences, USA) as described previously [22] with 
minor adaptations. Briefly, animals were anesthetized using the isoflurane-anesthesia 
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system, their abdomen was shaved and D-luciferin dissolved in PBS (100 mg/kg; Caliper Life Science, Belgium) was injected subcutaneously (in the neck). Animals were kept anesthetized during the measurements, which were performed within 3-5 minutes after the injection 
of D-luciferin. Bioluminescence imaging was acquired with a 10 cm FOV, medium binning 
factor and an exposure time of 300 seconds. Quantitative analysis of bioluminescence was 
performed by measuring the luminescence signal intensity using the ROI settings of the 
Living Image 3.0 software. The ROI was set to measure the abdominal area at the location of 
the liver. ROI measurements are expressed in total flux of photons. 
Mononuclear cell isolation from blood, spleen and liver
Before and after challenge, C57BL/6J mice were euthanized by isoflurane inhalation after i.v. 
injection of 50 i.u. of heparin. Blood, spleen and livers were collected after perfusion of the 
livers with 10ml of PBS. Cell suspensions of livers and spleen were made by pressing the 
organs through a 70-µm nylon cell strainer (BD Labware). Liver cells were resuspended in 
35% Persoll (GE Healthcare) and centrifuged at 800g for 20min. Liver and spleen erythrocytes were lysed by a 5 min incubation of the cells on ice in ACK lysing buffer. After erythrocyte 
lysis, hepatic mononuclear cells (HMC) and splenocytes were resuspended in RPMI medium 
(Gibco, 1640). Isolation of peripheral blood mononuclear cells (PBMC) was performed using 
Histopaque-1077 ( Sigma-Aldrich ) according to the manufacturer’s recommendation.
Phenotyping CD8+ effector and memory T cells
Five-color staining of PBMC, HMC and splenocytes was performed using the following 
monoclonal anti-mouse antibodies: Pacific blue-conjugated anti CD3 (17A2), Peridinin 
Chlorophyll Protein (PerCP)-conjugated anti CD4 (RM4.5), Alexa fluor 700-conjugated anti 
CD8a (53-6.7), fluorescein isothiocyanate (FITC)–conjugated anti-CD44, allophycocyanin 
(APC)– or phycoerythrin-Cy7 (PE-Cy7)-conjugated anti-CD62L (MEL-14). All antibodies 
were purchased from Biolegend (San Diego, CA). Briefly, 106  cells were resuspended in cold 
assay buffer (PBS supplemented with 0.5% bovine serum albumin – Sigma-Aldrich ) and 
incubated for 30min at 4°C with monoclonal antibodies. Cells were fixed with Fix & Perm 
medium A (Invitrogen) and resuspended in assay buffer for measurement. Flow cytometry 
was performed on a 9-color Cyan ADP (Beckman Coulter) and data analysis using FlowJo 
software (version 9.1 ; Tree Star). 
Ex vivo sporozoite stimulation and intracellular IFNγ staining
HMC and splenocytes in complete RPMI 1640 culture medium [23] were co-cultured in 
presence of cryoconserved sporozoites or salivary glands from uninfected mosquitoes. 
Cells were stimulated at 37°C/5%CO2 for 24 hours during which Brefeldin A (Sigma) was 
added for the last four hours (10µg/ml  final concentration). As a positive control to the 
stimulation, PMA and Ionomycin (Sigma) were added simultaneously with Brefeldin A at 
a final concentration of 100ng/ml and 1.25µg/ml respectively.  Cells were harvested after 24-hours in vitro stimulation and stained with labeled monoclonal antibodies against CD3, 
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CD4, CD8a and CD44 as cited above. Fixed cells were stained with APC-conjugated anti- IFNγ 
for 30min at 4°C with Fix & Perm medium B (Invitrogen). Flow cytometry was performed on 
a 9-color Cyan ADP (Beckman Coulter) and data analysis using FlowJo software (version 9.1 
; Tree Star). For the analysis of cytokine production, background responses to salivary glands 
was subtracted from PbSPZ responses respectively for each individual mouse.
Transgenic PbGFP-Luccon sporozoites neutralization assay
The transgenic sporozoite neutralization assay (TSNA) was performed as described [24]. Mice 
were sacrificed and plasma was collected 1 day before challenge. PbGFP-Luccon sporozoites 
(9x104 in 30 μl RPMI) were pre-incubated for 30 minutes on ice with 30µl (1:1 ratio) plasma 
of naive or immunized mice. Pre-incubated freshly isolated sporozoites were added to wells containing monolayers of 1x105 pre-seeded Huh-7 hepatocyte cultures (1 ml/well in 24 well 
plates). Human liver hepatoma cells (Huh-7) were suspended in 1ml of ‘complete’ DMEM 
(DMEM, Gibco, supplemented with 10% FCS, 1% penicillin/streptomycin and 1% Glutamax) 
the day prior to infection and were seeded overnight in 24 well plates (105 cells/well). For each plasma sample, duplicates of 3x104 sporozoites were added per well and plates were 
centrifuged 10 minutes at 1800 G (eppendorf centrifuge 5810 R).
At 40 hours post sporozoite addition, cells were washed and lysed in 200 µl of cell culture lysis 
reagent obtained from the Promega Luciferase Assay System Kit® (Promega, PT). Samples 
in Promega lysis buffer were measured for luminescence intensity with the Lumina system. 
70 µl of Luciferase Assay Substrate (Promega Luciferase Assay System Kit®) was added to 
20 µl of lysed hepatocyte cultures in a white 96-well plate. Bioluminescence images were 
acquired with a 7 cm FOV, medium binning factor and exposure time of 10-30 seconds. 
Quantitative analysis was performed by measuring the luminescence signal intensity  per well 
using the ROI settings of the Living Image 3.0 software. ROI measurements are expressed in 
total flux of photons. Percent inhibition was calculated by the following formula; 1 – (average 
bioluminescence in immune plasma sample/average bioluminescence in naive plasma 
sample) * 100%. 
Statistical analysis
In all experiments and assays, comparisons between two groups were performed by a Mann-
Whitney U test using PRISM software version 5.0 (Graphpad, San Diego, CA). p < 0.05 are 
considered statistically significant. Overall comparisons over three groups or more was 
performed by Kruskas-Wallis test. Calculations of sample sizes were performed (power 0.85; 
α = 0.05) by estimation of differences between IV and ID groups.
Results 
RAS and CPS ID immunization induce less protection compared to the IV route
To compare protective efficacy conferred by ID or IV immunization, mice immunized by either RAS or CPS protocols were challenged by infectious mosquito bites. 
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Irrespective of the immunization protocol, ID immunization induced lower 
protection in BALB/cByJ (50%) and C57BL/6J (7-13%) mice as compared to 90-
100% protection after IV immunization (Table 1). Development of blood stage 
parasites in unprotected ID immunized mice showed no significant delay compared to control mice.  
Table 1. Protection by intravenous and intradermal immunizations
No. protected/ No. challenged (% protection)
pre-patency (days) BALB/c50K C57BL6/j10k/10k/10kIntravenous Intradermal Intravenous Intradermal
RAS 9/10 (90)7 5/10 (50)6 15/15 (100) 1/15 (7) 6
CPS 10/10 (100) 5/10 (50)6 15/15 (100) 2/15 (13)6
Naive 0/9 (0)5.5 1/11 (9)5
C57BL/6j and BALB/cByJ mice were immunized with RAS or CPS by IV or ID. Challenged by bites of 5-11 infected mosquitoes was performed 3 to 4 weeks after the last immunization (two weeks after 
chloroquine treatment). Parasitaemia was monitored by Giemsa staining of tail-vein blood slides up to 21 days after challenge. 
ID injection of PbGFP-Luccon sporozoites results in lower parasite liver load
To evaluate whether infection by IV or ID routes resulted in different magnitude 
of liver infection,  we measured in vivo parasite liver loads in C57BL/6 mice by 
real-time imaging after IV or ID injection of identical doses of fresh PbGFP-Luccon 
sporozoites. Mice that received IV injection showed a clear bioluminescent signal 
originating from the site of the liver as from 30 hours post infection onwards. This 
signal subsequently further increased covering the whole liver area at 44 hours post 
infection (Figure 1A). In contrast, ID injection did not result in a bioluminescent signal distinct from background at 30 and 35 hours post infection while a weak 
signal was visible at 44 hours. After ID injection, mice showed approximately a 30 
fold lower parasite liver load (p < 0.0001) compared to IV injected mice (Figure 1B). 
These data show a strong association (p<0.001 (χ2 = 49.08, (df 1)) between the 
number of parasites reaching the liver in this experiment and the level of protection conferred by different routes of sporozoite administration as shown in preceding immunization experiments.
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Figure 1. Liver stage development of PbGFP-Luccon sporozoites after IV or ID injection.
A) Representative rainbow images of luminescence (photons/sec/cm2) in livers of live C57BL/6 mice at 44 h after infection. Mice were injected with 5x104 sporozoites by intravenous (left) or intradermal (right) inoculation. B) Real-time measurement of the parasite liver load in mice injected with 5x104 sporozoites 
by IV (n=5) or ID  (n=5) inoculation, at different time points (30, 35 and 44 hours post infection). Dots 
represent the luminescent intensity (photons/sec/cm2) of the Regions of interest (ROI’s) overlaying the 
livers, as depicted in A. The dotted line represents the threshold of luminescent signaling. *** p ≤  0.0001.
Expansion of CD8+ effector memory T cells and sustained sporozoite-specific 
IFNγ responses in IV but not in ID immunized mice.
We next assessed cellular immune responses after IV or ID immunization of 
C57BL/6j mice. Following RAS or CPS IV immunization, proportions of CD8+ T 
cells with effector memory phenotype (Tem) were significantly increased in both 
liver (p = 0.008) and spleen (p = 0.008). With the exception of one CPS mouse, this 
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expansion of CD8+ Tem cells was not observed in any of the ID immunized mice, 
remaining at baseline levels similar to naïve mice (Figure 2A). Because IFNγ has 
been shown to play an essential role in protection against liver stages [12,15] we 
studied IFNγ responses of  T cells in liver and spleen of IV or ID immunized mice. 
Overall, RAS or CPS immunizations resulted in sporozoite specific IFNγ responses 
in the liver (p = 0.03) and spleen (p = 0.008). Although not reaching statistical 
significance, there was a tendency of higher sporozoite specific IFNγ response by T 
cells with memory phenotype (CD44hi) in liver and spleen (Figure 2B) cells from IV 
immunized compared to ID immunized C57BL/6J mice. Within the T cell population, 
similar observations were made for CD8+CD44hi T cells. Furthermore, the levels 
of CD8+ Tem cells in both IV and ID groups correlated with the IFNγ response in 
liver (R= 0.63, p = 0.003) and spleen (R= 0.54, p=0.01). Three weeks after challenge, 
the observed high levels of liver CD8+ Tem cells (Figure 2C) and increased IFNγ 
responses (Figure 2D) were sustained in IV immunized mice. No data were obtained 
from ID immunized mice as these did not survive challenge infection (Table 1). 
Both IV and ID immunization induce antibodies blocking sporozoite hepatocyte 
invasion 
Finally, functionality of RAS and CPS induced antibodies was tested in the sporozoite 
neutralization assay, testing their capacity to invade and subsequently develop in 
liver cells [24]. Sporozoite invasion was strongly reduced in the presence of plasma 
from both RAS and CPS immunized mice (p≤0.05) with,  stronger inhibition by IV 
immunized mice within the RAS group (p <0.01) (Figure 3). Since CPS ID immunized 
mice showed similar blocking activity compared to IV immunized mice, antibodies 
may contribute but are by themselves likely not sufficient to induce complete protection. 
Discussion
Our findings show that ID immunization with whole live malaria parasites confers 
a far lower protective efficacy when compared to IV immunization. The reduced 
protective efficacy clearly associates with a lower number of sporozoites reaching 
the liver. Lower protective efficacy by ID immunization was observed in both BALB/c 
and C57BL6/j mice using two independent immunization protocols; i.e. sporozoite 
liver cell invasion only with early developmental arrest (RAS) or full completion of 
liver maturation and early abrogation of blood stage multiplication (CPS). Moreover, 
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Figure 2.  Liver and spleen CD8+ T cells with effector memory phenotype and IFNγ responses after 
intravenous or intradermal immunizations.     
A) Percentages of cells with effector memory phenotype (Tem: CD44hiCD62L-) per total CD8+ T cells were measured ex vivo in liver and spleen of C57BL/6j mice on day 39 after RAS and CPS IV or 
ID immunization. B) Percentages of IFNγ producing T cells or CD8+ T cells with memory phenotype 
(CD44hi) were measured by intracellular staining after stimulation of liver and spleen cells from RAS and 
CPS immunized mice with cryoconserved sporozoites. Total salivary gland background responses were 
similar between groups (mean(SD): 0.42% (0.18) in the liver and 0.29% (0.16) in the spleen). Three 
weeks after challenge, IV immunized mice showed C) sustained levels of liver CD8+ Tem cells and D) 
higher anti-sporozoite IFNγ responses in the liver. In the spleen, measured responses were similar to pre-
challenge results (data not shown). A and C: Individual values and median are presented. B and D: Error 
bars represent standard error of the mean. * p ≤ 0.04, ** p ≤ 0.008, *** p ≤  0.0001.
both RAS and CPS IV immunizations induce higher cellular immune responses 
compared to ID.
Our data confirm the earlier formulated hypothesis by Epstein et al.: based on low 
hepatic immune responses in ID immunized animals and low protection level in 
a clinical trial, the authors suggest that the degree of parasite liver load following 
sporozoite administration associates with protective efficacy [18]. However, ID 
immunization can induce high levels of protection provided that sufficiently high 
numbers of sporozoites (i.e. 9x104 P. yoelii) are injected [17]. The necessity of high 
numbers of sporozoites for ID induced protection supports the notion that liver 
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   Sporozoite neutralization
Figure 3. Transgenic PbGFP-Luccon sporozoite neutralization assay   
Sporozoite invasion inhibition (mean ± sd) in Huh-7 liver cells of PbGFP- Luccon sporozoites pre-incubated 
with plasma from CPS or RAS immunized C57BL/6 mice by either IV or ID route. The baseline represents 
the mean invasion inhibition by plasma from naive mice. P-values represent significance in invasion 
inhibition between plasma from immunized mice and baseline values or between groups of immunized 
mice. Infectivity was quantified by analyzing the luminescent flux (p/sec/cm2) in each well. * p ≤ 0.05, ** 
p ≤ 0.01.
parasite load might be important for protective efficacy of whole sporozoite 
immunization. ID injection of P. yoelii sporozoites results in a 10-20 fold lower 
parasite liver load compared to IV injection as determined by q-RTPCR analysis 
of parasite 18S rRNA [25], possibly related to a slower or inefficient migration of 
sporozoites to the liver. IV inoculated parasites reach the liver within minutes [26], whereas sporozoites inoculated into the skin slowly trickle out of the inoculation 
site over a period of one to three hours [27].  Our results indicate that the lower 
parasite liver load after ID inoculation is unlikely to be explained by a delayed arrival 
of sporozoites in the liver. Comparison of the parasite liver load at 35 hours post ID 
injection was still ±15 times lower compared to the parasite liver load at 30 hours 
post IV injection (Figure 2). Despite differences between parasites species, including 
among others infectivity [28] or host cell preference [29,30,31], our data in P. berghei 
parallel previous results in P. yoelii studies [25]. Therefore, the relatively low level of 
parasites capable of reaching the liver after ID injection is likely a common feature among Plasmodium species.
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CD8+ T cell responses are known to be essential for protection induced by attenuated 
live sporozoite immunization in rodent models. Our data corroborate previous studies on P. berghei RAS-induced immunity showing expansion of CD8+ memory 
T cells, mainly in the liver, together with high IFNγ production in IV immunized mice [12,13,14,15]8-11. The low immune responses observed after ID immunization 
likely follow the low parasite liver load. RAS ID and subcutaneous immunization of 
human volunteers also show low protection levels, and in non-human primates and 
mice subcutaneous or ID immunization lead to lower IFNγ responses compared to 
IV sporozoite immunization [18]. Despite differences in phenotyping and gating 
strategy, CD8+ effector (memory) T cells (CD44hi CD62L-) and not central memory 
T cells (CD44hi CD62L+) are identified as induced T-cell subset. In another study using the P. yoelii model, major CD8+ T cell responses were  generated in the draining 
lymph nodes after infected mosquito bites or  ID inoculation of sporozoites. Although 
parasite liver load was reduced, complete protection defined as impediment of 
blood stage infection was not evaluated [32]. We did not test the regional lymph nodes response and cannot exclude a possible contribution  but our data clearly 
demonstrate that ID inoculation is inefficient in inducing protection. In addition, 
a measure of sporozoite load in regional lymph nodes following ID inoculation 
would have been informative. Unfortunately, in vivo visualization of PbGFP-Luccon 
is not possible due to a relatively low luciferase expression at the sporozoite stage 
[22]. Next to cellular components, antibody responses can contribute to protection 
by whole sporozoite immunization [8]. Our data suggest that induced functional antibodies may contribute to protection but are more likely related to exposure. 
CPS-induced antibodies do not show significant functional differences in in vitro 
sporozoite invasion inhibition between plasma of mice immunized by IV or ID 
inoculations. On the contrary, RAS induced antibodies after IV injection compared 
to ID immunization are more potent and also more predominant as determined by 
IFA titration (data not shown). However, others have previously shown that RAS and 
GAP protection does not rely on induced sporozoite-specific antibodies. In B-cell 
deficient RAS or GAP immunized mice, protection upon challenge was unaffected 
[33,34]. Moreover, GAP immunized IFNγ -/- mice produced sporozoite-specific 
antibodies but were not protected against a WT challenge [34]. Overall, our findings 
corroborate the conclusions of a meta-analysis by Guilbride et al., emphasizing the 
poor capacity to induce protective efficacy after sporozoite inoculation via the skin 
as compared to the IV route [35].
Although in human volunteers whole parasite immunization by bite of infected 
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mosquitoes can induce complete protection [6,36,37,38], mosquito bites are 
obviously not a practical route of immunization. Further studies with luciferase expressing P. berghei parasites are in progress, evaluating various administration 
routes, injection volumes and doses as well as numbers of injections. By a stepwise 
selection process we aim to find the best regimen to achieve maximal parasite liver loads and subsequently protection. Such regimen may form a critical element in the future for a successful immunization strategy in humans with attenuated whole-sporozoites. 
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Abstract
One of the bottlenecks in the development of a whole sporozoite malaria vaccine is 
the route and method of sporozoite administration. Immunization and challenge of 
human volunteers by mosquito bites is effective, but cannot be used as a vaccine. 
Intravenous immunization with sporozoites is effective in rodents and non-human 
primates, and being studied in humans, but is not yet used for licensed vaccines 
for infectious diseases. Intradermal and subcutaneous immunization regimens 
show a strong decrease in protective efficacy, which in rodents, is associated with a 
decreased degree of parasite liver infection during immunization. The objective of 
this study was to explore alternative routes of sporozoite administration to increase 
efficiency of liver infection. Using in vivo imaging, we found that IM injection of 
sporozoites resulted in a greater parasite liver load compared to ID and SC injection. 
The use of small inoculation volumes and multiple injections further increased the 
subsequent liver load. These observations were corroborated in a P. yoelii model 
using cryopreserved sporozoites administered ID. Our findings provide a rationale for the design of clinical trials to optimize needle and syringe administration of P. 
falciparum sporozoites.
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Introduction
A considerable effort is now being made to develop a malaria vaccine based on live 
Plasmodium falciparum sporozoites [1,2]. This initiative is based on the fact that 
immunization of volunteers by bites of mosquitoes infected with irradiated or live 
P. falciparum sporozoites induces sterile and sustained protection [3,4,5,6,7]. One of the challenges to translate this successful protection into a practically applicable 
technology is replacement of mosquitoes by needle and syringe. Overcoming this challenge will require optimization of the route and method of sporozoite administration to ensure successful infection and protection [2].
In the first clinical trial with radiation attenuated purified, cryopreserved P. 
falciparum sporozoites, the PfSPZ Vaccine was administered intradermally (ID) or 
subcutenuously (SC) and immunogenicity and protective efficacy were sub-optimal 
[2]. Parallel and other studies in mice and non human primates (NHPs) demonstrated 
that intravenous (IV) inoculation of sporozoites was significantly more efficient in 
inducing antibody and T cell responses and/or protective immunity than ID or SC 
administration of fresh or purified, cryopreserved sporozoites [2,8]. Based on these 
results a clinical trial of the PfSPZ Vaccine administered IV is underway. 
However, it is clearly preferable if non-IV administration could be made as efficient 
as IV administration. Comparing ID and IV immunizations using bioluminescent P. 
berghei sporozoites and in vivo imaging in mice, we recently demonstrated a clear 
association between the capacity to induce protective efficacy and the degree 
of liver infection with increased protective efficacy with higher liver loads [9]. In this study, we used this in vivo imaging model as a fast-track technical platform to pursue a systematic and stepwise selection process to study the effects of route of 
administration, number of injections and location and volume of sporozoite injection 
on subsequent parasite liver infection. The results were corroborated by infection 
studies using blood stage parasitaemia as the outcome variable. 
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Material and Methods
Experiments with bioluminescent P. berghei and P. yoelii sporozoites
Mice and parasites
Female C57BL/6J and BALB/c mice, eight weeks of age, were purchased from Elevage 
Janvier (France). All studies were performed according to the regulations of the Dutch 
“Animal On Experimentation act” and the European Directive 2010/63/EU. Mice were 
housed in the presence (except experiment in Fig. 2) of a treadmill. Approval was obtained 
from the Radboud University Experimental Animal Ethical Committee (RUDEC 2010-
229). In this study we used the previously described transgenic P. berghei line 676m1cl1 line (PbGFP-Luccon) [10,11] and the transgenic P. yoelii line 1971 cl1 (PyGFP-Luccon) [12]. 
Mosquito infection and preparation of sporozoites
Sporozoites were obtained by hand-dissection of the salivary glands of infected female 
A. stephensi mosquitoes 21 days (P. berghei at 21 °C) or 17 days (P. yoelii at 24 °C) after 
infected blood meal feeding. Salivary glands were collected in DMEM supplemented with 
1% human serum albumin (Albuman) and homogenized in a homemade glass grinder. The free sporozoites were counted in a Bürker-Türk counting chamber using phase-contrast microscopy.
Injection of sporozoites
Prior to administration of sporozoites, mice were anesthetized using isoflurane and the site 
of injection was shaved (SC, ID, IM) in order to optimize the precision of administration. 
Sporozoites were administered by IV injection (200 µL in the tail vein), or by SC, ID or IM 
injection in various volumes and at distinct locations. All groups of mice (5 mice per group) were infected with a total of 5x104 P. berghei or 1-2 x104 P. yoelii sporozoites. SC, ID and IM injections were administered in a single or multiple (4 times) injections at both lateral sites 
(e.g both thighs). The volume per injection site ranged from 50 to 1 µL. Injection of high 
volumes (50 µL) was performed using a 27 gauge needle and 1 ml syringe (BD); low volumes 
(10-1 µL) were injected using a 35 beveled gauge needle and a NanoFil syringe (World 
Precision Instruments).
Real-time in vivo imaging of liver stage development  
At various time points post injection of sporozoites, luciferase activity was visualized through imaging of whole bodies using the in vivo imaging system Lumina (Caliper Life Sciences, USA) 
as described previously [11] with minor adaptations. Briefly, animals were anesthetized using 
the isoflurane-anesthesia system, their abdomens were shaved and D-luciferin dissolved in 
PBS (150 mg/kg; Caliper Life Science, Belgium) was injected SC (in the neck). Animals were kept anesthetized during the measurements, which were performed 4 minutes after the 
injection of D-luciferin. Bioluminescence imaging was acquired with a 10 cm field of view, 
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medium binning factor and an exposure time of 180 or 300 seconds (based on the number 
of mice per experiment). The color scale limits were set automatically and the quantitative analysis of bioluminescence was performed by measuring the luminescence signal intensity 
using the region of interest (ROI) settings of the Living Image 3.2 software. The ROI was set 
to measure the abdominal area at the location of the liver. ROI measurements are expressed 
in total flux of photons. Statistical analysis was performed by Kruskal-Wallis and subsequent 
individual comparisons were performed by a Dunn’s multiple comparisons test using the 
GraphPad Prism 5.0 software.
Experiments with wildtype cryopreserved P. yoelii sporozoites
          
Mice and parasites
Four to six week-old HSD:ICR (CD-1®) mice (Harlan Bioproducts, Indianapolis, IN) infected with P. yoelii (clone 1.1) [13] were used to infect five day-old heat-selected female A. stephensi 
mosquitoes. Six to eight week old BALB/c mice were used for assessment of sporozoite 
infectivity. The IACUC committee of the University of Maryland (UMD), (College Park, 
Maryland) approved experiments with mice used to generate stocks of cryopreserved P. yoelii 
sporozoites and assessment of their infectivity described in this study. UMD’s animal facility 
at Rockville was used to house the mice and all experiments were conducted at UMD.
Preparation of sporozoites
After a 15 minute feed on infected HSD:ICR mice, mosquitoes were maintained for 14–17 days 
at 24 °C to allow for sporozoite development. Infected mosquito salivary glands were hand 
dissected into M-199 medium supplemented with 1% human serum albumin (HSA).  PySPZ 
were released from salivary glands by multiple passages through a 1 mL syringe fitted with a 
26½ gauge needle and purified by a proprietary method used in purification of the PfSPZ in 
the PfSPZ Vaccine [1]. PySPZ were cryopreserved as for the PfSPZ Vaccine [2], and stored in 
liquid nitrogen vapor phase until use. All experiments were performed with cryopreserved 
PySPZ from one lot.  
Injection of sporozoites
Mice were injected ID in the upper thigh either at a single or multiple sites with cryopreserved 
PySPZ reconstituted in volumes as indicated in the description of results. Infections in mice 
were determined by examining Giemsa-stained thin blood smears (at 1000× magnification) 
for the presence of blood stage parasites on days 7 and 14 after infection.
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Results 
Comparison of parasite liver load following IV, IM, SC, and ID administration of 
P. berghei  sporozoites.
First, we studied the effect of different routes of administration on parasite liver load. Mice were injected with PbGFP-Luccon sporozoites by IV injection (200µL) in the tail, 
or by IM, ID and SC injection (50µL) in each thigh. IV injection resulted in significantly 
higher (approximately 50 fold) liver loads compared to ID and SC injection. IM 
injection gave 2-3 fold higher liver loads compared to ID or SC injection (p<0.05) 
at each time point (Fig. 1). The liver load after IM injection was approximately 5% 
(p<0.01) of the liver load post IV injection. Thus, IV injection resulted in a 20-fold 
increase in liver load as compared to IM and 40-60 fold increase in liver load as 
compared to ID or SC administration. We next explored the effect of the location of sporozoite injection on sporozoite 
invasion and development in the liver. Sporozoites were injected IM or ID at two 
and four different locations, respectively. Since SC and ID injection of sporozoites showed similar results , SC administration was not further included in subsequent 
experiments. The location of sporozoite injection was of minor influence on the 
parasite liver load (Fig. S1). ID administration always resulted in lower parasite liver 
loads as compared to IM administration.
Effect of injection volume on parasite liver load. 
To next assess the influence of injection volume, mice were inoculated IM and ID 
with sporozoites delivered in different volumes (50µL, 10µL and 1µL). A decrease of 
injection volume increased the liver load after IM and ID sporozoite injection (Fig. 2A-C). Although there was a tendency to higher infection rates, the differences in 
parasite liver loads following IM injection in various volumes did not reach statistical 
significance (p=0.10). In contrast, ID injection in a low (1µL) injection volume 
resulted in a significantly higher liver load compared to a high (50µL) injection 
volume administered in both the upper front leg (p<0.01) and the ear (p<0.05). In 
this particular experiment, IM injection did not result in higher parasite liver loads 
compared to ID injection; possibly due to the omission of a treadmill in the cage.
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Figure 1: Liver loads following IV, IM, SC and ID administration of P. berghei sporozoites. 
Liver loads in C57Bl/6 mice were determined by real-time in vivo imaging of luminescence signals in mice injected with 5x104 PbGFP-Luccon sporozoites by IV injection (200µL) in the tail or IM, SC, or ID 
injection (50µL) in the thigh (n=5 per group). Measurements were performed at 30, 35 and 44 hours 
post infection and liver loads are presented as luminescent intensities (photons/sec/cm2) of the ROI’s 
overlaying the livers from individual mice measured for 300 seconds. The dotted line represents the mean 
(threshold) luminescent signal of uninfected mice. In A the liver loads are shown and in B representative 
rainbow images of luminescence signals in C57BL/6 mice at 30 hours post infection. Mice received an IV 
(upper left corner), IM (upper right corner), SC (lower left corner) or ID (lower right corner) injection. 
Luminescence scales are set to match the scale in ID injected mice.
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Figure 2: Liver loads following IM and ID injection of different volumes of sporozoite 
suspensions.                 
Liver loads in C57Bl/6 mice were determined by real-time in vivo imaging of luminescence signals in mice injected with 5x104 PbGFP-Luccon sporozoites in different volumes (50, 5 and 1µL) by A) IM or B+C) ID 
injection (n=5 per group), at 30, 35 and 44 hours post infection. Liver loads are presented as luminescent 
intensities (photons/sec/cm2) of the ROI’s overlaying the livers from the individual mice measured for 
180 seconds. The dotted line represents the mean (threshold) luminescent signal of uninfected mice. *P 
<0.05, ** P<0.01
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Effect of number of injections on parasite liver load.  
Next, mice were IM inoculated with sporozoites delivered by a single or multiple (4 
in each upper front leg) injections of 1µL or 10µL. Multiple 1µL injections resulted in 
a higher liver load compared to multiple 10 µL injections (p<0.05) but not to a single 
1µL injection (p=0.10). For all administration regimens (1 or 10µL in multiple or 
single injections), the liver load following IM administration was significantly higher 
compared to ID administration in multiple 1µL volumes (p<0.05).  
To ensure that the observed differences in parasite liver load at 44 hours were not 
due to a delay of sporozoites reaching the liver [13] following different routes of 
administration, parasite distribution in the liver and blood was determined in mice 
60 and 75 hours post IV, IM and ID injection (Fig. S2). After IV injection parasites 
were observed in the blood at 60 and 75hpi and we did not observe an unexpected 
increase in luminescence signals in livers at these time points after IM and ID 
injection. These results indicate that the route of injection is of minor influence 
on the time it takes for sporozoites to reach the liver and therefore quantitative 
differences in parasite liver load measured at 44 hour after injection do not result 
from a delayed liver invasion.
Figure 3: Liver loads following IM and ID injection of sporozoites; single injection versus multiple 
injections.             
Liver loads in C57Bl/6 mice were determined by real-time in vivo imaging of luminescence signals in mice injected with 5x104 PbGFP-Luccon sporozoites by IV injection in the tail (200µL), IM in the upper front leg 
by single or multiple injections of 1 or 10µL and ID injection in the upper front leg by multiple injections 
of 1µL  (n=5 per group). Measurements were performed at 30, 35 and 44 hours post infection. Liver 
loads are presented as luminescent intensities (photons/sec/cm2) of the ROI’s overlaying the livers from 
mice measured for 180 seconds. The dotted line represents the mean (threshold) luminescent signal of uninfected mice. 
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Parasite liver load following P. yoelii infection.To further study the effects of different sporozoite administration regimes, P. 
yoelii sensitive BALB/c mice were inoculated by IV, IM and ID with PyGFP-Luccon 
sporozoites (Fig. 4). Similar to P. berghei, multiple injections of P. yoelii sporozoites 
in small volumes, administered IM led to a significantly increased parasite liver 
load compared to ID administration (p<0.05). Application of a topical vasodilator 
(Midalgan) did not increase the parasite liver load following ID injection. IM administration of 2x104 sporozoites approximated the parasite liver load of mice 
receiving 1x104 sporozoites IV, whereas for P. berghei, the parasite liver load after IM 
administration of sporozoites did not exceed 15-20% of IV (Fig. 3). 
Infectivity experiments with purified, cryopreserved PySPZ. 
The cryopreserved sporozoites were obtained from a wildtype P. yoelii XNL line 
which does not express a luminescent reporter protein. Therefore, infectivity of these sporozoites and effect of administration was not determined by imaging, 
but by measuring parasitaemia in mice injected with sporozoites. Infectivity was 
defined as the percentage of mice that developed a patent parasitaemia. The process 
of cryopreservation decreases the viability of sporozoites as compared to freshly 
isolated sporozoites. Although approximately 70% of the P. yoelii sporozoites shows 
membrane integrity after cryopreservation, it takes approximately 7 times as many 
cryopreserved sporozoites, compared to fresh sporozoites to induce a similar blood 
stage infection in mice after i.v. injection (Roestenberg, M, Bijker, E et al, in press).
At the outset we determined that infection of mice with cryo PySPZ followed a dose 
response with 100% of mice infected with a total of 30K cryo PySPZ injected in two 
sites on the thigh in a volume of 50µL each (Fig. 5 dark grey bars). The volume of 
50µL and number-of-sites combination was the baseline against which all other 
inoculation variables were then compared. We showed that inoculation of 5,000 or 
10,000 cryo PySPZ in two sites in 50µL each gave between 20% and 70% infection 
rates (Fig. 5, dark grey bars). In all experiments, either decreasing the volume or 
increasing the number of sites increased the infectivity, but only once did we achieve 
100% (10,000 cryo PySPZ in four 5 µL injections), and in no case were the differences 
statistically significant. 
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Figure 4: Liver loads following IV, IM and ID administration of P. yoelii sporozoites.  
Liver loads in BALB/c mice were determined by real-time in vivo imaging of luminescence signals in mice injected with 1x104 PyGFP-Luccon sporozoites by IV injection in the tail (200µL) or 2x104 PyGFP-Luccon 
sporozoites by IM or ID injection in the upper front leg (n=5 per group), at 24, 36 and 44 hours post 
infection. IM or ID inoculation was by multiple (4 in each upper front leg) 1µL injections. Liver loads 
are presented as luminescent intensities (photons/sec/cm2) of the ROI’s overlaying the livers from 
mice measured for 180 seconds. The dotted line represents the mean (threshold) luminescent signal of 
uninfected mice. In A the liver loads are shown. One group of mice (ID+VAS) received a topical vasodilator 
(Midalgan) prior to the ID injection. In B representative rainbow images of luminescence signals are 
shown in live BALB/c mice at 24 hours post infection. Mice received an IV (upper left corner), IM (upper 
right corner), ID (lower left corner) or ID+VAS (lower right corner) injection. Luminescence scales are set 
to match the scale in ID+VAS injected mice.
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Figure 5: Effect of volume of inoculum and multiplicity of injection sites on infectivity of 
cryopreserved P. yoelii sporozoites (cryo PySPZ) in BALB/c mice.
Mice were infected with cryo PySPZ suspensions, in several volume/numbers of site combinations. A 
single batch of cryo PySPZ was used for all experiments. Infectivity is defined as the percentage of mice 
that developed a patent blood parasitemia. Dark grey = 50 µL each in 2 sites, checkerboard = 40 µL each 
in 8 sites, light grey = 10 µL each in 2 sites, brick stone = 10 µL each in 8-10 sites, diagonal hatch = 5 µL in 
4 sites. Due to biological variability in infectivity readouts each single experiment is denoted as a distinct group of data, with all points within a group being directly comparable. All experiments did not include 
all tested volume/number of injection sites combinations. Group 1 and group 2 were two independent 
experiments both using 5000 cryo PySPZ per mouse, and likewise group 3 and group 4 both used 10000 
cryo PySPZ per mouse. The number of animals per treatment in each experiment are denoted below the x-axis labels.     
The effect of increasing the number of inoculation sites from 2 to 8 while keeping 
the volume constant (40µL) resulted in a marginal increase in infectivity from 70% 
to 80% with 10K cryo PySPZ (Fig. 5 checkerboard bar). Decreasing the volume 
alone (from 50µL to 10µL), while injecting in 2 sites showed no difference with 5K 
cryo PySPZ, but resulted in more mice being infected with 10K cryo PySPZ (90% 
compared to 70%, light grey bars). While decreasing volume or increasing the 
number of inoculations independently gave better outcomes, combining the two 
variables (10µL injections in 8-10 sites, brick stone bars) consistently improved 
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infectivity of mice compared to a 50µL x 2 regimen across all dose ranges. Using 5µL 
injections in 4 sites gave the best outcome with 10K cryo PySPZ (100% infection, 
diagonal hatch bars), but was not as good as the 10µL x 8 regimen with 5K PySPZ. In 
summary, the highest infectivity was obtained with cryo PySPZ inoculated in 5-10 µL 
volumes over 4 – 10 sites. To be able to show significant differences we may have to 
decrease the number of cryo PySPZ further. 
Discussion
In P. berghei and P. yoelii models our data demonstrate that multiple variables 
significantly influence parasite liver loads after administration of sporozoites by 
needle and syringe. Firstly, IM administration of sporozoites resulted in higher 
parasite liver loads compared to either ID or SC administration. Secondly, the use 
of smaller inoculation volumes of sporozoite suspensions increased efficiency of 
infection that was further improved when the sporozoite suspensions were applied 
as multiple injections over multiple sites. 
As previously reported, IM immunization with attenuated P. berghei sporozoites 
induces stronger protective immune responses compared to SC [8,14], IP [15] 
and ID immunizations [8,15]. Protection was, however, always less than 50% and 
inferior to IV immunizations. These combined results corroborate our previous 
notion that higher parasite liver loads while dependent on the route of sporozoite 
immunization are associated with superior protection [9]; after IV administration, 
the IM route results both in the highest parasite liver loads and strongest protective 
immune responses. The relative contribution of sporozoites that have not invaded 
the liver, but are cleared in the skin, lymph nodes or spleen, to total protective 
immunity remains to be determined. Following ID injection many sporozoites likely remain in the dermis and in P. yoelii these sporozoites can prime the first cohort 
of CD8+ T cell responses in the draining lymph nodes [16]. The role in immune 
priming/suppression mediated by sporozoites in the skin, remains to be elucidated 
and will have considerable impact on studies on anti-Plasmodium vaccines based on 
attenuated sporozoite. However, it is quite clear that it requires far fewer sporozoites 
to achieve high level protective immunity when the sporozoites are injected IV as 
compared to ID or SC [2]. Thus, regardless of what immunity may be induced in the skin and draining lymph nodes it is not as potent as that induced in the central 
compartment, which include liver, spleen and draining lymph nodes.
Density of the vascular bed in the skin or muscle may well influence the exit of 
sporozoites [17] and may explain the higher liver loads observed after IM compared 
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to ID injection. Interestingly, the effect of vasodilatation and increased blood flow was illustrated in one experiment in which the treadmill was omitted from the mice 
cage; in that latter case parasite liver load following IM injection was not superior 
to ID injection. This suggests that muscle exercise and subsequent increased blood 
flow may have a positive effect on sporozoite egress from the IM injected site. 
Nevertheless, application of a topical vasodilator (Midalgan) did not increase the 
parasite liver load subsequent to ID sporozoite injection.
The relationship among IV, IM, and ID infections was similar for P. yoelii and P. berghei. 
Nonetheless, IM and ID injection of P. yoelii parasites more closely approximated 
the liver load following IV injection compared to P. berghei, indicating that P. yoelii 
sporozoites are more efficient in establishing liver infections. The infectivity of P. 
yoelii sporozoites might more closely resemble that of P. falciparum than P. berghei 
[18]. While one cannot directly compare the infectivity of P. yoelii and P. falciparum, 
our preliminary data from human studies (Roestenberg, M, Bijker, E et al, in press) indicate that when administered by the intradermal route, P. yoelii and P. falciparum 
have similar infectivity. Therefore, our findings suggest that P. yoelii may be good indicators for clinical P. falciparum sporozoite administration studies. 
Future (pre-) clinical studies with needles, and indeed with newly developed devices, 
delivering sporozoites at the various sites at the best formulation (e.g. multiple 
injections, low injection volume) will be important to further optimize the infection 
rates that then engender the greatest protective immunity.
Different injection volumes and number of sites did not show such distinct outcomes 
on asexual erythrocytic stage infections as on liver loads. This is likely due to the 
reduced sensitivity to detect differences in blood stage infections between study 
groups, since one sporozoite can lead to an asexual stage infection. However, in 
general these experiments also suggest that decreasing volume and increasing the number of sites will increase infection rates.
P. falciparum sporozoites are the only immunogens that have ever been shown 
to induce sustained (at least 28 months), high level (>90%) protection against 
controlled human malaria infection in humans [6,7]. Thus, there is now a major 
effort to develop whole P. falciparum sporozoite vaccines. The first challenge 
addressed was how to manufacture the aseptic, purified, cryopreserved, potent P. 
falciparum sporozoites (PfSPZ) required for such vaccines [19]. This challenge has 
been overcome [1,2]. The second major challenge is to determine how to optimally 
administer such sporozoites [19].  There is no question that IV administration of 
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P. falciparum sporozoites is the best route and thus far non-IV administration has 
been far less efficient and effective [2]. Recently, the first clinical trial demonstrated 
that human volunteers can be successfully infected with graded numbers of aseptic, 
purified, cryopreserved PfSPZ, a product called PfSPZ Challenge, by ID administration 
(Roestenberg, M, Bijker, E et al, in press).  However, the administration strategy 
needs to be further optimized. Our rodent malaria model system developed to quantify in vivo the magnitude of the effects of varying administration variables on 
in vivo liver stage infection, will be used to guide the clinical development plan of 
PfSPZ Challenge. Clinical trials are now planned to assess the effect of route, volume, and number of sites on infection rates in humans, and thereby accelerate whole 
sporozoite vaccine development against malaria.
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Supplementary Information
Supplementary Figure 1: Influence of location of sporozoite injection on liver infection. 
Liver loads in C57Bl/6 mice were determined by real-time in vivo imaging of luminescence signals in mice injected with 5*104 PbGFP-Luccon by IM or ID injection at different locations (n=5 per group). 
Measurements were performed at 30, 35 and 44 hours post infection. Liver loads are presented as 
luminescent intensities (photons/sec/cm2) of the ROI’s overlaying the livers from mice measured for 300 seconds. The dotted line represents the mean (threshold) luminescent signal of uninfected mice. 
Supplementary Figure 2: Parasite development overview (IV, IM and ID).   
Rainbow images of luminescence signals in C57BL/6 mice at various time points post administration of 
sporozoites by IV, IM (multiple injections, 1µL volume) and ID (multiple injections, 1µL volume) routes. 
Luminescence scales in figures representing IV and IM injected mice are set to match the scale in ID injected mice for each time point.
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Chapter 9
A vaccine against malaria and specifically against P. falciparum infection is pressingly 
needed. In human volunteers, life sporozoites are the only immunogens that, by 
immunization with mosquito bites, have ever been shown to induce sustained and 
high levels of protection against a malaria infection. The GAP vaccine approach is 
considered the safest and best option for a life sporozoite vaccine. At the outset of this 
thesis we aimed at developing tools for the quantification of liver stage murine malaria 
parasites that could be used to address two essential criteria for the development of a 
GAP vaccine; GAP safety and efficacious delivery of sporozoites. We have created and 
characterized luminescent P. berghei parasites to test the safety of various GAPs, which 
eventuated in the development and characterization of a fully safe murine GAP with 
multiple gene deletions, full protective efficacy and an ortholgue in P. falciparum. The 
safety of the P. falciparum GAP is currently assessed. Efficacious vaccination of human 
volunteers with future GAP will be dependent on the protective effect of the sporozoite 
inoculum. With the aid of luminescent murine malaria sporozoites we studied the 
effect of varying administration variables on in vivo liver stage infection. The results 
are now used to guide the clinical development plan of whole sporozoite vaccination.
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Assessment of parasite liver load by luciferase expressing parasites. 
A quantitative analysis of the liver stage of Plasmodium parasites has long been subject 
to time-consuming and costly techniques with low sensitivity. Malaria parasites 
expressing bioluminescent reporters have greatly simplified the quantification of 
the parasite liver stage. In this thesis we have made extensive use of a transgenic 
P. berghei parasite, PbGFP-Luccon expressing the bioluminescent reporter protein 
luciferase, allowing for a direct quantification and visualization of the parasites in both 
in vitro hepatocyte cultures and whole bodies of live mice (Chapter 2).The impact 
of this transgenic parasite and the novel possibilities it offers malaria research are broad. PbGFP-Luccon parasites can be used to evaluate the immunity against malaria in both in vitro and in vivo models (Chapter 3). Incorporated in the genome of a GAP 
the bioluminescent reporter can be used to provide in vivo real-time information 
on the (lack of) parasite liver stage development (Chapter 4, 6 and 7). Moreover, 
these transgenic parasites were used to study the liver load following sporozoite 
administration by different routes and injection variables (Chapter 8 and 9). Others 
have used PbGFP-Luccon parasites to characterize important features of the parasite 
such as the development of P. berghei in the skin at ultra low frequencies [1] and the 
preclusion of a liver stage superinfection in the presence of an asexual parasitemia [2].     The PbGFP-Luccon parasites can be used to assess the effects of anti-malarial drugs on 
the parasite liver stage. With an increasing resistance of Plasmodium for the currently 
available anti-malarials directed [3] there is a pressing need for replacement drugs 
[4]. New drugs against the liver stage have a tactical advantage over blood stage 
drugs as the relatively low number of parasites in the liver stage might delay the 
development of resistance [5]. Moreover, new drugs directed against the liver stage might also kill the hypnozoites of P. vivax, responsible for recurrent blood stage infections. At present, the only drug that is known to act on these hypnozoites is primaquine, which unfortunately causes hemolytic anemia in patients with glucose-
6-phospate dehydrogenase deficiency [6] attesting yet again the need for new liver stage drugs. Already, the PbGFP-Luccon parasite has been used in high throughput 
drug screens [7] and was instrumental in the characterization of potential new 
anti-malarial drugs like Primaquine-Artemisinin hybrids [8], Halofuginone [9] and Decoquinate [10].
Notwithstanding these applications, the in vivo visualization of parasites in the liver can be further optimized. Both the transgenic P. berghei and P. yoelii parasites used in this thesis (PbGFP-Luccon and PyGFP-Luccon respectively) express the bioluminescent 
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reporter under control of the eef1α promoter [11,12], which allows for the in vivo 
visualization of mature liver schizonts. Transgenic parasites which express luciferase under the control of other promoters might facilitate in vivo parasite visualization 
throughout the whole liver stage. Analysis of a transgenic P. berghei parasite that expresses luciferase under the control of the promoter of the circumsporozoite protein, enabled the in vivo detection of sporozoites in the skin at the site of mosquito 
bite measured directly after mosquito feeding. Nonetheless, we were unable to 
detect sporozoites in the liver by in vivo imaging [11]. Next generation transgenic parasites that express (a stronger) luciferase under the control of for instance the 
HSP70 promoter, might allow for a more continuous visualization throughout the 
liver stage.While the application of luciferase expressing rodent malaria parasites has been broadly assessed, a transgenic luminescent P. falciparum parasite (Pf-luc) has not yet been described. Pf-luc can possibly enable the visualization of the liver stage in humanized mice engrafted with human hepatocytes [13]. This could open up new 
opportunities to study the effect of anti-malarial drugs. Moreover, Pf-luc could be 
used in the evaluation of immunity against a P. falciparum infection. Most of the 
broadly used immunological techniques in clinical malaria research are descriptive 
and do not provide functional information. Routinely used sporozoite ELISA’s 
and IFATs cannot make a distinction between antibody binding and functional neutralizing responses. Similarly, assessment of cellular responses in immunized 
human volunteers is most often descriptive and a functional characterization of 
for instance the cytotoxic effect of CD8 T cells on infected hepatocytes is lacking. A transgenic sporozoite neutralization assay (Chapter 3) could be easily adapted to meet the perquisites for Pf-luc parasites. Hepatocytes derived from the Rhesus 
macaque can be infected with [14] and allow full development (unpublished data) of P. falciparum parasites. Following pre-incubation with plasma from immunized 
human volunteers developing Pf-luc sporozoites can be easily quantified in 
(frozen) rhesus hepatocytes. In the future, adoptive transfer of immune cells from 
immunized volunteers into an immunodeficient humanized mice, infected with Pf-
luc, would possibly allow for a direct quantification of the cytotoxic effect of these 
immune cells on the infected hepatocytes. Near-infrared fluorescent imaging of the 
adoptively transferred immune cells can possibly allow for a live visualization of infected human hepatocyte killing.
The hunt for a Genetically Attenuated Parasite malaria vaccine. 
In this dissertation the P. berghei GAP ∆p52+p36, ∆b9, Δfabb/f and Δ(b9)slarp are 
187
General Discussion
thoroughly tested for their safety and conferred protective efficacy following immunization. Based on a complete arrest of P. yoelii and P. falciparum  ∆p52+p36 
GAP in the liver [15,16], it was considered the leading GAP vaccine candidate. In 
chapter 4 we show that in the P. berghei model ∆p52+p36 are able to generate a 
blood stage infection. Moreover, we provide evidence that low numbers of Δp52&p36 
P. falciparum sporozoites, develop into replicating liver stages. ∆b9 parasites arrest 
in the liver stage at a nearly similar time point and, alike Δp52&p36 these parasites 
are capable of developing into replicating P. berghei liver schizonts in very low numbers (Chapter 6). As described for P. berghei Δp52&p36 GAP (Chapter 5), P. 
berghei ∆b9 liver schizonts develop in the absence of an apparent PVM (Chapter 6). The exact mechanism by which P. berghei Δp52&p36 and Δb9 enter the hepatocyte 
and start replicating in the absence of an apparent PVM remains elusive. Supposedly, 
these parasites develop by means of an undisclosed non-conventional pathway which is present in wildtype parasite. Just like intranuclear replicating P. yoelii and P. falciparum parasites which are deprived of a PVM [17], cytosolic replicating 
P. berghei Δp52&p36 might arise from sporozoites that start developing following 
an arrest after hepatocyte transmigration. Nevertheless, the difference between a 
sporozoite that invades the hepatocyte in the absence of a PVM and one that arrests in the hepatocyte upon transmigration might be a matter of semantics. Despite a reported discrepancy in P. berghei and P. yoelii GAP breakthrough [15,18], 
it was observed that high inoculations of P. yoelii ∆p52+p36 sporozoites can result 
in a breakthrough infection in BALB/c mice, depending on the subtype of BALB/c 
mice [19]. In P. berghei, C57BL/6 mice were more susceptible for a ∆p52 blood 
stage infection compared to BALB/c mice [20]. These results, yet again, attest the 
importance of GAP safety assessment in multiple malaria models (i.e P. berghei and P. 
yoelii) and multiple mice strains before advancing into further clinical development 
of a GAP vaccine candidate. Corresponding the observed replicating Δp52&p36 P. 
falciparum parasite in a primary human hepatocyte culture, in a recent clinical trial 
others observed a blood infection in one volunteer, immunized with Δp52+p36 P. 
falciparum [19].
The late liver stage arresting GAP Δfabb/f completely aborts development in the P. 
yoelii model while a considerable number of mutant P. berghei parasites develops into a blood stage parasitemia (Chapter 4). The (partial) arrest of the Δfabb/f GAP results from an impaired de novo fatty acid synthesis, which is of particular importance in 
late liver stage development (i.e membrane formation of merosomes) [21].  Possibly, 
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the discrepancy in GAP phenotype results from a difference in the length and speed 
of parasite liver stage maturation between the two models. The capacity to infect hepatocytes is similar for both P. berghei and P. yoelii, but the efficiency to amplify 
in hepatocytes is markedly different. In BALB/c mice, the P. berghei parasite liver load increases approximately 35 fold whereas the P. yoelii liver load increases over 
400 fold, from 20 to 40 hours post sporozoite injection [22]. Likely, Δfabb/f P. yoelii 
parasites replicate relatively fast and fully arrest due to a complete dependence on the de novo fatty acid synthesis whereas P. berghei parasites develop somewhat slower and are less dependent on this pathway.
Our hunt for a genetically attenuated malaria vaccine has lead to the development and  characterization of the Δb9Δslarp GAP. In P. berghei these mutants fully arrest in 
the liver stage and none develops into a mature liver schizont (Chapter 6). Moreover, immunization of mice with P. berghei Δb9Δslarp leads to a longlived protection in 
mice. There is no clear advantage of using a b9 gene deletion instead of a p52+p36 
gene deletion in the multiple attenuated GAP, other than that deletion of b9 might result in a slightly better protection in mice (Chapter 4 and 6). The generation of a quadruple attenuated Δp52+p36Δb9Δslarp GAP is not sensible since both 
Δp52+p36 and Δb9 parasites incidentally develop in the hepatocyte, likely by the 
same mechanism and there is no additive safety of a quadruple GAP over Δb9Δslarp.The multiple attenuated Δb9Δslarp GAP arrests in early liver stage and it has been 
argued that late liver stage arresting GAP induce superior anti-malarial immunity 
[23]. This superior immunity supposedly result from a more diverse set of antigens 
that are recognized by CD8 T cells, and potentially additional arms of the immune 
system reacting with multi-stage expressed antigens [23]. However, immunization 
of both BALB/c and C57BL/6 mice with P. berghei sporozoites under azithromycin or chloroquine profylaxis, which allows for full development of parasites in the liver, does not result in a superior immune response compared to immunization with RAS sporozoites  [24,25], or Δb9 sporozoites (unpublished data, Ploemen I). If results 
in rodents, comparing the efficacy of GAP, RAS and CPS immunization (Chapter 6 
and 7), are in any way predictive for the outcome of future clinical trials we can rest 
assure; the protective efficacy conferred by CPS immunization in human volunteers 
is unprecedented by any malaria vaccination approach. Regardless, as long as a fully 
arresting late liver stage P. falciparum GAP is absent these considerations are of little use.
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Clinical administration of a whole sporozoite vaccine
Immunization with irradiated sporozoites has since long been the point of reference 
for the development of an efficacious malaria vaccine. In spite of a track record of 
proven efficacy in rodents [26], monkeys [27]and man [28,29,30] the pursuit of a 
whole sporozoite malaria vaccine was largely abandoned, mainly because it was 
thought impractical to vaccinate people with live sporozoites. Recent progress in 
i) the cryopreservation of sporozoites by Sanaria Inc. [31], and ii) the development 
of tailor-made genetically attenuated parasites that fail to complete the liver stage 
[20,32] have renewed the interest in a whole sporozoite vaccine. The successful 
immunization of human volunteers by the bites of a mere three rounds of 15 
P. falciparum-infected mosquitoes under chloroquine prophylaxis gave further momentum [33]. 
Once the phenotype of the P. berghei Δb9Δslarp GAP has been confirmed in the orthologue P. falciparum mutant, this GAP is ready to go into clinical testing. Ultimately, 
these sporozoites could be successfully cryopreserved [31] for later administration 
into humans, albeit that the efficiency of  cryopreservation might be a bit low. The major challenge will be to determine how to optimally administer these sporozoites 
in human volunteers. Administration of P. falciparum sporozoites by mosquito 
bites and IV injection are likely effective, but these techniques are not suitable for 
vaccination campaigns in Sub-Saharan Africa. In a recent clinical study, SC or ID immunization with irradiated P. falciparum sporozoites showed suboptimal immune 
responses and protective efficacy [14]. In Chapter 7 we show that the protective 
immunity following IV and ID P. berghei RAS and CPS immunization associates with an 
increase in parasite liver loads following sporozoite administration. These findings 
encouraged us to determine which variables, associated with sporozoite inoculation, 
could influence the parasite liver load (Chapter 8). As assessed in our PbGFP-Luccon and PyGFP-Luccon in vivo imaging models, multiple variables significantly influence 
the parasite liver loads after administration of sporozoites by needle and syringe. 
Multiple intramuscular injections of sporozoites in small volumes resulted in the 
highest parasite liver load, thereby most likely comprising the most optimal non-IV 
sporozoite administration. Our studies in rodent models provide rational guidance 
for the development of clinical trials, which are now planned to assess the effect of 
route, volume, and number of sites on infection rates in humans. These studies will 
accelerate the development of a whole sporozoite vaccine against malaria.
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Future outlook and directions      
Less than a decade ago, the first GAP vaccine candidates were characterized in 
rodent models [20,32]. Now, we have generated and characterized in a P. berghei 
model a fully arresting and protective GAP with multiple gene deletions. The phenotype of the orthologue mutant in P. falciparum is presently studied in primary human hepatocytes ( Unpublished data Ben van Schaijk). Results from the P. yoelii 
model indicate that the development of the mutant is fully aborted in the liver 
[34]. Potential future immunization trials in human volunteers with P. falciparum 
Δb9Δslarp GAP will be key in determining the potential of this vaccine approach. 
Considering the efficiency of CPS and RAS immunization in human volunteers the 
prospects for a GAP immunization good. While travelers and military personal can 
possibly be immunized by IV inoculation with sporozoites in a clinical setting, large 
GAP vaccination campaigns in Africa will require non-IV delivery. There is a need 
for a device that is capable of delivering the sporozoites at the right perquisites. 
Injection systems such as needle free jet-injectors and hollow microneedle arrays 
might be up for the task; alternatively a device might need to be newly designed. The success of the sporozoite inoculation will largely determine the speed by which the 
GAP vaccine approach further evolves. Other advancements in the GAP approach can 
possibly be made by optimization of the sporozoite cryopreservation process.
It will require a major effort to implement a whole sporozoite vaccine strategy in 
the field. However, there is no time to falter since, as explained by the philosopher 
Thomas Pogge [35], the development of an effective malaria vaccine is not a matter 
of scientific bonhomie, rather is it a moral obligation. 
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Summary 
Malaria remains one of the most devastating infectious diseases responsible for 
approximately 225 million clinical cases and 750.000 deaths annually. A vaccine 
against malaria and specifically against P. falciparum infection, is pressingly needed. An infection with the malaria parasite originates from the bite of an infected 
mosquito, which deposits malaria sporozoites in the skin. In a controlled clinical 
setting, immunization with live sporozoites proved to induce sustained and high 
levels of protection against a homologous P. falciparum infection in human volunteers. 
This vaccine approach requires a full cessation of parasite development in the host, 
before the onset of a pathogenic blood stage parasitemia. By genetic modification, 
sporozoites can be tailor made to arrest in the liver stage. Immunization of mice 
with these so called genetically attenuated parasites (GAP) can lead to protection. 
Work described in this thesis aimed to develop and characterize a GAP that i) fully arrests in the liver stage with ii) full protective efficacy in a murine P. berghei malaria model and iii) a clear orthologue in P. falciparum
Once a GAP candidate has been developed that meets these perquisites it is essential 
to characterize the best route for human GAP vaccination. This thesis additionally aimed to 
iv) determine which factors are predictive for the protective efficacy conferred by different routes of sporozoite immunization 
v) determine by which parameters sporozoites can best be administered 
in order to optimize the efficiency of human immunization.
Prior to addressing these aims, it was essential to develop and validate new tools 
for the quantification of liver stage parasites. In Chapter 2 we describe a transgenic 
P. berghei parasite, PbGFP-Luccon expressing the bioluminescent reporter protein 
luciferase, allowing for a direct quantification and visualization of the parasites in both in vitro hepatocyte cultures and whole bodies of live mice. These transgenic parasites are powerful research tools for the studies performed in subsequent 
chapters. In Chapter 3 we describe the use of PbGFP-Luccon in the evaluation of 
immunity against malaria, both in live mice and cultured hepatocytes. In live mice, 
PbGFP-Luccon can provide quantitative information about the relation between 
the parasite liver load and protection against malaria in real-time. Moreover in 
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a cultured hepatocyte model, fast and reproducible results were obtained by introducing a transgenic sporozoites neutralization assay, measuring functional antibody-mediated immune responses.
One of the most important requisites of a GAP vaccine candidate is that it is safe; 
i.e does not lead to a pathogenic blood stage malaria infection. In Chapter 4 we 
describe the lack of complete attenuation of two leading GAP, ∆p52+p36 and 
∆fabb/f parasites. At low frequencies, these mutant parasites fully developed inside hepatocytes leading to a blood stage infection in the murine P. berghei model. 
Moreover, replicating ∆p52+p36 P. falciparum parasites were observed in a primary 
hepatocyte culture. These GAPs are therefore not safe and we proposed a minimal 
set of screening criteria to assess adequacy of GAP sporozoite attenuation necessary 
before advancing into further clinical development and studies in humans. In 
Chapter 5 we studied the phenotype of developing intrahepatic ∆p52+p36 P. berghei 
parasites and describe a non-conventional pathway, by which these parasites are likely capable of maturing into blood stage parasites. These P. berghei GAP apparently 
lack the need for a parasitophorous vacuole membrane (PVM) for full liver stage 
development. The PVM has been considered essential for parasite development 
and normally shields the parasite from the interior of the hepatocyte. Our findings 
might have implications for the development of a GAP vaccine insofar that GAPs 
with a gene deletion involved in the formation or maintenance of the PVM are likely unsafe. Chapter 6 describes the development and characterization of the ∆b9 GAP. 
This GAP conferred sterile protection in mice and abrogated development soon 
after hepatocyte invasion, associated with a compromised PVM. Again however, low numbers of P. berghei ∆b9 matured in the absence of an apparent PVM. We 
therefore developed and characterized the multiple gene deleted ∆b9∆slarp GAP. 
Immunization of both BALB/c and C57BL/6 mice with P. berghei  ∆b9∆slarp resulted in sterile and sustained protection. Also, the  ∆b9∆slarp GAP fully abrogated liver 
stage development in various mice strains and none of the parasites developed into the pathogenic blood stage. The orthologue mutant in P. falciparum has been 
generated and its development inside the hepatocyte will need to be assessed. If the P. falciparum ∆b9∆slarp GAP indeed arrests in the hepatocyte alike the P. berghei 
GAP, it will likely constitute the leading GAP vaccine candidate.  
In Chapter 7 we describe the relation between the parasite liver load following 
sporozoite immunization and the level of protection conferred in mice. Intravenous 
sporozoite immunizations of both BALB/c and C57BL/6 mice resulted in a superior protection compared to intradermal immunization. The decrease in protection 
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was associated with a decreased parasite liver load following sporozoite injection. 
However, IV injection is not the preferred immunization route for large scale 
application in Sub-Saharan Africa.  In Chapter 8, we therefore determined which 
variables, associated with sporozoite injection, influence the parasite liver load. As assessed in our PbGFP-Luccon and PyGFP-Luccon in vivo imaging models, multiple 
variables significantly influenced the parasite liver loads after administration of sporozoites by needle and syringe. Multiple intramuscular injections of sporozoites 
in small volumes resulted in the highest parasite liver load, thereby most likely 
comprising the most optimal non-IV sporozoite administration. These data provide 
rational guidance for the development of clinical trials, in search of the most optimal 
method for sporozoite immunization and hopefully the development of a whole 
sporozoite vaccine against malaria. 
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Samenvatting
Malaria is tot op heden een van de meest verwoestende infectieziektes ter wereld. 
Jaarlijks worden om en nabij de 225 miljoen mensen klinisch ziek, waarbij ongeveer 
750.000 mensen sterven aan de gevolgen van de ziekte. Een vaccin tegen malaria, 
en dan vooral tegen P. falciparum infecties, is daarom ook hard nodig. Een infectie 
met de malariaparasiet begint met de beet van een geïnfecteerde mug die malaria 
sporozoieten in de huid brengt. In een gecontroleerde klinische setting is het mo-
gelijk om vrijwilligers met intacte levende sporozoieten te immuniseren. Dit zorgt 
voor langdurige bescherming tegen een homologe P. falciparum infectie in een hoog 
percentage van de vrijwilligers. Deze vaccinstrategie vereist een volledig tot stil-
stand komen van de ontwikkeling van de parasiet in de gastheer, voorafgaand aan 
het pathogene bloedstadium. Middels genetische modificatie kunnen sporozoieten 
worden gecreëerd die specifiek in de lever tot stilstand komen. Immunisatie met 
genetisch geattenueerde parasieten (GAP) kan leiden tot bescherming tegen malaria in muizen.
Het werk beschreven in deze thesis had tot doel een GAP te ontwikkelen en te kara-kteriseren welke
i)  volledig tot stilstand komt in de lever 
ii)  volledige bescherming biedt in een muizen malariamodel (P. berghei) 
iii)  een duidelijke ortholoog heeft in P. falciparum.
Wanneer er een GAP kandidaat is ontwikkeld, die aan deze eisen voldoet, is het es-
sentieel om de meest optimale route voor humane GAP immunisatie te karakter-iseren.
Deze thesis doelde daarbij tevens op
iv) het bepalen van de factoren die voorspellend zijn voor de protectieve 
effectiviteit geïnduceerd door de verschillende routes van sporozoiet immunisatie en
v) het bepalen van de manier waarop sporozoieten het best toegediend 
kunnen worden teneinde de efficiëntie van de uiteindelijke immunisa-
tie van mensen te optimaliseren. 
Voordat wij ons op deze doelstellingen konden richten was het essentieel om nieu-
we technieken te ontwikkelen en te valideren voor de kwantificatie van parasieten 
in het leverstadium. In Hoofdstuk 2 beschrijven we een transgene P. berghei para-
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siet, PbGFP-Luccon welke het bioluminescente reporter eiwit luciferase tot expressie brengt. PbGFP-Luccon maakt een directe kwantificatie en visualisatie van parasieten mogelijk in zowel een in vitro levercelkweek als in levende muizen. Deze transgene 
parasieten zijn essentieel voor de studies in de volgende hoofdstukken. In Hoofd-
stuk 3 beschrijven we het gebruik van PbGFP-Luccon in de evaluatie van immuniteit 
tegen malaria, zowel in levende muizen als in een in vitro levercelmodel. In levende muizen, kan PbGFP-Luccon live kwantitatieve informatie verschaffen over de relatie 
tussen de hoeveelheid parasieten in de lever (parasieten lever load) en de bescherm-
ing tegen malaria. Deze parasieten kunnen tevens in een in vitro levercelmodel wor-
den gebruikt, waarbij er snel reproduceerbare resultaten worden verkregen door 
de introductie van de zogenaamde transgene sporozoiet neutralisatie test, welke de functionele antilichaam-gemedieerde immuunrespons meet.
Een van de belangrijkste vereisten van een GAP vaccinkandidaat is veiligheid; d.w.z. 
dat de parasieten zich niet kunnen ontwikkelen tot het pathogene bloedstadium. In 
Hoofdstuk 4 beschrijven we het gebrek aan veiligheid van twee GAPs, ∆p52+p36 
en ∆fabb/f parasieten. Deze GAPs kunnen zich in zeer lage frequenties volledig 
ontwikkelen in de levercel en daarbij een bloedstadiuminfectie veroorzaken in het 
P. berghei muizenmodel. Tevens werden er replicerende ∆p52+p36 P. falciparum 
parasieten gevonden in een kweek van primaire humane levercellen. Deze GAPs 
zijn klaarblijkelijk niet veilig en we stelden daarom een aantal screening criteria op 
voor het bepalen van de veiligheid van GAP kandidaten, voorafgaand aan verdere 
klinische ontwikkeling en studies in mensen. In Hoofdstuk 5 bestuderen we het 
fenotype van ∆p52+p36 P. berghei parasieten die zich in de lever ontwikkelen. Deze 
parasieten blijken zich op onconventionele wijze te kunnen ontwikkelen tot bloed-
stadium parasieten. Het parasitophorous vacuole membraan (PVM) schermt de par-
asiet normaal gesproken af voor herkenning door de levercel en wordt als essentieel 
beschouwd voor de ontwikkeling van de parasiet. We lieten zien dat ∆p52+p36 P. 
berghei parasieten zich zonder het PVM volledig kunnen ontwikkelen in de levercel. 
Deze bevindingen kunnen implicaties hebben voor de ontwikkeling van een GAP 
vaccin, aangezien GAPs met een gen deletie betrokken bij de formatie of het onder-
houden van het PVM waarschijnlijk onveilig zijn. Hoofdstuk 6 beschrijft de ontwik-
keling en karakterisatie van de ∆b9 GAP. Deze GAP kan steriele bescherming indu-
ceren in muizen.  De afgebroken ontwikkeling van de parasiet, vlak na de invasie in 
de levercel, lijkt samen te hangen met een gecompromitteerde PVM. Een laag aantal 
P. berghei ∆b9 GAP bleek zich te kunnen ontwikkelen in de afwezigheid van een PVM. 
We ontwikkelden vervolgens een P. berghei ∆b9∆slarp GAP, bestaande uit een para-
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siet met meerdere gen deleties. Deze meervoudig geattenueerde GAP komt volledig 
tot stilstand in de lever van muizen en ontwikkelt zich nooit tot het pathogene bloed 
stadium. Immunisatie van BALB/c en C57BL/6 muizen met P. berghei ∆b9∆slarp 
GAP resulteerde in steriele en langdurige bescherming. De ortholoog mutant in P. 
falciparum is reeds gegenereerd en de ontwikkeling van deze GAP in de levercel zal moeten worden bestudeerd. Als de P. falciparum ∆b9∆slarp GAP inderdaad volledig 
tot stilstand komt in de levercel, evenals de P. berghei GAP, zal het zeer waarschijnlijk 
de meest veelbelovende GAP vaccinkandidaat vormen.
In Hoofdstuk 7 beschrijven we de relatie tussen de parasieten lever load als gevolg 
van sporozoieten immunisatie en de mate van bescherming in muizen. Intraveneuze 
sporozoieten immunisatie van zowel BALB/c als C57BL/6 muizen resulteerde in een 
hogere mate van bescherming in vergelijking met intradermale immunisatie. De af-name in bescherming na intradermale immunisatie bleek samen te hangen met een 
relatief laag aantal parasieten dat de lever wist te bereiken. Hoewel hoogstwaarschi-
jnlijk zeer effectief, vormt IV injectie niet de meest preferente immunisatie meth-
ode voor grootschalige toepassing in Sub-Sahara Afrika. In Hoofdstuk 8 bestuderen 
we derhalve welke variabelen, betrokken bij sporozoiet injectie, de parasieten lever 
load beïnvloeden. Met behulp van luminescente PbGFP-Luccon en PyGFP-Luccon para-
sieten bepaalden we in muizen welke toedieningsvariabelen (bijvoorbeeld locatie 
van injectie, injectie volume) de parasieten lever load beïnvloeden. Meervoudige in-
tramusculaire injecties van sporozoieten in kleine volumina resulteerde in de hoog-
ste parasieten lever load en vormt daarmee hoogstwaarschijnlijk de meest optimale 
route van non-IV sporozoieten immunisatie. Deze data verschaffen een richtlijn voor 
toekomstige klinische trials, op zoek naar de meest optimale methode van sporo-
zoieten immunisatie en hopelijk voor de ontwikkeling van een sporozoietenvaccin tegen malaria.
202
Chapter 10
List of Publications
Ploemen IH, Croes HJ, van Gemert GJ, Wijers-Rouw M, Hermsen CC, Sauerwein RW. 
Plasmodium berghei ∆p52&p36 Parasites Develop Independent of a Parasitophorous 
Vacuole Membrane in Huh-7 Liver Cells. PLoS One 2012, 7:e50772.
Ploemen IH, Chakravarty S, van Gemert GJ, Annoura T, Khan SM, Janse CJ, Hermsen 
CC, Hoffman SL, Sauerwein RW. Plasmodium liver load following parenteral sporozoite administration in rodents. Vaccine in press 
Nganou-Makamdop K*, Ploemen I*, Behet M, van Gemert GJ, Hermsen C, 
Roestenberg M,Sauerwein RW. Reduced Plasmodium berghei sporozoite liver load 
associates with low protective efficacy after intradermal immunization. Parasite 
Immunol 2012, 34:562-569.
Annoura T*, Ploemen IH*, van Schaijk BC*, Sajid M, Vos MW, van Gemert GJ, 
Chevalley-Maurel S, Franke-Fayard BM, Hermsen CC, Gego A, et al: Assessing the 
adequacy of attenuation of genetically modified malaria parasite vaccine candidates. 
Vaccine 2012, 30:2662-2670.
Ploemen I, Behet M, Nganou-Makamdop K, van Gemert GJ, Bijker E, Hermsen C, 
Sauerwein R. Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites. Malar J 2011, 10:350.
McCall MB*, Ferwerda B*, Hopman J, Ploemen I, Maiga B, Daou M, Dolo A, Hermsen 
CC, Doumbo OK, Bedu-Addo G, van der Meer JW, Troye-Blomberg M, van der Ven AJ, 
Schumann RR, Sauerwein RW, Mockenhaupt FP, Netea MG. Persistence of full-length caspase-12 and its relation to malaria in West and Central African populations. Eur 
Cytokine Netw 2010, 21:77-83.
McCall MB*, Hopman J*, Daou M, Maiga B, Dara V, Ploemen I, Nganou-Makamdop K, 
Niangaly A, Tolo Y, Arama C, Bousema JT, ban der Meer JW, van der Ven AJ, Troye-
Blomberg M, Dolo A, Doumbo OK, Sauerwein RW.  Early interferon-gamma response against Plasmodium falciparum correlates with interethnic differences in 
susceptibility to parasitemia between sympatric Fulani and Dogon in Mali. J Infect 
Dis 2010, 201:142-152.
203
Summary, Samenvatting, List of publications, Dankwoord-Acknowledgments, C.V
McCall MB, Roestenberg M, Ploemen I, Teirlinck A, Hopman J, de Mast Q, Dolo A, 
Doumbo OK, Luty A, van der Ven AJ, Hermsen CC, Sauerwein RW. Memory-like IFN-
gamma response by NK cells following malaria infection reveals the crucial role of T 
cells in NK cell activation by P. falciparum. Eur J Immunol 2010, 40:3472-3477.
Ploemen IH*, Prudencio M*, Douradinha BG, Ramesar J, Fonager J, van Gemert GJ, 
Luty AJ, Hermsen CC, Sauerwein RW, Baptista FG, Mota MM, Waters AP, Que I, Lowik 
CW, Khan SM, Janse CJ, Franke-Fayard BM. Visualisation and quantitative analysis of 
the rodent malaria liver stage by real time imaging. PLoS One 2009, 4:e7881.
van Drongelen J, Ploemen IH, Pertijs J, Gooi JH, Sweep FC, Lotgering FK, Spaanderman 
ME, Smits P: Agingattenuates the vasodilator response to relaxin. Am J Physiol Heart 
Circ Physiol 2011, 300:H1609-1615.
*These authors contributed equally.
204
Chapter 10
Dankwoord - Acknowledgments
Met een ogenschijnlijk gemak (met de nadruk op ogenschijnlijk) is het nu af. Al-
thans….bijna af. Ik begon mijn promotie met het doel een bijdrage te leveren aan 
de ontwikkeling van een malaria vaccin. Zoals zo veel promovendi raakte ik al snel 
verknocht aan mijn onderwerp en werd het een echte jacht op de ultieme GAP. Nu, een aantal jaartjes later en wijzer hoop ik dat ik mijn eigen steentje bij heb kunnen 
dragen.. Time will tell! Het was in ieder geval nooit gelukt zonder de hulp van een groot aantal mensen. 
Robert, als eerste wil ik graag jou bedanken. Jij gaf me de kans om aan een fantas-
tisch mooi promotieproject te werken. De outline van het project was simpel ‘zorg 
ervoor dat er over 4 jaar een GAP kandidaat klaarligt’. Daarbinnen was er heel veel 
mogelijk. Ik wil je enorm bedanken voor het vertrouwen dat je me de afgelopen jaren 
hebt gegeven, de (soms) noodzakelijke nuances die je in mijn stukken aanbracht en 
de ruimte die je me gaf me steeds verder te ontwikkelen. Experimenten verzinnen 
en uitvoeren lukte meestal wel; jij leerde me de reultaten in duidelijke taal te ver-
vatten. Waar het vinden van een goede GAP 4 jaar geleden een grote uitdaging was, 
lijkt dat nu overgenomen te worden door de route van immunisatie. Graag wil ik ook 
deze ‘hobbel’ in de toekomst samen met jou en het team tackelen.
Chris, al heel vroeg in mijn promotie betrok je me bij het werk dat in Leiden wordt 
uitgevoerd. Samen met Blandine gaf je met de pb-luc parasieten een kick-start aan 
mijn promotie. Ik kan niet genoeg benadrukken hoe belangrijk deze parasieten 
zijn geweest voor mijn boekje. Als de GAP P. berghei expert was je via skype altijd 
beschikbaar voor vragen en overleg. Je had altijd wel even een minuutje. Dank daar-
voor! Waar het gebruik van de pb-luc parasieten aan de voet stond voor de ene helft 
van dit boekje, staan de Knock-outs dit voor de andere helft. Shahid, Takeshi, Sev-
erine and Saj thanks for all the GAP lines. While the word breakthrough has a whole 
new connotation in my dictionary I am glad we were able to close the deal in the end.
I would very much like to thank the collaborators from Sanaria. It has been a privi-lege to work in a consortium with such a strong commitment to one goal. Steve, 
thank you for  your inspirational ‘just do it’ mentality. I hope that in the future, our 
roads will cross and I can continue the work with you and your team on the develop-
ment of a ‘sporoject’. Sumana, Peter, Eric, Kim Lee and Judy (U.S Military Malaria 
205
Summary, Samenvatting, List of publications, Dankwoord-Acknowledgments, C.V
Vaccine Program) thanks for all the helpful discussions.
Mijn dank gaat ook zeker uit naar TIPharma. Dankzij jullie funding heb ik niet al-
leen mijn promotieonderzoek kunnen uivoeren maar heb ik ook allerlei nuttige cur-
sussen kunnen volgen die me in staat hebben gesteld mijn kennis te verbreden en 
carrière te ontwikkelen. Het concept van public private partnership werkt zeker!
Geert-jan, ik kan me geen betere compagnon hebben gewenst voor het muggen en 
muizenwerk. Vijf parasietenlijnen tegelijk opwerken, ‘ff ’ sporozoieten verzamelen 
voor de immunisatie van 180 muizen, ‘ff ’ samen met de Volvo op en neer naar Leiden om muggen te dissecteren, niets was jou te gek… Bedankt, je inzet was ongekend! 
Jolanda, Laura, Astrid en Jacqueline, ontzettend bedankt voor het vele kweekwerk 
wat jullie hebben verricht. Claudia, Alex, Iris, Danielle, Michael, Marieke, Kitty, 
Bianca en Debby, bedankt voor alle biotechnische ondersteuning. Zonder jullie hulp was dit nooit gelukt.
Rob, bedankt voor de goede start. Als laboudste wist je me altijd van goede raad 
te voorzien. Ook wist je me, waar de expertise binnen het lab begrensd was, altijd 
wel met iemand in contact te brengen die me verder kon helpen. Daarnaast heb ik 
dankzij jou nooit een horloge hoeven dragen: jij vertelde me elke morgen hoe laat het was. Bedankt! Miguel and Maria, thanks a lot for teaching me the gliding and liv-
er stage assays. I really enjoyed the (short) stay in Lisbon. Huib en Mietske, bedankt 
voor alle hulp bij de electronenmicroscopie. Een speld in een hooiberg was wellicht 
makkelijker te vinden geweest. Conor and Anne, thank you for your expertise and 
insights in the use of microneedles, let’s hope the HM do the trick! 
Een van de leukste dingen van het promoveren is zeker wel het begeleiden van stu-denten. Marije, je bent tijdens jou stage enorm gegroeid en het is dan ook zeer ter-
echt dat je de stageprijs biomedische wetenschappen 2012 hebt mogen ontvangen. 
Ontzettend bedankt voor je inzet en je enthousiasme. Zet hem op en dan komen de 
mooie resultaten vanzelf! Moniek, je hebt een sterk verhaal afgeleverd dat zeker 
heeft bijgedragen aan de totstandkoming van dit boekje, bedankt.
Ben, we hebben hard gelachen! Het was tof om al die jaren een U-tje met je te delen. 
Die glijbaan naar het dak is er helaas nooit van gekomen. Een tip… zoals reeds aan-
getoond bij het kerststallenmailtje, indien er sprake is van twijfel: SEND!
Martijn, de man met de gouden handjes. Het P. berghei team zette hem voor, en jij 
206
Chapter 10
speelde hem (samen met Ben) de andere helft van het veld over. Bovenal een goede 
mtb-maat. We blijven zeker biken! Amrish, ineens zat je daar aan mijn labtafel. Nu 
viel het pas echt op hoeveel praktisch werk ik nog deed… thanks mate! ik ben aan het 
sparen voor Suriname en ik verheug me op doldwaze whiskyavondjes. Binnenkort gaan we op jouw promotie toosten!
Matthew, jij stond aan de wieg van mijn malaria avontuur. Een onvergetelijke tijd in Mali samen met jou en Joost zorgde er mede voor dat ik na een omzwerving terug ben gekeerd naar de afdeling. Teun, eerder nog wakkerde het blok outbreak epide-
miology de al aanwezige voorliefde voor infectieziektes verder aan. Bedankt voor je 
hulp bij de moeilijke statistiek, je goede whisky en je ‘goede’ grappen. Meta, Else en 
Guido, bedankt voor de klinische input bij de zoektocht naar de route van inoculatie. 
Op naar een immunisatie die echt goed werkt! Maurits, als je door de microneedles 
het bos niet meer ziet, bedenk dan… als je maar hard genoeg drukt raak je vanzelf 
een bloedvat. Annemieke, bedankt voor alle carrièretips! Anja, zsonder jou souden mijn teksten er zo uit heppen gezien… bedankt! Anne, bijna gelijk gestart, bijna 
gelijk klaar, heel veel succes met de laatste lootjes! Dat fietje hou je van me tegoed! 
Maarten, voor jou duurt het nog ff, als je straks afleiding zoekt van het schrijven 
moet je gewoon weer mee gaan fietsen. Mayke, heel veel geluk met de kleine en... Tot borrels! Marga, Will, Wouter, Theo, Pieter, Adrian, Karina, Krystelle, Rianne, 
Koen, Martijn, Helmi, Sanna, Kjerstin  and Stone bedankt voor alle gezelligheid bij 
de koffie tafel, bieravondjes, pokeravondjes en labuitjes.
Hans, samen rotsen beklimmen, samen thuiswerken, biertjes drinken, gezellige 
etentjes. Binnenkort weer in dezelfde stad! Ik ben trots de 27e April achter jou en Mirte te mogen staan. Sten, nog ff doorbijten en dan ben je er ook… wie had dat ooit 
gedacht?! Libië schijnt weer veilig te zijn… what do thou say? Koen, als een van de 
weinige van groepje wit ging jij ook in Nijmegen promoveren. Bedankt voor je vr-
iendschap, onvergetelijke tijgermomenten en OMB3! Als ik in de States ben kom ik 
zeker langs! Een promotie zonder vakantie is overigens als spaghetti zonder saus….
erg saai. Gelukkig waren er de snowboard vakanties om het hoofd ff leeg te boarden: 
groepje WIT… Bedankt! Maar ook als er geen sneeuw lag was er altijd wel een ma-nier om wat kilometers te maken: Bram, Jasper, Joep & Stijn bedankt voor onver-
getelijke wielren/mtb weekendjes; ik zeg een barbecue, een steengril, een zwavel-
huisje een midgetgolfbaan en een paar flessen Erdinger…Pap en mam, Juud en Alex 
bedankt voor alles. Binnenkort kunnen jullie ook bij ons komen logeren! 
207
Summary, Samenvatting, List of publications, Dankwoord-Acknowledgments, C.V
Lieve Pien, jou steun en begrip zijn onbegrensd. Je bent een held en mijn weirdo! Nu, 
na twee jaar dan eindelijk saampjes het avontuur tegemoet, een nieuwe stad, een 
nieuwe plek, heel veel chille weekendjes met het busje aan kabbelende beekjes en 
nog vele memory boeken die we samen gaan vullen. Je maakt dat ik een beter mens 
ben en ik hou van je!
  
   Ivo
208
Chapter 10
Curriculum Vitae
Ivo Henry Johannes Ploemen, de schrijver van dit proefschrift, werd op 2 februari 
1984 geboren te Heerlen. In 2002 behaalde hij zijn gymnasiumdiploma aan 
het Trevianum in Sittard. Aansluitend begon hij aan de studie biomedische 
wetenschappen in Nijmegen waar hij in 2005 zijn bachelordiploma behaalde. Voorts 
startte hij in 2004 met het 2-jarige extra-curriculaire Honours Programma van de 
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dr. Matthew McCall. Deze stage betrof onderzoek naar de relatie tussen NK cel 
activiteit en susceptibiliteit tegen P. falciparum binnen twee etnische stammen en 
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het LUMC onder leiding van Dr. Chris Janse. De voornaamste resultaten van dit 
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voor een vervolgtraject, waarbij hij van mei tot november 2012 betrokken was bij 
de uitvoering en de coördinatie van translationeel vaccinonderzoek. Vanaf januari 
2013 is hij als scientist vaccine delivery werkzaam bij Intravacc, voorheen onderdeel 
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